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Summary
Cytochromes P450 are a superfamily o f haem-thiolate proteins found in all kingdoms 
of life. To date 11294 enzymes have been identified and have been shown to be 
involved in the metabolism of a wide variety o f substrates, including hydrocarbons 
and xenobiotics. In yeast and fungi the hydroxylation o f alkanes is associated with a 
family o f cytochromes P450 enzymes known as CYP52s. These enzymes are 
involved in the terminal hydroxylation o f long-chain alkanes resulting in the 
production o f alcohols, which can be further converted to form fatty acids and 
diacids. In vivo such hydrocarbons can be subjected to P-oxidation for use in growth. 
Alternatively, the products formed by CYP52 catalysed hydroxylation in vitro can be 
used in biotechnological applications. They can be used as platform chemicals in the 
production o f a number o f industrial products, including plastics, fragrances and 
antibiotics.
The p-oxidation of fatty acids has been less well documented for Candida albicans 
than for other Candida species, therefore it was the aim o f this study to investigate a) 
did cytochromes P450 exist in C. albicans that could possibly fulfil this function and 
b) to definitively assign function to a single cytochrome P450. Using a bioinformatic 
approach, five putative CYP52s were identified in C. albicans. O f these CYP52s, 
Alkl was shown to have the greatest homology to the archetypal alkane-assimilating 
CYP52, CYP52A3 from C. maltosa. ALK1 heterologous gene expression in the 
brewer’s yeast Saccharomyces cerevisiae allowed growth on hexadecane (C l6:0) as 
the sole carbon source. This showed for the first time that Alkl is involved in the 
hydroxylation o f long-chain alkanes as normally S. cerevisiae is unable to utilise 
alkanes for growth. This study has also shown that Alkl is able to interact with 
sterol substrates suggesting a possible role for CYP52s in sterol metabolism, which 
was previously unknown.
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Chapter 1: Introduction
1.1 Candida albicans
Candida albicans is a diploid fungus, which can exist in three different 
morphological forms: yeast, pseudohyphae and hyphae (figure 1.1).
Figure 1.1 -  The three morphologies of C. albicans: yeast, pseudohyphae and 
hyphae (taken from Sudbery et al., 2004). a) Yeast -  In this unicellular form, a 
new daughter cell buds off the mother cell to form two cells (Sudbery et al, 2004; 
Whiteway & Bachewich, 2007). b) Pseudohyphae — Pseudohyphae form when a 
daughter bud remains fused to the mother cell. Once the septum has formed, the 
daughter bud elongates to resemble true hyphae (Sudbery et al., 2004). c) Hyphae 
(also known as true hyphae) -  Rapid switching between the yeast and hyphal forms 
of C. albicans has been implicated in the pathogenesis of this fungus (Brown & 
Gow, 1999). It is thought the hyphal form allows C. albicans to penetrate and invade 
the host tissues leading to infection (Gow, 1994).
C. albicans can be located harmlessly in the flora o f healthy human gastrointestinal 
and genitourinary tracts and on the skin (Berman & Sudbery, 2002). However, 
changes in the host environment (such as changes in pH or glucose concentration) or 
a weakened immune system (as a result of illnesses, such as cancer or AIDS) can 
result in the manifestation of superficial or systemic infections (Lopez-Martinez,
2010). Superficial candidosis can manifest as oral thrush (figure 1.2a), a rash/itching 
in the creases of the body, such as the armpits and in between the fingers (figure 
1.2b), vulvovaginal thrush or paronychia, which results in soreness and discoloration 
of the (finger)nails (figure 1.2c) (Lopez-Martinez, 2010). In patients with a
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suppressed/weakened immune system, such as those undergoing chemotherapy, C. 
albicans can enter the bloodstream and cause potentially life threatening infections 
(Sudbery et al., 2004).
Figure 1.2 -  Examples of superficial Candida infections (taken from Lopez- 
M artinez, 2010). a) Oral thrush -  most common infection, b) Infection in the 
crevices between the fingers, c) Paronychia -  painful irritation of the fingernails.
Although C. albicans is the major pathogen of fungal infections in humans, other 
Candida spp. are also emerging as causes of these infections due in part to the over­
prescription of anti fungal agents by doctors (Kothavade et al., 2010; Lopez- 
Martinez, 2010). These non-albicans species include: C. dubliniensis, C. krusei, C. 
lipolytica and C. tropicalis, which is the major non-albicans species causing fungal 
infections in humans (Kothavade et al., 2010; Lopez-Martinez, 2010). Interestingly, 
C. tropicalis has not only been shown to be involved in pathogenesis, but it has also 
been shown to have potential biotechnological applications too. C. tropicalis is able 
to grow on hydrocarbons, such as alkanes (figure 1.3) and fatty acids (figure 1.4), 
when they are used as the sole carbon source. The derivatives produced through 
metabolism by cytochrome P450 enzymes can be used as platform chemicals to form 
the basis of a number of industrial products, including hot-melting adhesives, 
plastics, lubricants, fragrances and antibiotics (Eschenfeldt et al., 2003; Liu et al.,
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2003). Other Candida spp., including the soil-dwelling, non-pathogenic fungus C. 
maltosa, have also been shown to have similar capabilities.
Dodecane (C12:0) Tetradecane (C14:0)
Hexadecane (C16:0) Octadecane (C18:0)
Figure 1.3 -  Examples of different alkane compounds. Alkanes are made up of 
the chemical elements carbon and hydrogen and have the molecular formula CnH2n+2-
Saturated Fattv Acids Unsaturated Fatty Acids
Laurie Acid (C12:0) Oleic Acid (C18:lt
Mvristic Acid (C14:0) Linoleic Acid (C 18:21
Palmitic Acid (C16:0)
Figure 1.4 -  Examples of different saturated and unsaturated fatty acids. Fatty 
acids contain an alkyl chain joined to a carboxyl (COOH) group and exist in two 
forms: saturated and unsaturated. Saturated fatty acids do not contain any double 
bonds, whereas unsaturated fatty acids contain at least one.
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1.2 Cytochromes P450
Cytochromes P450 are a superfamily o f haem-thiolate proteins, which catalyse the 
oxidation o f a wide variety o f structurally diverse, organic compounds, such as fatty 
acids, steroids and xenobiotics. They were first observed in liver microsomes in 
1958 by Garfinkel and Klingenberg (independently) and were described as an 
unusual carbon monoxide binding pigment with an absorbance maximum at 450nm 
(Garfinkel, 1958; Klingenberg, 1958). However, it was not until 1964 that Omura 
and Sato characterised the pigment as a cytochrome protein (Omura & Sato, 1964). 
Cytochromes P450 get their name from the Soret peak, which is produced at a 
wavelength o f 450nm when carbon monoxide binds to the sodium dithionite reduced 
haem protein (Omura & Sato, 1964).
Cytochromes P450 have presently been found in all kingdoms o f life (animals, lower 
eukaryotes, plants and bacteria) and currently, there are 11294 enzymes (February
2011) in the cytochrome P450 superfamily (http://dmelson.utshc.edu/Cvtochrome 
P450.html). This number, however, is continually increasing and a nomenclature 
system has been implemented to identify these genes.
Cytochromes P450 can be identified by the CYP prefix, e.g. CYP4 (Nebert et al., 
1989, Nelson, 2006). This is followed by a number, which represents the family to 
which the cytochrome P450 belongs. Individual genes become part o f this family if 
they share more than 40% amino acid identity with the other cytochromes P450 
already in that family, e.g. CYP4 (Nelson et a l , 1993; Nelson et al., 1996; Werck- 
Reichhart & Feyereisen, 2000; Kelly et a l, 2003; Schuler & Werck-Reichhart, 
2003). The cytochromes P450 can then become part o f a specific subfamily if  they 
share more than 55% amino acid identity with the other cytochromes P450 and this is 
represented as a letter in the nomenclature, e.g. CYP4F (Werck-Reichhart & 
Feyereisen, 2000; Kelly et al., 2003; Schuler & Werck-Reichhart, 2003). The final 
number, e.g. CYP4F11. is the unique gene identifier for that specific cytochrome 
P450 (Werck-Reichhart & Feyereisen, 2000). Figure 1.5 shows an overview o f this 
nomenclature system.
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Subfamily Letter 
Prefix/Root Symbol (greater than 55% identity)
'  /
CYP 4 F 11
\
Gene Number
Figure 1.5 - Overview of the cytochrome P450 nom enclature system. The
example used is CYP4F11. CYP represents the prefix/root symbol. The first 
number (4) is the family number (which requires greater than 40% identity amongst 
members). The subfamily is denoted by a letter (F) and requires members to have 
greater than 55% identity. The final gene number (11) is a unique gene identifier.
1.2.1 Cytochrome P450 Monooxygenase System
Cytochromes P450 are involved in the catalysis of many different reactions, 
including carbon hydroxylation (alcohol formation), heteroatom release (also known 
as dealkylation) (oxidative cleavage at atoms on the molecule that are neither carbon 
nor hydrogen), heteroatom oxygenation (formation of a heteroatom oxide) and 
epoxidation (formation of epoxides from the addition of oxygen to alkenes and 
aromatic compounds) (Guengerich & MacDonald, 1984; Porter & Coon, 1991; 
Groves, 2005; Guengerich, 2007) (see figure 1.6).
Family Number
(greater than 40% identity)
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a) Hvdroxvlation b) Heteroatom Release
RH ROH RXR ------► R=0 + HXR
c) H eteroatom  Oxygenation d) Epoxidation
RX RXO
O
R=R ------► R ^ R
Fi2 ure 1.6 -  Reactions catalysed by cytochromes P450. a) Hydroxylation. 
Alcohol formation, b) Heteroatom release. Oxidative cleavage at atoms on the 
molecule that are neither carbon nor hydrogen, c) Heteroatom oxygenation. 
Formation o f a heteroatom oxide, d) Epoxidation. Formation o f epoxides from the 
addition o f oxygen to alkenes and aromatic compounds. R represents a hydrocarbon 
side-chain, O represents oxygen and X represents a halogen molecule.
For each o f these described reactions to occur an oxygen atom needs to be 
incorporated into the substrate to produce the required product. This is achieved by 
the substrate being subjected to the cytochrome P450 monooxygenase catalytic cycle 
(figure 1.7). The cycle begins with the haem iron centre (Fe) in its resting state (1). 
The organic substrate (RH) docks near the haem centre (2), enhancing the 
cytochrome P450’s ability to accept electrons (Porter & Coon, 1991) from an 
associated electron donor (e.g. NADPH-cytochrome P450 reductase) (see section 
1.2.2) (Groves, 2005). This electron transfer causes the haem centre to become 
reduced (3) allowing molecular oxygen to bind (4) producing a cytochrome P450- 
dioxygen complex (Groves, 2005). A second electron is transferred from the 
associated electron donor (5) to cleave the oxygen, incorporating one oxygen atom 
into the organic substrate and allowing the second to be released as water (Groves, 
2005). The monooxygenase cycle is completed when product dissociation occurs (6) 
and the haem centre is restored back to its original resting state (Porter & Coon, 
1991; Groves, 2005).
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©
©
RH ©
Fe3+ » Fe3+ — RH ©ROH
Fe3+ — RH Fe2+— RH
© ©Fe3+ — RH * * Fe2+ — RH
Figure 1.7 -  Cytochrome P450 monooxygenase system. Catalytic cycle showing 
the steps required to incorporate oxygen into the substrate (RH) at the haem centre 
(Fe). RH = organic substrate, Fe = haem centre, O = oxygen and ROH = oxidised 
state o f the organic substrate.
1.2.2 Classes of Cytochromes P450
For the monooxygenase cycle to progress, electrons are required from an associated 
electron donor. However, the electron donor required for this process differs 
depending on the cytochrome P450 enzyme being used. Therefore, cytochromes 
P450 are separated into ten different classes based on this criterion.
1.2.2.1 Class I
Class I proteins encompass bacterial and mitochondrial cytochromes P450, which 
require an FAD-containing reductase (ferrodoxin reductase, FdR) as well as an iron 
sulphur redoxin (iron-sulphur-cluster, Fdx) for the transfer o f electrons to occur 
(Werck-Reichhart and Feyereisen, 2000; Paine et al., 2005). In bacterial class I 
systems (figure 1.8a), each o f these components are soluble, however, in 
mitochondrial systems (figure 1.8b) the Fdx is soluble (found in the mitochondrial 
matrix), but the cytochrome P450 and FdR are membrane-bound (bound to the inner 
mitochondrial membrane) (Hannemann et al., 2007). Electrons are transferred in 
both classes from NAD(P)H to FdR to Fdx and then finally to the cytochrome P450 
for completion o f the monooxygenase cycle (Werck-Reichhart & Feyereisen, 2000; 
Paine et al., 2005). Examples of members o f this class are the bacterial cytochrome
7
P450 CYP101D1 from Novosphingobium aromaticivorans, which is involved in the 
synthesis of camphor to 5-exo-hydroxycamphor (Bell et al., 2010) and the 
mammalian mitochondrial cytochrome P450 CYP11A1 (P450scc) involved in 
steroid hormone biosynthesis (Black et al., 1994).
a)
m
N A D H  +  H+
NAOMIS < = >  4 8
Figure 1.8 -  Class I cytochromes P450 (adapted from H annem ann et al., 2007).
a) Bacterial -  all components are soluble, b) Mitochondrial -  soluble iron sulphur 
redoxin (Fdx) and membrane-bound cytochrome P450 complex and ferredoxin 
reductase (FdR).
1.2.2.2 Class 11
The cytochromes P450, which make up class II are microsomal proteins that require 
NAD PH-cytochrome P450 reductase (CPR) for electron transfer (figure 1.9) (Werck- 
Reichhart & Feyereisen, 2000; Paine et al., 2005). CPR is a flavoprotein containing 
equal amounts of the cofactors FAD (ferredoxin reductase) and FMN (flavodoxin) 
(He & Chen, 2005; van Bogaert et al., 2007), which are required for electron transfer 
from NADPH. Initially the hydride ion of NADPH transfers electrons to FAD then a 
single electron is transferred to FMN from FAD (Gigon et al., 1969; van Bogaert et 
al., 2007). The electron is transferred to the haem centre o f the cytochrome P450. 
The haem iron then becomes reduced allowing molecular oxygen activation and the 
eventual formation of the alcohol complex (van Bogaert et al., 2007). A member of 
this class of proteins is the sterol 14a-demethylase CYP51 (Lamb et al., 2001).
b)
N A D P H  +  H f
N A D P FdR < = >
M atrix
Inner M itochondrial 
M em brane
NADPH + H"
N A DP+
Cytoplasm
ER M embrane
Figure 1.9 -  Class II cytochromes P450 (adapted from Hannem ann et al., 2007).
Membrane-bound NAD PH-cytochrome P450 reductase (CPR) and cytochrome P450 
complex.
1.2.2.3 Class 111
Class III is a bacterial system used by CYP176A1 (P450cm - involved in the 
biodegradation of cineole 1) from Citrobacter braakii (figure 1.10) (Hawkes et al., 
2002; Meharenna et al., 2004). It resembles class I as both use a (soluble) three 
component system to transfer electrons from NAD(P)H. However, unlike the class I 
system, class III proteins utilise FMN rather than the iron-sulphur-cluster (Fdx) to 
deliver electrons from FAD to the haem iron (Hannemann et al., 2007). Electron 
transfer between the redox centres of FAD and FMN also resembles the system 
utilised by class II proteins, but FAD and FMN are bound to two separate proteins in 
the class III system whereas they are bound to one protein, CPR, in class II 
(Hannemann et al., 2007). Although, the electron transfer system utilised by 
CYP176A1 shares aspects of both the class I and class II systems, it does not fully 
satisfy the remits of either thus giving rise to a separate group of proteins classified 
as class III.
Fiuure 1.10 -  Class III cytochromes P450 (adapted from Hannem ann et al., 
2007). Soluble, bacterial system utilising FAD and FMN.
NAD(P)H + H4
NAD(P)
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1.2.2.4 Class IV
The electron transfer system associated with CYP119 from Sylfolobus 
acidocaldarius belongs to class IV (figure 1.11) (Lim et al., 2010). CYP119 is a 
thermophilic cytochrome P450, which can remain stable at high temperatures (up to 
85°C) (Koo et al., 2000) and unlike the other classes it is not NAD(P)H dependent 
(Puchkaev & Ortiz de Montellano, 2005). Instead of using NAD(P)H, electrons are 
transferred from pyruvic acid to a 2-oxoacid-ferredoxin oxidoreductase and then to a 
thermostable ferredoxin before being delivered to the haem centre of the cytochrome 
P450 (Puchkaev & Ortiz de Montellano, 2005).
Pyruvate
CoA Acetyl CoA
Figure 1.11 -  Class IV cytochromes P450 (adapted from Hannem ann et al., 
2007). Novel thermophilic system.
1.2.2.5 Class V
CYP51 (a 14a-demethylase) from Methylococcus capsulalus is the sole member of 
class V (figure 1.12) (Jackson et al., 2002). Like the class I system, it utilises FdR 
and Fdx, however, this is a novel system as the Fdx is fused to the C-terminus of the 
cytochrome P450 complex (Hannemann et al., 2007). Therefore, in this system, 
electrons are transferred from NADH to the soluble FdR before being passed onto 
the FdX-cytochrome P450/CYP51 fusion protein (Hannemann et al., 2007).
NADH + H+
l l S INAD
Figure 1.12 -  Class V cytochromes P450 (adapted from Hannem ann et al.,
2007). Fdx-cytochrome P450 fusion protein.
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1.2.2.6 Class VI
The class VI system also utilises a novel fusion cytochrome P450 fusion protein in 
the passage of electrons from NADPH (figure 1.13) (Hannemann et al., 2007). The 
sole member of this class is XplA from Rhodococcus rhodochrous strain 11Y, which 
is involved in the biodegradation of RDX (Royal Demolition Explosive -  hexa- 
hydro-l,3,5-trinitro-l,3,5-triazine) (Jackson et al., 2007). It consists of a Fldx redox 
partner fused at the N-terminus of a cytochrome P450 domain, which accepts 
electrons from NADPH (Jackson et al., 2007). Electrons are transferred from 
NADPH to the fusion protein by XplB, a potential adrenodoxin reductase found 
upstream of XplA (Jackson et al., 2007).
Figure 1.13 -  Class VI cytochromes P450 (adapted from Hannem ann et al., 
2007). N-terminally linked Fdx-cytochrome P450 fusion protein.
1.2.2.7 Class VII
Cytochromes P450 belonging to Class VII are novel fusion proteins that have a 
phthalate dioxygenase reductase domain linked to the C-terminus o f the cytochrome 
P450 (figure 1.14) (Hannemann et al., 2007). The first member o f this class was 
CYP116B2 (P450RhF) from Rhodococcus sp. (Roberts et al., 2002). This enzyme 
has been show to produce 7-hydroxycoumarin in vivo without the need for additional 
redox partners (Hunter et al., 2005). Interestingly, unlike the other members of this 
class CYP116B2 has a preference for NADPH as an electron donor over NADH 
(Roberts et al., 2003).
NAD(P)H + H+
NAD(P)
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NAD(P)H + H*
N A D (P)J
Figure 1.14 -  Class VII cytochromes P450 (adapted from H annem ann et al., 
2007). Phthlate-family oxygenase reductase (PFOR) fused to a cytochrome P450 
complex.
1.2.2.8 Class VIII
Class VIII cytochromes P450, like class II proteins, utilise CPR as a redox partner to 
transfer electrons from NAD(P)H (figure 1.15). However, the CPR and cytochrome 
P450 complex exist as a single fusion protein in this system. Two examples are the 
fusion proteins CYP102A1 (P450bm -3) from Bacillus megaterium (Miura & Fulco, 
1974) and CYP505A1 (P450foxy) from Fusarium oxysporum (Nakayama et al., 
1996). Both are self-sufficient monooxygenases that are involved in the sub-terminal 
hydroxylation of fatty acids (Miura & Fulco, 1974; Nakayama et al., 1996; Warman 
et al., 2005).
Figure 1.15 -  Class VIII cytochromes P450 (adapted from H annem ann et al., 
2007). CPR-cytochrome P450 fusion protein.
1.2.2.9 Class IX
The nitic oxide reductase, CYP55 (P450nor) is the sole family belonging to class IX 
(figure 1.16). It is found in F. oxysporum (Nakahara & Shoun, 1996), 
Cylindrocarpon tonkinense (Usuda et al., 1995; Kudo et al., 1996), Trichosporon 
cutaneum (Zhang et al., 2001) and Aspergillus oryzae (Kaya et al., 2004). In 
anaerobic conditions, CYP55 can accept electrons from NADH to catalyse the 
conversion of nitrogen oxide to nitrous oxide (Kaya et al., 2004; Daiber et al., 2005).
NADPH + H+
NADP
CPR
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This transfer of electrons is achieved without the use of redox partners (Kaya et al.,
2004).
NADH + H+
NAD
Figure 1.16 -  Class IX cytochromes P450 (adapted from Hannem ann el al.,
2007). Nitric-oxide reductase cytochrome P450 system.
1.2.2.10 Class X
Class X cytochromes P450 are membrane-bound proteins found in the endoplasmic 
reticulum of plants and mammals (figure 1.17) (Hannemann et al., 2007). These 
proteins are able to synthesise organic substrates independently of electron transfer 
(via redox partners) (Hannemann et al., 2007). Examples of cytochromes P450 
belonging to this class are: CYP74A (allene oxide synthase) (Song et al., 1993), 
CYP74B (hydroperoxide lyase) (Matsui et al., 1996), CYP74C (allene oxide 
synthase) (Stumpe et al., 2006) and CYP74D (divenyl ether synthase) (Stumpe et al., 
2001), which are all found in chloroplasts and involved in cell defence through the 
lipoxygenase pathway (Froehlich et al., 2001). As these enzymes neither require 
oxygen nor a redox partner, they use the acyl hydroperoxide from the substrate to 
drive the reaction (Lau et al., 1993; Shibata et al., 1995; Itoh & Howe, 2001).
Figure 1.17 -  Class X cytochromes P450 (adapted from H annem ann el al., 
2007). Independent cytochrome P450 system.
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1.3 Alkane and Fatty Acid Hvdroxvlating Cytochromes P450. CYP52s. from 
Fungi and Yeast
CYP52s are a family o f alkane-inducible cytochromes P450 found only in yeast and 
fungi, such as Candida spp., that can utilise alkanes for growth. Within this family 
multiple genes have been identified. For example, approximately 23 cytochromes 
P450 have been found in C. tropicalis o f which 18 belong to the CYP52 family (this 
study). However, in Saccharomyces cerevisiae, a yeast strain which cannot use 
alkanes for growth, only 3 cytochromes P450 have been identified (Kelly et al., 
2005). These genes are CYP51 (also called ERG11 and 14a-demethylase), CYP61 
(also called ERG5 and 22-desaturase) and CYP56 (also called DIT2) (Kelly et al., 
2005).
Cytochrome P450 enzymes were first implicated in alkane and fatty acid 
hydroxylation in 1971 (Lebeault et al., 1971). C. tropicalis was grown on 
tetradecane (C20:0) and the harvested cells, containing cytochrome P450, were used 
to hydroxylate various fatty acids and alkanes (Lebeault et al., 1971). The 
cytochromes P450 in C. tropicalis were shown to preferentially hydroxylate mid- to 
long-chain fatty acids, especially lauric acid (C l2:0) and alkanes (hexadecane 
(C16:0), decane (C10:0) and octane (C8:0)) (Lebeault et al., 1971). However, the 
first alkane-inducible cytochrome P450, P450alk, from C. tropicalis was isolated and 
cloned in 1987 (Sanglard et al., 1987). This was later characterised and identified by 
Sanglard and Loper as the first member o f the CYP52 family, CYP52A1, in 1989 
(Sanglard & Loper, 1989). To date (February 2011), 52 CYP52s have been 
identified in C. tropicalis, C. maltosa, C. albicans, C. apicola, C. bombicola, 
Yarrowia lipolytica, Aspergillus nidulans, A. fumigatus, A. oryzae and 
Debaryomyces hansenii (http://dmelson.uthsc.edu/CvtochromeP450.html).
1.3.1 Metabolism of Alkanes and Fatty Acids by CYP52s
An overview of the pathway involved in the metabolism of alkanes and fatty acids by 
CYP52s is shown in figure 1.18
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Figure 1.18 -  Overview of the metabolic pathway used to convert alkanes and/or 
fatty acids to diacids. Fatty acids and diacids, produced through a- and co- 
oxidation, are transferred to the |3-oxidation pathway. This in turns produces acetyl 
CoA, which enters the Krebs cycle (Porter & Coon, 1991; Jiao et al., 2000; 
Eschenfeldt et al., 2003). CAT = Carnitine Acetyltransferase
In vivo the production of diacids from long-chain alkanes and fatty acids occurs in 
the endoplasmic reticulum. Initially, the long-chain alkane undergoes a-oxidation 
and is hydroxylated to its respective primary alcohol by the NADPH-dependent 
CYP52s. This is the rate-limiting step of this pathway (Scheller et al., 1998). The 
primary alcohol can subsequently be converted to its respective aldehyde either by 
the same CYP52 or by alcohol dehydrogenase. Aldehyde dehydrogenase or CYP52 
can then be used to catalyse the insertion of an oxygen atom into the aldehyde 
producing the respective long-chain fatty acid. This fatty acid can either be 
transported to the peroxisome for use in P-oxidation and eventual cell growth or can 
be further hydroxylated to the diacid (Porter & Coon, 1991; Jiao et al., 2000; 
Eschenfeldt et al., 2003).
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The fatty acid is hydroxylated at the ©-carbon (the carbon on the alkyl chain furthest 
away from the carboxyl side group (see figure 1.19)) during ©-oxidation to produce 
the fatty alcohol. The fatty alcohol can then be further converted to the fatty 
aldehyde and the diacid either by CYP52 or by alcohol dehydrogenase and aldehyde 
dehydrogenase respectively. The diacid can then be transported from the 
endoplasmic reticulum to the peroxisome to be subjected to the P-oxidation pathway 
for use in growth (Porter & Coon, 1991; Jiao et al., 2000; Eschenfeldt et al., 2003).
Figure 1.19 -  Position of the terminal (©-) carbon of a fatty acid chain 
highlighted on myrisitic acid (C14:0) as an example. Also indicated on this 
molecule is the sub-terminal (©1-) carbon, which is found adjacent to the ©-carbon.
Figure 1.20 shows an overview of the structural changes (described above) that occur 
at the ©-carbon during the production o f fatty acids and diacids.
" © “ © © /°
r - C - H  » R -C -O H  » R -C  » R -C
I I  x \
H H H OH
Alkyl Side- Alcohol Aldehyde Carboxyl
Chain Side-Chain
Figure 1.20 -  Overview of the structural changes that occur during the 
metabolism of alkanes and fatty acids. 1) The rate-limiting step o f the pathway. 
CYP52 catalyses the insertion o f oxygen into the alkyl side-chain to produce an 
alcohol. 2) CYP52 or alcohol dehydrogenase catalyse the formation on an aldehyde 
from the alcohol. 3) CYP52 or aldehyde dehydrogenase catalyse the insertion of 
oxygen into the aldehyde to produce a carboxyl side-chain. This results in the 
production o f a fatty acid or diacid molecule. R =: hydrocarbon side-chain, C == 
carbon, H = hydrogen and O = oxygen.
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As indicated above, CYP52 enzymes could generate diacids alone, which is a benefit 
from a biotechnological standpoint. However, in vivo, this would result in the 
depletion of NADPH as it would require three times as many electrons to produce 
aldehydes from alcohols as it would to generate only the alcohol from the alkane 
and/or fatty acid (Scheller et al., 1998). Therefore, in vivo, cytochromes P450 might 
be used to enhance the overall productivity o f the other enzymes (i.e. alcohol 
dehydrogenase and aldehyde dehydrogenase) in the a- and co-pathways, but are not 
required to carry out the further conversions o f alcohols and aldehydes by themselves 
(Scheller et al., 1998; Eschenfeldt et al., 2003).
1.3.2 Functions of CYP52s
As mentioned (section 1.3), approximately 52 CYP52s have been identified in a 
number of fungal species to date. Many have been shown to be induced 
preferentially by various alkanes and fatty acids using experimental procedures, such 
as QC RT-PCR (which is used to determine the transcriptional induction o f similar 
sequences by appropriate substrates) (Craft et al., 2003). For example, CYP52A18 
from C. tropicalis was shown to be preferentially induced by octadecane (C l8:0) and 
CYP52A17 (from the same species) by oleic acid (C l8:1) (Craft et al., 2003). 
However, very few o f the CYP52s discovered thus far have been studied at the 
protein level.
1.3.2.1 Diacid-Producing CYP52s
O f the CYP52s identified to date only CYP52A3, CYP52A4, CYP52A13 and 
CYP52A17 have been shown to produce diacids from a mixture o f mid- to long- 
chain alkanes and fatty acids.
CYP52A3 from the soil-dwelling fungi C. maltosa is the archetypal alkane- 
hydroxylating CYP52. It has been shown to produce 1,16-hexadecanedioic acid 
(C16:0 diacid) (figure 1.21) from hexadecane (C16:0) (Scheller et al., 1998). When 
incubated with myristic acid (C l4:0), palmitic acid (C l6:0) and oleic acid (C l8:1), 
CYP52A3 has also been shown to produce the respective co-hydroxy fatty acid 
without converting the molecule to the diacid (Zimmer et al., 1996).
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Figure 1.21 -  1,16-Hexadecanedioic acid (C16:0 diacid).
CYP52A4, also from C. maltosa, was shown to produce a diacid upon incubation 
with a hydrocarbon substrate. Unlike CYP52A3, CYP52A4 preferentially 
hydroxylates fatty acids. It is involved in the conversion of lauric acid (C l2:0) to 
1,12-dodecanedioc acid (C12:0 diacid) (figure 1.22) (Zimmer et al., 1995). It is also 
able to hydroxylate dodecane (C l2:0), hexadecane (C l6:0) and myristic acid (C l4:0) 
at the co-carbon to the corresponding alcohol (Zimmer et al., 1996).
Figure 1.22 -  1,12-Dodecanedioic acid (C12:0 diacid).
CYP52A13 from C. tropicalis is able to convert multiple unsaturated fatty acids 
(oleic acid (C l8:1), linoleic acid (C l8:2) and arachadonic acid (C20:4)) to their 
respective diacids (Eschenfeldt et al., 2003). It is also able to produce fatty alcohols 
by oo-hydroxylating capric acid (C10:0), lauric acid (C12:0), myristic acid (0 4 :0 ) ,  
palmitic acid (0 6 :0 )  and stearic acid (Cl 8:0) (Eschenfeldt et al., 2003).
Another CYP52 from C. tropicalis, CYP52A17 is also able to produce diacids. Like 
CYP52A13, it can convert multiple unsaturated fatty acids (oleic acid (0 8 :1 ) ,  
linoleic acid ( 0 8 :2 )  and arachadonic acid (C20:4)) to the corresponding diacid, as 
well as several saturated fatty acids (lauric acid (0 2 :0 ) ,  myristic acid (0 4 :0 ) ,  
palmitic acid (0 6 :0 )  and stearic acid (C18:0)) (Eschenfeldt et al., 2003). 
CYP52A17 is also able to hydroxylate capric acid ( 0 0 :0 )  to its relative alcohol 
(Eschenfeldt et al., 2003).
1.3.2.2 Other Products of CYP52s
CYP52A21 (Alk8) from C. albicans has been shown to hydroxylate lauric acid 
(C l2:0) to the co-hydroxy fatty acid, as well as, to a lesser extent, the sub-terminal or 
col-hydroxylated version (Kim et al., 2007). The col-hydroxy fatty acid produced is 
thought to be used for growth like the co-hydroxy form, but the actual mechanism by 
which this occurs is unclear. However, the following route can be proposed (see 
figure 1.23). The fatty alcohol undergoes sub-terminal oxidation whereby an oxygen 
atom is inserted between the col - and co2-carbons. This oxidation results in cleavage 
and the production of two molecules: an co-hydroxy fatty acid and acetic acid. The 
hydroxy fatty acid can then be further converted to the diacid and used in p- 
oxidation. The acetic acid enters into the Krebs cycle.
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Alcohol Hydroxylated at the jj,
Sub-terminal Carbon 3
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Alcohol Hydroxylated at 
the Terminal Carbon R -O H
H O
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I \
H OH
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Production
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Figure 1.23 -  Proposed sub-terminal oxidation of wl-hydroxy fatty alcohol.
Based on the subterminal oxidation of secondary alcohols (Ratledge, 1984; van 
Bogaert et al., 2011). Oxygen is inserted into the molecule between the col - and (02- 
carbons. The molecule is then cleaved between the oxygen atom and the col-carbon 
producing an co-fatty alcohol and acetic acid. R = hydrocarbon side-chain, C = 
carbon, O = oxygen and H = hydrogen.
In C. apicola and C. bombicola, CYP52s are involved in the production of 
sophorolipids (Lottermoser et al., 1996; van Bogaert et al., 2008). Sophorolipids are 
extracellular glycolipids, which can be used commercially as biosurfactants (Konishi 
et al., 2008). They are made up o f a disaccharide sophorose sugar, which is linked 
glycosidically to a (saturated or unsaturated) fatty acid o f usually 16 to 18 carbons in 
length (figure 1.24) (Casas & Garcia-Ochoa, 1999; Nunez et al., 2001; Shah et al.,
2005). The glycosidic link occurs at the hydroxyl group found on the col-carbon of 
the fatty acid (Shah et al., 2005), which is thought to arise due to hydroxylation by
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CYP52E1 and CYP52E2 from C. apicola (Lottermoser et al., 1996) and CYP52E3 
from C. bombicola (van Bogaert et al., 2008).
Figure 1.24 -  Sophorolipids. Sophorolipids can exist in two conformations: open 
and closed. The carboxyl group o f the fatty acid can bind to the -O H  group o f the 
sophorose sugar to produce a closed ring or it can remain unbound to produce an 
open compound.
1.4 Novel Cytochrome P450 Enzymes Involved in the Hvdroxvlation of Fatty 
Acids in Yeast and Fungi
Members o f the CYP52 family are not the sole cytochrome P450 enzymes in yeast 
and fungi to be involved in the catalysis o f fatty acids. Two novel cytochrome P450 
enzymes, P450foxy and PpoA, have also been identified.
Open Sophorolipid 
OAc
Closed Sophorolipid 
OAc
HO
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1.4.1 P450foxv (CYP505A11
P450foxy (CYP505A1) is a cytochrome P450-CPR fusion protein from F. 
oxysporum (Nakayama et al., 1996). It is involved in the sub-terminal and in-chain 
hydroxylation (col- to co3-carbons) o f several fatty acids, including lauric acid 
(C12:0), myristic acid (C14:0), palmitic acid (C l6:0) and stearic acid (C l8:0) 
(Nakayama et al., 1996). However, unlike members of the CYP52 family P450foxy 
is not involved in the hydroxylation o f alkanes (Nakayama et al., 1996).
1.4.2 PpoA
PpoA is a novel fusion protein from Aspergillus nidulans that exists as a haem 
peroxidase (a dioxygenase enzyme) fused to a cytochrome P450 domain and is 
involved in the production o f precocious sexual inducer (psi) factors from 
polyunsaturated fatty acids, such as linoleic acid (Cl 8:2) (Brodhun et al., 2009). The 
haem peroxidase converts linoleic acid (C l8:2) to (8R)-hydroperoxyoctadecadienoic 
acid ((8R)-HPODE) by incorporating two oxygen atoms into the structure at carbon 
8 (see figure 1.25) (Brodhun et al., 2009). (8R)-HPODE is then converted, by the 
cytochrome P450 enzyme, to produce 5,8-dihydroxyoctadecadienoic acid (5,8- 
DiHODE), a psi factor involved in sexual cleistothecia and asexual conidiospore 
development (see figure 1.25) (Brodhun et al., 2009).
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Linoleic acid
Haem Peroxidase
(8R)-hydroperoxyoctadecadienoic acid 
OH ((8R)-HPODE)
Cytochrome P450
OH
OH
OH
5,8-Dihydroxyoctadecadienoic acid
Figure 1.25 -  Conversion of linoleic acid (C18:2) to the PSI factor 5,8- 
dihydroxyoctandecadienoic acid by the novel cytochrome P450 fusion protein, 
PpoA.
1.5 Alkane and/or Fatty Acid Hvdroxvlating Cytochromes P450 from Other 
Organisms
Alkane and/or fatty acid hydroxylating cytochromes P450 are not solely found in 
yeast and fungi, they can also be found in many other kingdoms o f life, including 
bacteria, plants and animals. Table 1.1 shows an overview o f these cytochrome P450 
families, which are discussed in further detail below.
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Bacteria Plants Animals
CYP 102 CYP76 CYP1
CYP 105 CYP77 CYP2
CYP 107 CYP78 CYP4
CYP119 CYP81
CYP 124 CYP86
CYP 152 CYP92
CYP 153 CYP94
CYP703
CYP704
CYP709
CYP726
Table 1.1 -  Cytochrome P450 families involved in the hydroxylation of alkanes 
and/or fatty acids from bacteria, plants and animals.
1.5.1 Alkane and Fatty Acid Hvdroxvlating Cytochromes P450 from Bacteria
To date 13 proteins from 7 cytochrome P450 families in bacteria have been shown to 
catalyse the hydroxylation o f alkanes and fatty acids in vitro (see table 1.2). As with 
CYP52, the physiological roles o f many o f these enzymes are undocumented, 
however, their activities are discussed below.
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1.5.1.1 CYP102A1. CYP102A2. CYP102A3. CYP102A7 and CYP102B1
P450bm-3 (also known as CYP102A1) from Bacillus megaterium is a catalytically 
self-sufficient cytochrome P450-CPR fusion protein (Warman et al., 2005). It can 
catalyse the hydroxylation o f long-chain, saturated fatty acids (lauric acid (C l2:0) to 
stearic acid (C l8:0)) at the ml-, m2- and co3-carbons (but not at the terminal co- 
carbon) (Miura & Fulco, 1975; Boddupalli et al., 1992; Schneider et al., 1998; 
Gustafsson et al., 2004; Lamb et al., 2010) as well as the hydroxylation and 
epoxidation o f arachidonic acid (C20:4) (Schneider et al., 1998; Lamb et al., 2010). 
The rate o f hydroxylation o f fatty acids by P450bm-3 is the highest amongst all 
cytochrome P450 enzymes (for example, the catalytic rate is greater than 15000mm'1 
when arachidonic acid is used as the substrate) (Noble et al., 1999; Girvan et al.,
2006) and the structure remains the most studied within the superfamily.
Other members o f the CYP102A subfamily have also been expressed and 
characterised. These include: CYP102A2 and CYP102A3 from B. subtilis 
(Gustafsson et al., 2004) and CYP102A7 from B. licheniformis (Dietrich et al.,
2008), which, like P450bm-3, are all cytochrome P450-reductase fusion proteins. 
CYP102A2 and CYP102A3 are both involved in the hydroxylation o f myristic acid 
(C l4:0) with CYP102A2 preferentially hydroxylating the co2- and co3-carbons and 
CYP102A3 the col-carbon (Gustafsson et al., 2004). The CYP102A7 protein can 
catalyse the hydroxylation of col-, oo2- (preferred) and co3-carbons o f a variety o f 
fatty acids, including straight-chained saturated (lauric acid (C l2:0) to palmitic acid 
(C l6:0)) and unsaturated (palmitoleic acid (C l6:1) and linoleic acid (C l8:2)) 
molecules as well as branched versions o f myrisitic acid (C l4:0) (12-methyl-myristic 
acid and 13-methyl-myristic acid) (Dietrich et al., 2008).
Interestingly, members o f the CYP102B subfamily can also hydroxylate fatty acids, 
but unlike the members o f CYP102A they are not fusion proteins and, therefore, 
require the addition o f redox partners for activity. CYP102B1 from Streptomyces 
coelicolor A3(2) is involved in catalysing the hydroxylation and epoxidation of 
arachidonic acid (C20:4) in the presence o f spinach ferredoxin and spinach 
ferredoxin reductase (Lamb et al., 2010). As with P450bm-3, CYP102A2 and 
CYP102A3, the physiological role o f this enzyme is unknown as the production o f a
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transposon mutant o f CYP102B1 did not result in any alterations in cell growth and 
the detectable metabolites produced (Lamb et al., 2010).
1.5.1.2 CYP105D5
CYP105D5 from S. coelicolor A3(2) is involved in the hydroxylation o f lauric acid 
(C l2:0) at the col-, co2-, co3- and compositions and oleic acid (C l8:1) at the col- 
carbon, however, no co-hydroxylation has been identified to date (Chun et al., 2007). 
Despite in vivo and in vitro experiments showing the role of CYP105D5 as a fatty 
acid hydroxylase, the physiological role o f this enzyme is unknown much like 
CYP102B from the same species (Chun et al., 2007).
1.5.1.3 CYP107H1
P450Bioi (CYP107H1) from B. subtilis is involved in fatty acid hydroxylation and C- 
C bond cleavage (Cryle et al., 2003). Fatty acids, including myrisitic acid (C l4:0) 
and palmitic acid (C16:0) are hydroxylated at either the co-, col-, co2-, co3-, co4- or co5- 
carbons and then subjected to chain-shortening through C-C bond cleavage, which is 
also catalysed by P450Bioi (Cryle et al., 2003). This results in the formation o f 
pimelic acid a diacid 7 carbons in length (figure 1.26) (Cryle et al., 2003). Pimelic 
acid can then be used in the synthesis o f biotin, a water-soluble vitamin B complex 
(Cryle et al., 2003). The specific cleavage o f the C-C bond at carbons 7 and 8 is 
thought to occur with the aid o f an acyl carrier protein (ACP) linked to a fatty acid as 
experiments using ACP from E. coli and P450BiOi have shown to produce pimelic 
acid (Cryle & Schlichting, 2008). The fatty acyl-ACP complex binds tightly to the 
P450Bioi causing the alkyl chain o f the fatty acid to form a U-shape, presenting the 7th 
and 8th carbons to the haem (Cryle & Schlichting, 2008). This, in turn, results in the 
cleavage of the hydrocarbon chain and the eventual formation o f pimelic acid (Cryle 
& Schlichting, 2008).
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Pimelic Acid
Fieure 1.26 -  Pimelic acid, a 7-carbon chain diacid, which is the product of fatty 
acid hydroxylation and C-C bond cleavage by P450br>I‘
1.5.1.4 CYP119
CYP119 is a novel thermophilic cytochrome P450, which is stable at 85°C and found 
in the hot-spring archaebacteria, Sulfolobus acidocaldarius (Koo et al., 2000; Lim et 
al., 2010). Although, the physiological function o f CYP119 is unknown, it has been 
shown to be capable o f the co-hydroxyl ation o f lauric acid (Cl 2:0) (Lim et al., 2010).
1.5.1.5 CYP124
CYP124 from Mycobacterium tuberculosis is active in the terminal hydroxylation o f 
methyl-branched fatty acids, including 15-methyl palmitic acid and phytanic acid 
(3,7,11,15-methyl palmitic acid) (figure 1.27), to produce the respective co-hydroxy 
fatty acids (Johnston et al., 2009). Due to the methyl groups being situated on the 
sub-terminal carbon in both branched fatty acids mentioned, no hydroxylation occurs 
at the col -position. However, when palmitic acid (Cl 6:0) is used as a substrate, 
CYP124 is involved in its hydroxylation at the co-, col- and co2-carbons (Johnston et 
al., 2009). The in vivo uses of co-hydroxy methyl-branched fatty acids in M. 
tuberculosis are undocumented, but they are thought to be utilised by the P-oxidation 
pathway (Johnston et al., 2009).
Other methyl-branched hydrocarbons, known as isoprenoids, can also be 
hydroxylated at the co-position to form the respective hydroxy version (Johnston et 
al., 2009). These substrates include: famesol, geranylgeraniol and famesyl 
diphosphate (figure 1.28), all o f which can be used by the isoprenoid biosynthetic 
pathway in M. tuberculosis (Johnston et al., 2009). This pathway is essential as it is 
involved in the production o f the cell wall (Brown et al., 2010).
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15-Methvl Palmitic Acid
Phvtanic Acid
Figure 1.27 -  The structures of 15-methyl palmitic acid and phytanic acid 
(3,7,11,15-methyl palmitic acid).
Famesol
Geranvlgeraniol
Famesvl Diphosphate
O \ O \ OH 
OH OH
Figure 1.28 -  Isoprenoids: farnesol, geranylgeraniol and farnesyl diphosphate.
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1.5.1.6 CYP152A1. CYP152A2 and CYP152B1
The CYP152 family of cytochromes P450 are involved in the a- and/or p- 
hydroxylation o f long-chain fatty acids. Hydroxylation occurs at the second (a) and 
third (p) carbons rather than at the terminal (to) and sub-terminal (con) carbons (figure 
1.29). Members of the CYP152 A subfamily are able to catalyse the hydroxylation of 
both a- and p-carbons to produce 2-hydroxy and 3-hydroxy fatty acids respectively 
(figure 1.30) (Lee et al., 2003; Girhard et al., 2007). However, P450bsp 
(CYP152A1) from B. subtilis is considered a p-hydroxylase as it preferentially 
hydroxylates at the P-carbon (Lee et al., 2003), whereas CYP152A2 is thought o f as 
an a-hydroxylase (Girhard et al., 2007). P450spa (CYP152B1) from Sphingomonas 
paucimobilis is also an a-hydroxylase, however, it does not catalyse P-hydroxylation 
(Lee et al., 2003). The 2-hydroxy and 3-hydroxy fatty acids produced by these 
enzymes are important in the production o f membrane lipids, including 
sphingolipids. S. paucimobilis is a rich source o f 2-hydroxy myristic acid-containing 
sphingolipids, which is the product o f myrisitic acid (C l4:0) hydroxylation by 
P450Sp« (Matsunaga et al., 1997; Imai et al., 2000).
Figure 1.29 -  Position of the a- and p- carbons of a fatty acid chain highlighted 
on myristic acid (C14:0) as an example. The carbon that makes up the carboxyl 
group is numbered 1. The adjacent carbon (2) is the a-carbon and the third carbon in 
the chain is the P-carbon. These carbons are hydroxylated by members o f the 
CYP152 family o f cytochromes P450.
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2-Hvdroxv Fatty Acid
3-Hvdroxv Fattv Acid
Figure 1.30 -  Structural examples of 2-hydroxy and 3-hydroxy fatty acids, the 
respective products of a- and p-hydroxylation.
CYP152 enzymes are peroxygenases rather than monooxygenases (Imai et al., 2000; 
Lee et al., 2003; Girhard et al., 2007). Therefore, instead o f an oxygen atom from 
atmospheric oxygen being incorporated into the fatty acid, the oxygen atom comes 
from hydrogen peroxide (Imai et al., 2000; Lee et al., 2003; Girhard et al., 2007). 
The use o f hydrogen peroxide in this manner fits with the hypothesis that one o f the 
functions o f CYP152 in vivo is as a rapid hydrogen peroxide scavenging enzyme 
(Girhard et al., 2007).
1.5,1.7 CYP153A6
CYP153 from Eubacteria are capable o f metabolising alkanes o f a variety o f chain 
lengths (C6:0 to C16:0) (Funhoff et al., 2007). For instance, CYP153A6 from 
Mycobacterium sp. HXN-1500 has been shown to hydroxylate a range o f short-chain 
alkanes from hexane (C6:0) to undecane (Cl 1:0) at the terminal carbon producing 
the co-hydroxy alcohol (Funhoff et al., 2006). This hydrocarbon, in turn, can be 
further metabolised as alcohol dehydrogenase and aldehyde dehydrogenase convert 
the alcohol to its respective aldehyde and fatty acid (Wentzel et al., 2007). The fatty 
acid can then be subjected to p-oxidation and used for growth (Wentzel et al., 2007). 
Interestingly, unlike the CYP52 family, no CYP153 enzymes to date have been 
shown to metabolise the alcohol further.
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1.5.2 Fatty Acid Hvdroxvlating Cytochromes P450 from Plants
Unlike the fatty acid hydroxylating cytochromes P450 from yeast/fungi and bacteria, 
the physiological roles o f many o f these enzymes in plants have been identified. 
They have been shown to be implicated in evoking defence mechanisms within the 
plant, reproduction function and in the synthesis o f cutin and suberin (Pinot & 
Beisson, 2011). Cutin and suberin are lipid polymers, which are found in the 
hydrophobic regions of the cell walls in plants (Pollard et al., 2008). Cutin is 
primarily found in the water-repellent protective layer o f the epidermis known as the 
cuticle, whereas suberin is found in the roots and plays a role in ion uptake and water 
control (Pollard et al., 2008). They mostly consist o f hydroxy fatty acids, 
functionalised fatty acids (e.g. epoxides) and diacids linked by ester bonds (Pollard et 
a l , 2008).
To date 19 fatty acid hydroxylating cytochromes P450 from 11 families have been 
expressed at the protein level and characterised (see table 1.3). These enzymes are 
discussed below.
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1.5.2.1 CYP76B9
CYP76B9 from Petunia hybrida is involved in the ©-hydroxylation o f capric acid 
(C l0:0) and lauric acid (C l2:0) (Imaishi & Petkova-Andonova, 2007). The 
physiological function of the resultant ©-hydroxy products are unclear, but they are 
thought to play a role in growth regulation as treatment o f the roots o f Arabidopsis 
thaliana with these products results in inhibited growth and elongation (Imaishi & 
Petkova-Andonova, 2007). However, treatment with lauric acid (C l2:0) and capric 
acid (C l0:0) did not have any effect (Imaishi & Petkova-Andonova, 2007). The 
response of the root to the ©-hydroxy products may suggest the hydroxylation of 
these fatty acids signals a shift from growth to defence in the plant.
1.5.2.2 CYP77A4 and CYP77A6
CYP77A4 and CYP77A6 from A. thaliana are the only members o f the CYP77A 
subfamily to be characterised to date (Li-Beisson et al., 2009; Sauveplane et al., 
2009). Both o f these enzymes have been shown to be involved in the in-chain 
hydroxylation o f long-chain fatty acids, including lauric acid (C l2:0) and palmitic 
acid (C l6:0) (and its hydroxy alternative) (Li-Beisson et al., 2009; Sauveplane et al.,
2009). However, only CYP77A4 has been shown to catalyse the epoxidation o f the 
unsaturated C l8 fatty acids: oleic acid (C l8:1), linoleic acid (C l8:2) and linolenic 
acid (C l8:3) (Sauveplane et al., 2009). The products formed by both o f these 
enzymes are thought to be involved in the formation o f cutin (Pollard et al., 2008; Li- 
Beisson et al., 2009; Sauveplane et al., 2009; Pinot & Beisson, 2011).
Upon incubation with oleic acid (C l8:1), CYP77A4 has been shown to catalyse the 
formation of 9,10-epoxystearic acid (see figure 1.31) (Sauveplane et al., 2009). This 
epoxide is thought to play a role in the defence mechanisms within the plant as the 
epoxide versions o f linoleic acid (C l8:3) have been implicated in the resistance of 
rice plants to rice blast disease (Kato et al., 1993). 9,10-epoxystearic acid can also 
be further converted to 18-hydroxy-9,10-epoxy stearic acid in the presence of an ©- 
hydroxylase for use in cutin synthesis (see figure 1.31) (Sauveplane et al., 2009). 
Alternatively, it can be converted to 9,10-dihydroxystearic acid by an epoxide 
hydrolase, which in turn can be hydroxylated at the terminal carbon to form 9,10,18- 
trihydroxystearic acid (Sauveplane et al., 2009). This product is thought to evoke the 
defence mechanism of the plant (see figure 1.31) (Sauveplane et al., 2009).
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CYP77A6 plays a role in the pathway converting palmitic acid (C l6:0) to 
dihydroxypalmitic acid, which can then be linked to other molecules via ester bonds 
to form cutin (see figure 1.32) (Li-Beisson et al., 2009; Pollard et al., 2008). The 
initial terminal hydroxylation of palmitic acid to 16-hydroxypalmitic acid is 
catalysed by another cytochrome P450, CYP86A4 (Li-Beisson et al., 2009). The
tViproduct o f this conversion is further hydroxylated at the 10 (co6-) carbon by 
CYP77A6 to form 10,16-hydroxypalmitic acid, which can then be used in cutin 
formation (see figure 1.32) (Li-Beisson et al., 2009).
O
Palmitic Acid
OH
CYP86A4
HO
OH
16-Hydroxypalmitic Acid
CYP77A6
HO
OH
OH
10,16-Hydroxypalmitic Acid
Figure 1,32 -  Overview of the enzymes involved in the conversion of palmitic 
acid (C16:0) to dihydroxypalmitic acid for use in cutin synthesis.
1.5.2.3 CYP78A1
CYP78A1 from Zea mays (maize/com) has been shown to hydroxylate lauric acid 
(C12:0) at the terminal carbon to produce the co-hydroxy version (Imaishi et al., 
2000; Imaishi & Ohkawa, 2002). The enzyme has been implicated in flower 
development and reproduction as it has been shown to be expressed in vivo during 
the initial phase o f maize tassel formation (Imaishi et al., 2000). The maize tassel is 
found at the top o f the stem in male flowers and upon maturation pollen is released 
from its anthers and dispersed by the wind to produce more maize crops.
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1.5.2.4 CYP81B1
CYP81B1 is a fatty acid hydroxylase found in the tuber (nutrient store) o f Helianthus 
tuberosus and is involved in the in-chain (col- to co5-) hydroxylation o f capric acid 
(C10:0), lauric acid (C12:0) and myrisitic acid (C14:0) (Cabello-Hurtado et al., 
1998). Although, the physiological function of this enzyme has yet to be elucidated, 
it may be involved in the initiation of defence mechanisms and/or cutin synthesis like 
CYP77A4 and CYP77A6 from A. thaliana, which have similar functions.
1.5.2.5 CYP86A1. CYP86A4. CYP86A8 and CYP86A22
Four CYP86 enzymes have been characterised and they are CYP86A1, CYP86A4 
and CYP86A8 from A. thaliana and CYP86A22 from Petunia hybrida (Benveniste 
et al., 1998; Wellesen et al., 2001; Li-Beisson et al., 2009; Han et al., 2010). The 
enzymes from A. thaliana are involved in the terminal (co) hydroxylation of a range 
of fatty acids including the saturated fatty acids: lauric acid (C l2:0), myrisitic acid 
(C l4:0) and palmitic acid (C l6:0) and the unsaturated fatty acids: oleic acid (C l8:1) 
and linoleic acid (C l8:2) (Benveniste et al., 1998; Wellesen et al., 2001; Li-Beisson 
et al., 2009; Han et al., 2010). Originally these three enzymes were thought to have 
a putative role in cutin synthesis (Benveniste et al., 1998; Wellesen et al., 2001; Li- 
Beisson et al., 2009; Han et al., 2010). However, CYP86A1 has been shown to be 
essential in the synthesis o f suberin (Hofer et al., 2008). It has been found localised 
in the roots o f A. thaliana where suberin accumulates and in CYP86A1 knockout 
strains the concentration o f this biopolymer is reduced by 60% indicating the 
importance o f CYP86A1 in suberin synthesis (Hofer et al., 2008).
Unlike the other CYP86 enzymes mentioned above, CYP86A22 is involved in the co- 
hydroxylation o f oleic acid (Cl 8:1), C l 6:0 fatty acyl-CoA, C l 8:0 fatty acyl-CoA and 
C l8:1 fatty acyl-CoA, but not palmitic acid (C l6:0) and stearic acid (C l8:0) (Han et 
al., 2010). Interestingly, CYP86A22 is the only cytochrome P450 so far to be shown 
to hydroxylate fatty acyl-CoAs (Han et al., 2010). The oo-hydroxy fatty acyl-CoAs 
formed by CYP86A22 have been identified in the stigma o f P. hybrida, therefore 
implicating a role for CYP86A22 in the synthesis o f estolide (a lipid polyester) in the 
stigma o f the plant (Han et al., 2010).
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1.5.2.6 CYP92B1
CYP92B1 from Petunia hybrida is involved in the co-hydroxylation o f lauric acid 
(C l2:0) to form 12-hydroxylauric acid (Petkova-Andonova et al., 2002). Although, 
the physiological function o f CYP92B1 in this plant is unknown, this enzyme does 
possess a similar function to CYP78A1 from Zea mays, which has been implicated in 
flower development (Imaishi et al., 2000). In metabolism studies, CYP92B1 was 
also shown to be able to metabolise linoleic acid (C l8:2) and linolenic acid (C l8:3) 
(Petkova-Andonova et al., 2002). However, the products o f these conversions are 
unknown as they were not produced at a high enough concentration to be detected on 
a GCMS trace, although, they were detectable on a TLC (thin layer chromatography) 
plate (Petkova-Andonova et al., 2002). Comparing the metabolites produced to ©- 
hydroxylinoleic acid and co-hydroxylinolenic acid standards showed that CYP92B1 
is not responsible for the co-hydroxylation o f linoleic acid (Cl 8:2) and linolenic acid 
(C l8:3) (Petkova-Andonova et al., 2002). This suggests that CYP92B1 may be 
involved in the epoxidation or in-chain hydroxylation o f these hydrocarbons.
1.5.2.7 CYP94A1. CYP94A2. CYP94A5 and CYP94C1
Four members o f the CYP94 family have been expressed and characterised to date. 
They are CYP94A1 and CYP94A2 from Vicia sativa (Tijet et al., 1998; Kahn et al., 
2001), CYP94A5 from Nicotiana tabacum (tobacco) (Le Bouquin et al., 2001) and 
CYP94C1 from A. thaliana (Kandel et al., 2007). Each o f these enzymes is thought 
to be involved in the synthesis o f cutin (and suberin) and eliciting defence 
mechanisms, but the substrate specificity and pattern o f regioselectivity for each is 
different (Tijet et al., 1998; Kahn et al., 2001; Le Bouquin et al., 2001; Kandel et al., 
2007).
CYP94A1 is involved in the co-hydroxylation o f a broad variety o f fatty acids, 
including the saturated fatty acids ranging from capric acid (C l0:0) to palmitic acid 
(C l6:0) and the unsaturated fatty acids: oleic acid (C l8:1), linoleic acid (C l8:2) and 
linolenic acid (C l8:3) (Tijet et al., 1998). However, CYP94A2, which shares a 76% 
amino acid similarity to CYP94A1, only hydroxylates lauric acid (C12:0), myristic 
acid (C l4:0) and palmitic acid (C l6:0) at the terminal and/or in-chain carbons (Kahn 
et al., 2001). Interestingly, the pattern o f regioselectivity differs dependent on the 
chain-length o f the fatty acid (Kahn et al., 2001). Myristic acid (C l4:0 -  the
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preferred substrate) is hydroxylated at the go- and col-carbons, whereas lauric acid 
(C l2:0) is only hydroxylated at the co-carbon and palmitic acid (C l6:0) at the col­
and co2-carbons (Kahn et al., 2001).
CYP94A5 and CYP94C1, like CYP52A3 and CYP52A4 from C. maltosa and 
CYP52A13 and CYP52A17 from C. tropicalis, not only hydroxylate fatty acids to 
produce the respective alcohol, but can also convert the hydrocarbon further to 
produce diacids (which are major components o f suberin) (Le Bouquin et al., 2001; 
Kandel et al., 2007; Pollard et al., 2008). CYP94A5 initially converts 9,10- 
epoxystearic acid to the co-alcohol, 18-hydroxy-9,10-epoxystearic acid, then further 
catalyses it to the respective diacid (Le Bouquin et al., 2001). This enzyme can also 
hydroxylate a variety o f other fatty acids at the terminal carbon to produce the co­
alcohol (Le Bouquin et al., 2001). These fatty acids are lauric acid (C12:0), myristic 
acid (C l4:0), palmitic acid (C l6:0), oleic acid (C l8:1), linoleic acid (C l8:2) and 
linolenic acid (C l8:3) (Le Bouquin et al., 2001). CYP94C1 has been shown to 
convert lauric acid (C l2:0) to its respective diacid, dodecanedioic acid (Kandel et al., 
2007).
1.5.2.8 CYP703A2
CYP703A2 is an in-chain hydroxylase from A. thaliana, which has been shown to 
monohydroxylate capric acid (C l0:0) (at the 6th (co4-), 7th (co3-) or 8th (oo2-) carbon), 
lauric acid (C l2:0) (at the 6th (co6-), 7th(a>5-), 8th (co4-) or 9th (co3-) carbons), myristic 
acid (C l4:0) (at the 6th (oo8-), 7th (oo7-) or 8th (co6-) carbon) and palmitic acid (C l6:0) 
(potentially at the 6th (colO-), 7th (oo9-) or 8th (co8-) carbon) (Morant et al., 2007). It
thpreferentially hydroxylates lauric acid (C l2:0) at the 7 (co5-) carbon and its product 
(7-hydroxylauric acid) has physiological implications for the plant. 7-hydroxylauric 
acid is essential in the synthesis o f sporopollenin, which is found in the exine layer 
(tough outer walls) o f pollen and spores (Edlund et al., 2004; Morant et al., 2007). 
This layer plays an important role in pollination and protection (from pathogens and 
dehydration) (Edlund et al., 2004; Morant et al., 2007). A CYP703A2 knockout of 
A. thaliana was shown to have impaired development o f pollen, thus further 
confirming the role o f this enzyme in sporollenin synthesis (Morant et al., 2007).
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1.5.2.9 CYP704B1 and CYP704B2
As with CYP703A2, CYP704B1 from A. thaliana and CYP704B2 from Oryza sativa 
(rice) are involved in sporopollenin synthesis (Pinot & Beisson, 2011). However, 
unlike CYP703A2, CYP704B1 and CYP704B2 catalyse the terminal (©-) 
hydroxylation o f fatty acids rather than in-chain hydroxylation (Dobritsa et al., 2009; 
Li et al., 2010). These enzymes have been shown to produce the co-hydroxy versions 
o f palmitic acid (C l6:0), oleic acid (C l8:1) and linoleic acid (C l8:2) and linolenic 
acid (Cl 8:3) (Dobritsa et al., 2009; Li et al., 2010).
1.5.2.10 CYP709C1
CYP709C1 from Triticum aestivum (bread wheat) is active in the sub-terminal/in­
chain hydroxylation o f fatty acids (Kandel et al., 2005). It has been shown to 
metabolise a variety of fatty acids, including lauric acid (C l2:0), myristic acid 
(C14:0), palmitic acid (C16:0) and stearic acid (C l8:0) (Kandel et al., 2005). 
However, CYP709C1 preferentially hydroxylates 9,10-epoxystearic acid at the ool- 
and co2- carbons (Kandel et al., 2005). The product o f this metabolism, 17-hydroxy- 
9 ,10-epoxystearic acid, can be further hydrolysed by epoxide hydrolase to produce 
9,10,17-trihydroxystearic acid, which is involved in evoking defence mechanisms 
within the plant (see figure 1.33) (Pinot & Beisson, 2011).
1.5.2.11 CYP726A1
CYP726A1, found in the seeds o f Euphorbia lagascae, is involved in the epoxidation 
o f linoleic acid (Cl 8:2) and linolenic acid (Cl 8:3) at the double bond between the 12 
and 13 carbons (Cahoon et al., 2002). This results in the production o f vemolic acid 
(12,13-epoxyoctadeca-cis-9-enoic acid) (figure 1.34), which is a major component o f 
seed oils (Cahoon et al., 2002).
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9,10-Epoxystearic Acid
CYP709C1
17-Hydroxy-9,10-epoxystearic Acid
Epoxide Hydrolase
9,10,17-Trihydroxystearic Acid
Figure 1.33 - Overview of the enzymes involved in the conversion of 9,10- 
epoxystearic acid to 9,10,17-trihydroxystearic acid.
OH
Figure 1.34 -  Vernolic acid (12,13-epoxyoctadeca-cis-9-enoic acid), the major 
component of seed oils.
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1.5.3 Fatty Acid Hydroxylating Cytochromes P450 from Animals
Fatty acid hydroxylating cytochromes P450 have been identified in a number of 
animals including mammals, insects and amphibians (Miura, 1981; Simpson, 1997). 
However, many mammalian fatty acid hydroxylation cytochromes P450 have been 
shown to be active at the protein level and the physiological roles o f many o f these 
enzymes have been documented. Therefore, mammalian enzymes will be discussed 
in this section.
A build up o f fatty acids in the organs and tissues o f mammals with uncontrolled 
diabetes, chronic alcohol abuse or who have been on a starvation diet can be toxic. 
Therefore these hydrocarbons need to be converted to diacids for quick elimination 
through p-oxidation (Dhar et al., 2008; Fer et al., 2008). The initial step in this 
pathway, as with CYP52 enzymes, is the conversion o f the fatty acid to its relative 
alcohol, which is catalyzed by enzymes belonging to the CYP4 family. Members of 
this family are not solely involved in the hydroxylation o f fatty acids, but can also 
play a role in the epoxidation o f unsaturated fatty acids, such as arachidonic acid 
(C20:4).
Table 1.4 shows the mammalian fatty acid hydroxylating cytochromes P450 that 
have been expressed at the protein level and characterised. These enzymes are 
discussed below.
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1.5.3.1 CYP1A1
CYP1A1 has been identified in the lungs, placenta and brain o f humans and rats 
(Schwarz et al., 2004). In both animals, it has been shown to be an arachidonic acid 
(C20:4) hydroxylase, however, regioselectivity differences have been identified 
between the two copies (Schwarz et al., 2004). In rats, CYP1A1 preferentially 
hydroxylases arachidonic acid (C20:4) at the terminal position to produce 20- 
hydroxyeicosatetraenoic acid (HETE), whereas, in humans, CYP1A1 is involved in 
the sub-terminal hydroxylation o f arachidonic acid (C20:4) to produce 19-HETE (see 
figure 1.35) (Schwarz et al., 2004). The human CYP1A1 has also been shown to act 
as an epoxygenase when incubated with eicosapentaenoic acid (C20:5 - EPA) (see 
figure 1.36) (Schwarz et al., 2004). This reaction results in the formation of 17,18- 
epoxyeicosatetraenoic acid, which is thought to act as a vasodilator by stimulating 
calcium-activated potassium channels (Schwarz et al., 2004).
Arachidonic Acid
Terminal (co-) Hydroxylation Sub-terminal (col-) Hydroxylation
20-HETE 19-HETE
Figure 1.35 -  20-Hydroxyeicosatetraenoic acid (HETE) and 19-HETE, the 
products of terminal and sub-terminal hydroxylation of arachidonic acid 
(C20:4).
Eicosapentaenoic Acid (EPA)
Figure 1.36 -  Eicosapentaenoic acid (EPA).
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1.5.3.2 CYP2E1
CYP2E1 is a sub-terminal fatty acid hydroxylating cytochrome P450 that has been 
identified in the liver o f both rabbits and humans (Fukuda et al., 1994; Amet et al.,
1995). It is induced by ethanol and has been shown to be expressed at high levels in 
the liver following alcohol ingestion (in both acute and chronic alcoholics) and 
fasting, as well as in the livers o f diabetic patients (Amet et al., 1995). Unlike 
members o f the CYP4 family, CYP2E1 has been shown to be predominantly 
involved in the sub-terminal (col-) hydroxylation o f fatty acids, ranging from 
pelargonic acid (C9:0) to tridecylic acid (C l3:0) and in particular lauric acid (C l2:0) 
(Fukuda et al., 1994; Amet et al., 1995). Although, the physiological use of 11- 
hydroxylauric acid is unknown, CYP2E1 is thought to be the only human liver 
cytochrome P450 to be involved in the formation o f this hydrocarbon and is 
potentially involved in causing alcoholic liver disease (Morimoto et al., 1993; Amet 
et al., 1995).
1.5.3.3 CYP4A1-3. CYP4A6-7 and CYP4A11
The CYP4A subfamily o f cytochromes P450 have been shown to be involved in the 
terminal and, to a lesser extent, sub-terminal hydroxylation o f fatty acids, including 
lauric acid (C l2:0) and palmitic acid (C l6:0), and both the terminal hydroxylation 
and epoxidation o f arachidonic acid (C20:4) (Wang et al., 1996). The terminal 
hydroxylation of arachidonic acid (C20:4) results in the formation o f 20-HETE, 
which is a potent vasoconstrictor and has been implicated in (genetic) high blood 
pressure in rats (Lasker et al., 2000). However, the product o f arachidonic acid 
(C20:4) epoxidation, ll,12-epoxy-5,8,14-eicosatrienoic acid (11,12-EET) (figure
1.37) is not a vasoconstrictor, but rather a potent vasodilator and is implicated in 
reducing blood pressure (Lasker et al., 2000). Although, this product is produced at 
much lower levels than 20-HETE by the CYP4A subfamily, it does suggest a role for 
these enzymes in the regulation o f blood pressure in mammals.
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11.12-Epoxv-5.8.14-eicosatrienoic Acid (11.12-EET)
O
OH
Fi2ure 1.37 -  ll,12-Epoxy-5,8,14-eicosatrienoic acid (11,12-EET), formed 
following the epoxidation of arachidonic acid (C20:4).
Members of the CYP4A subfamily include: CYP4A1 (rat liver and kidney 
(Chaurasia et al., 1995; Wang et al., 1996)), CYP4A2 (rat kidney (Wang et al., 
1996)), CYP4A3 (rat kidney (Wang et al., 1996; Lasker et al., 2000)), CYP4A6 
(rabbit kidney and liver (Lasker et al., 2000)), CYP4A7 (rabbit kidney, liver and 
small intestine) (Lasker et al., 2000)) and CYP4A11 (human kidney (Wang et al.,
1996)).
1.5.3.4 CYP4B1
CYP4B1 from rabbit lung was initially considered a xenobiotic metabolising enzyme 
as it has been shown to be involved in the bioactivation o f a number o f compounds 
including valproic acid (an anti-convulsant drug) (figure 1.38) (Fisher et al., 1998; 
Kikuta et al., 1999). Valproic acid is a branched, 7-carbon chain fatty acid, with the 
carboxylate moiety situated at the centre o f the alkyl chain (Fisher et al., 1998). As 
this hydrocarbon is considered an isomer of caprylic acid (C8:0), a range o f fatty 
acids were used in experiments with CYP4B1 to elucidate whether this enzyme 
could also metabolise these substrates. It was shown that CYP4B1 is involved in the 
co-hydroxylation o f caprylic acid (C8:0 -  preferred substrate), pelargonic acid (C9:0), 
capric acid (C l0:0) and enanthic acid (C7:0) (Fisher et al., 1998). It was also shown 
to be involved in the co-hydroxylation o f alkanes, such as heptane (C7:0), octane 
(C8:0), nonane (C9:0) and decane (C l0:0) (Fisher et al., 1998). The physiological 
roles of the co-alcohols produced from fatty acids and alkanes by CYP4B1 are 
undocumented, however, this enzyme differs from the other known mammalian co- 
hydroxylating cytochrome P450 families, CYP4A and CYP4F as it is involved in the 
metabolism of drugs, alkanes and short-chain fatty acids rather than solely the co- 
hydroxylation o f medium- to long-chain fatty acids, such as lauric acid (C12:0).
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oHO
Figure 1.38 -  Valproic acid, a branched, 7-carbon chain fatty acid, with the 
carboxylate moiety situated at the centre of the alkyl chain.
1.5.3.5 CYP4F1. CYP4F3B. and CYP4F11
As with the CYP4A subfamily, the CYP4F subfamily o f enzymes is involved in the 
hydroxylation of fatty acids. However, the enzymes belonging to this subfamily are 
also involved in the metabolism of xenobiotics and catalyse the hydroxylation of 
eicosanoids, thus regulating their concentration during inflammation (Kalsotra & 
Strobel, 2006). Discussed below are those enzymes belonging to the CYP4F family 
that catalyse the hydroxylation o f fatty acids.
CYP4F1 from human liver and kidneys, CYP4F3B from human kidneys and 
CYP4F11 from human liver have all been shown to be involved in the terminal (co-) 
hydroxylation o f arachidonic acid (C20:4) to form the vasoconstrictor 20-HETE 
(Lasker et al., 2000; Harmon et al., 2006; Tang et al., 2010). Interestingly, 
CYP4F3B is also able to hydroxylate the co-3 fatty acids, EPA (C20:5) and 
docosahexaenoic acid (DHA) (C22:6), which are important dietary supplements 
(Harmon et al., 2006). These hydrocarbons elicit an antihypertensive effect by 
inhibiting the formation o f 20-HETE by CYP4F3B (Harmon et al., 2006). Although, 
arachidonic acid (C20:4) is the preferred substrate o f CYP4F3B at high 
concentrations EPA (C20:5) and DHA (C22:6) are able to prevent arachidonic acid 
(C20:4) from binding to the enzyme, thus inhibiting the formation o f 20-HETE 
(Harmon et al., 2006). This in turn leads to the production of 20-hydroxyEPA and 
22-hydroxyDHA, which elicit a vasodilatory effect (Harmon et al., 2006).
CYP4F11 has also been shown to be involved in the co-hydroxylation o f a number of 
other fatty acids, including palmitic acid (C l6:0), oleic acid (C l8:1), linoleic acid 
(C l8:2), DHA (C22:6) and 3-hydroxy palmitic acid (Tang et al., 2010). At present,
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it is unclear whether these hydrocarbons are the main substrates o f this enzyme as the 
effect o f CYP4A11 towards other substrates has yet to be documented (Tang et al., 
2010).
1.5.3.6 CYP4V2
CYP4V2, found in the human eye, is involved in the terminal hydroxylation of lauric 
acid (C12:0), myristic acid (C14:0) and palmitic acid (C16:0) (Nakano et al., 2009). 
Although, the physiological role for the alcohol formed in the eye is undocumented, 
mutations within the enzyme, which lead to impaired terminal hydroxylation of fatty 
acids have been implicated in the progressive eye disease, Bietti’s comeoretinal 
crystalline dystrophy (BCD) (Li et al., 2004; Wada et al., 2005; Nakamura et al., 
2006; Nakano et al., 2009). BCD is a rare eye disorder, which causes narrowing o f 
the visual field, atrophy o f the epithelial cells within the retina and night blindness 
(Nakano et al., 2009). The implication that CYP4V2 mutations are involved in this 
disease, suggest that CYP4V2 is required for maintaining healthy eyes.
1.6 Aims of this Thesis
As shown in this chapter, cytochrome P450 enzymes play an important role in the 
hydroxylation o f alkanes and/or fatty acids. However, the specific physiological 
roles o f the products produced are not well documented despite fatty acids playing 
known roles in signalling, cell growth and the formation o f structural lipids, such as 
phospholipids. The fatty acid derivatives produced have been shown to have roles as 
platform chemicals in biotechnology (i.e. diacids and surfactants) as chemical 
synthesis of the same compounds is limited and expensive and further products of 
value in health care are possible.
CYP52 enzymes from yeast and fungi are o f particular interest as o f the 52 members 
o f the family identified to date only 8 have been shown to be studied at the protein 
level. To understand the physiological role this family o f enzymes play in yeast and 
fungi and their uses in biotechnology, the enzymatic activity o f each protein needs to 
be thoroughly understood. To address this issue in C. albicans the objectives o f this 
thesis are:
• To determine the ability o f C. albicans to produce diacids.
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To identify the cytochrome P450 genes in C. albicans and the candidate gene 
with the greatest homology to the archetypal alkane-hydroxylating P450 
gene, CYP52A3 from C. maltosa using a bioinformatic approach.
To express the candidate cytochrome P450 in its native and soluble forms as 
well as CYP52A3 as a control using E. coli and yeast as the host organisms. 
To identify potential substrates and inhibitors o f the candidate cytochrome 
P450 using a spectrophotomer to detect spectral changes, 
o Potential substrates to be used include:
■ Long-chain alkanes
■ Long-chain fatty acids
■ Sterols
o Potential inhibitors to be used include:
■ Azole antifungal drugs
To establish the enzymatic activity o f the candidate cytochrome P450 (and 
CYP52A3) in vitro and in vivo by GCMS.
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Chapter 2: Materials and Methods
2.1 Materials
2.1.1 Chemicals
All chemicals and solvents were purchased from Fisher Scientific, unless otherwise 
stated. Isopropyl-p-D-thio-galactoside (IPTG), 5-aminolevulinic acid hydrochloride 
(Ala) and growth media were purchased from Formedium.
All restriction enzymes and restriction enzyme buffers were purchased from 
Promega.
All fatty acids and hexadecane were purchased from Sigma-Aldrich with purities o f 
98% or above. All sterols were synthesised and purified by Prof. David Nes (Texas 
Tech University), except cholesterol, which was purchased from Sigma-Aldrich. All 
azole antifungal agents were purchased from Sigma-Aldrich, except voriconazole, 
which was purchased from Discovery Fine Chemicals.
2.1.2 Candida Strains
Candida albicans SC5314 and C. maltosa IAM12247 were purchased from LGC 
Promochem (in partnership with the American Type Culture Collection (ATCC)).
2.1.3 Media
2.1.3.1 YEPD Media
Broth was made from 1% (w/v) yeast extract, 2% (w/v) peptone and 2% (w/v) 
glucose and was used to culture yeast cells overnight. 2% agar (w/v) was added to 
make agar plates to grow yeast colonies on.
2.1.3.2 YM Media
Yeast minimal media was made from 0.67% (w/v) yeast nitrogen base (without 
amino acids) and 1% (w/v) glucose.
2.1.3.3 Luria-Bertani fLB) Media
E. coli cells were grown overnight in broth made from 1% (w/v) bacto tryptone, 
0.5% (w/v) yeast extract and 1% (w/v) sodium chloride. Colonies were grown on
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plates made of the same media plus 2% (w/v) agar. Selection was made by adding 
1 OOpg/ml ampicillin to the media.
In blue/white selection experiments for identifying DNA insertion into plasmids, 
colonies were grown on LB agar plates containing lOOpg/ml ampicillin, 0.5mM 
IPTG and 80pg/ml 5-bromo-4-chloro-3-indolyl-p-D-galactoside (X-gal).
2.1.4 Buffers
2.1.4.1 50x TAE Buffer
242g of Tris base (Melford), 57.1ml o f glacial acetic acid and 100ml o f 0.5M EDTA 
(Sigma-Aldrich) pH8.0 was made up to 1L with distilled water. Stored at room 
temperature.
2.1.4.2 lx  TAE Buffer
20ml of 50x TAE was made up to 1L with distilled water. Stored at room 
temperature.
2.1.4.3 DNA Loading Dye (lOx Concentrate)
25mg bromophenol blue (Sigma-Aldrich) and 3g glycerol were added to 10ml 
distilled water and mixed.
2.1.4.4 Resolving Buffer (5x Concentrate)
1.88M Tris-HCl (Melford) pH8.8 dissolved in distilled water. Stored at 4°C.
2.1.4.5 Stacking Buffer (lOx Concentrate)
0.6M Tris-HCl (Melford) pH6.8 dissolved in distilled water. Stored at 4°C.
2.1.4.6 Stock Acrvlamide Solution
30% (w/v) acrylamide (Amersham) and 0.2% (w/v) N ’N ’-bis-methylene-acrylamide 
(Amersham) dissolved in distilled water. Stored at 4°C.
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2.1.4.7 Super Cracking Sample Buffer
10% (w/v) SDS (Melford), 5% (v/v) p-mercaptorthanol (Sigma-Aldrich), 120mM 
Tris-HCl (Melford) pH6.8, 20% (v/v) glycerol and bromophenol blue (a trace) 
(Sigma-Aldrich) were dissolved in distilled water. Stored at -20°C.
2.1.4.8 Resolving Gel
3.7ml o f the stock acrylamide solution, 2ml o f the resolving buffer (5x concentrate) 
and 0.2 ml o f 10% (w/v) SDS (Melford) were thoroughly mixed together and made 
up to a final volume of 10ml with distilled water. lOpl of TEMED (N,N,N’,N’,- 
tetramethylethylene diamine) (Sigma-Aldrich) and lOOpl o f APS (10% (w/v) 
ammonium persulphate) were then added to the mix.
2.1.4.9 Stacking Gel
lm l o f the stock acrylamide solution, 0.6ml o f the stacking buffer (lOx concentrate) 
and 0.12ml of 10% SDS (Melford) were added to 4.28ml of distilled water. lOpl of 
TEMED (Sigma-Aldrich) and lOOpl of APS were then added.
2.1.4.10 Protein Marker
Molecular weight 29,000-205,000 marker for SDS-PAGE (Sigma-Aldrich).
2.1.4.11 Electrode Tank Buffer (lOx Concentrate)
0.25M Tris Base (Melford) and 1.92M glycine dissolved in distilled water. Stored at 
room temperature.
2.1.4.12 Upper Tank Buffer
0.1% (w/v) SDS (Melford) was added to lx  electrode tank buffer. Stored at room 
temperature.
2.1.4.13 Lower Tank Buffer
0.5x electrode tank buffer diluted in distilled water. Stored at room temperature.
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2.1.4.14 Coomassie Blue Stain
1.25L methanol, 175ml glacial acetic acid and 6.25g coomassie brilliant blue R250 
were made up to a final volume of 2.5L with distilled water. Solution was filtered 
through Watman No. 1 filter paper. Stored at room temperature.
2.1.4.15 Coomassie Destain
30% (v/v) methanol or 30% (v/v) ethanol dissolved in distilled water. Store at room 
temperature.
2.2 Methods
2.2.1 Preparation of Competent E. coli Cells
Competent E. coli cells were made up for use in the laboratory by Ms Nicky Rolley 
based on the method in Sambrook et al., 2001.
DH5a and XL-1 E. coli cells were grown up overnight in 10ml o f LB at 37°C and 
200rpm. To the XL-1 cells 5mg/ml of tetracycline was also added.
lm l of the overnight culture was used to inoculate 100ml o f fresh LB. This culture 
was grown at 37°C, 200rpm until growth had reached an OD650 o f 0.5. The culture 
was then incubated on ice for 10 minutes. The culture was centrifuged at 3000g at 
40°C for 10 minutes. The supernatant was discarded and the pellet was resuspended 
in 20ml o f ice cold CM1 (lOmM sodium acetate (Sigma-Aldrich), 50mM manganese 
chloride and 5mM sodium chloride). This suspension was incubated on ice for 20 
minutes and then centrifuged at 3000g for 5 minutes at 4°C. The supernatant was 
discarded and the pellet was resuspended in 2ml o f CM2 (lOmM sodium acetate 
(Sigma-Aldrich), 70mM calcium chloride, 5mM manganese chloride and 5% (v/v) 
glycerol). The suspension was aliquoted into 50pl volumes and stored at -80°C.
2.2.2 Isolation of Genomic DNA from Yeast
Genomic DNA was extracted using a method based on the protocol printed in 
Sambrook et al., 2001.
10ml of overnight YEPD culture inoculated from a single colony C. albicans 
SC5314 or C. maltosa IAM12247 colony, lm l was pipetted into a 1.5ml Eppendorf
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tube and spun down for 1 minute at 13,000rpm in a tabletop microcentrifuge. The 
resultant pellet was washed in lm l of distilled water and resuspended in 300pl of 
SED (2M sorbitol (4.5ml), 1M EDTA (lm l) (Sigma-Aldrich), 1M DTT (500pl) and 
distilled water (4ml)). To this 7pl o f lyticase (lOunits/pl) was added and placed in 
the 37°C shaker for 120 minutes. The mixture was then spun down for 1 minute at 
13000rpm and resuspended in 200pl of Tris-EDTA. To this 30pl o f 10% (w/v) SDS 
(Melford) was added and incubated for 30 minutes at 65°C in a heat block. 
Following incubation, lOOpl o f 3M sodium acetate was added and placed on ice for 1 
hour. The mixture was spun down for 1 minute at 13,000rpm and the supernatant 
was added to a fresh 1.5ml Eppendorf tube containing 400pl of ice cold ethanol and 
then spun for 10 minutes at 13,000rpm. The supernatant was removed and the 
remaining pellet was washed with 400pl o f 70% (v/v) ethanol. The pellet was dried 
in the Speed Vac until all traces o f ethanol were removed and then resuspended in 
3 0 p lo f distilled water.
2.2.3 Gel Electrophoresis
The 1% (w/v) gel was cast by melting 0.5g o f agarose (Melford) in 50ml o f lx  TAE 
buffer until the agarose had entirely dissolved. The solution was poured into a mould 
and 5 pi o f SYBR safe (Invitrogen) or ethidium bromide was added before being left 
to solidify. Once hardened, the gel and the mould were placed into a gel tank, and 
the tank was filled with lx  TAE buffer, making sure the surface o f the gel was 
covered. DNA, mixed with lOx loading dye, was loaded into the wells. A 
GeneRuler™ 1Kb DNA ladder (Fermentas) was also loaded into the first lane as a 
reference marker. The gel tank was attached to a power pack and the gel was run at 
80 volts for 50 minutes. Following this, the gel was examined under UV light.
2.2.4 Extaction of DNA from Gels
Extraction o f DNA from a 1% (w/v) agarose gel was carried out using a QIAquick 
Gel Extraction kit (Qiagen) and the supplied protocol was followed. This method 
was based on that o f Vogelstein & Gillespie, 1979.
The DNA fragment was cut from a 1% (w/v) agarose gel, placed into a clean 1.5ml 
eppendorf tube and weighed. Three times the weight o f the gel slice o f buffer QG 
(e.g. to lOOmg of gel slice, add 300pl o f buffer QG) was added to the tube and
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incubated at 50°C in a heat block for 10 minutes. Once the gel slice had completely 
dissolved, one gel volume o f isopropanol was added and mixed. The mixture was 
pipetted into a QIAquick spin column and centrifuged for 1 minute at 13,000rpm. 
The flow-through was discarded. 0.5ml o f buffer QG was added to the same 
QIAquick spin column and was centrifuged at 13,000rpm for 1 minute. The flow­
through was discarded. The QIAquick spin column was washed by adding 0.75ml o f 
Buffer PE and was spun at 13,000rpm for 1 minute. The flow-through was discarded 
and the QIAquick spin column was centrifuged for an additional minute at 
13,000rpm. The QIAquick spin column was then placed into a fresh 1.5ml 
eppendorf tube. 50pl of distilled water was added to the QIAquick spin column and 
centrifuged at 13,000rpm for 1 minute. The QIAquick spin column was then 
discarded.
2.2.5 Isolation and Purification of Plasmids
Plasmid DNA was extracted and purified using the QIAprep Spin Miniprep kit 
(Qiagen) and the accompanying protocol was followed. This method was based on 
that o f Bimboim & Doly, 1979.
10ml o f LB + ampicillin E.coli culture was set up overnight, o f which lm l was 
pipetted into a new 1.5ml eppendorf tube and spun down for 1 minute at 13,000rpm. 
The supernatant was discarded and the pellet was resuspended in 250pl of Buffer PI 
(Qiagen). To this 250pl of Buffer P2 (Qiagen) was added and the tube was inverted 
4-6 times to make sure the solutions were mixed thoroughly. 350pl o f Buffer N3 
(Qiagen) was then added and again the solutions were mixed thoroughly by inverting 
the tube 4-6 times. The mixture was spun down for 10 minutes at 13,000rpm. The 
supernatant was carefully removed and pipetted into the supplied QIAprep spin 
column, which was then centrifuged for 1 minute at 13,000rpm. The flow-through 
was discarded. The QIAprep spin column was washed by adding 0.75ml o f Buffer 
PE (Qiagen) and again centrifuged at 13,000rpm for 1 minute. The flow-through 
was discarded and the QIAprep spin column was spun down for an additional minute 
to remove residual Buffer PE (Qiagen). The flow-through was placed into a new 
1.5ml eppendorf tube. The DNA was eluted by adding 50pl o f distilled water to the 
QIAprep spin column, letting it stand for 1 minute and finally centrifuging for 1 
minute at 13,000rpm.
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2.2.6 Restriction Enzyme Digest of the Plasmid
Extracted and purified plasmid DNA underwent either a single or a double restriction 
enzyme digest to isolate the gene o f interest.
2.2.6.1 Not I Digest -  Insert Check
A Not I digest was used to screen colonies for the gene of interest as the vector 
pGEM-T® easy contains a Not I restriction site on either side o f the cloning region, 
so a single enzyme can be used to release the gene.
2pl of distilled water, 2pl o f the purified plasmid, 0.5pl of Buffer D and 0.5pl o f Not 
I were mixed together. The digest mix was incubated at 37°C until completion.
2.2.6.2 Double Digest for Gene Extraction
A Nde I/Hind III double digest was used to release the gene of interest from pGEM- 
T® easy for ligation into pCWori+. For ligation into YEp51 a Sal 1/Hind III digest 
was used instead.
28pl of the purified plasmid, 4pl o f Buffer D, 4pl o f Nde I or Sal I and 4pl of Hind 
III were mixed together. The digest mix was incubated at 37°C until completion.
2.2.6.3 Double Digest -  Insert Check
A Nde UHind III double digest was used to check for the presence o f the gene of 
interest in the pCWori+ plasmid. Alternatively, a Sal UHind III digest was used to 
check for the gene o f interest in YEp51 plasmid.
6pl o f the purified plasmid, 1 pi o f Buffer D, 1 pi Nde I or Sal I and 1 pi of Hind III 
were mixed together. The digest mix was incubated at 37°C until completion.
All digests were visualised on a 1% (w/v) agarose gel.
2.2.7 Transformation of Plasmid into E. coli 
Based on the method of Hanahan, 1985.
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Plasmid DNA was transformed into E. coli cells using the heat-shock method. 2pl of 
DNA was added to an aliquot o f competent E. coli cells, and incubated on ice for 20 
minutes. The cells were heat-shocked for 45 seconds in a waterbath set at 42°C, and 
then immediately incubated on ice for 2 minutes. 900pl o f LB was added to the cells 
and placed in a shaker for 1 hour at 37°C, 170rpm. The cells were spun down at 
13,000rpm for 1 minute and the supernatant was removed by pipetting. Cells were 
resuspended in lOOpl of distilled water and spread onto a LB ampicillin agar plate. 
The plates were transferred to a 37°C incubator overnight.
2.2.8 Transformation of Plasmid into Saccharomvces cerevisiae
One S. cerevisiae (AH22 strain) colony was cultured overnight in 10ml o f YEPD at 
30°C and 150rpm. The S. cerevisiae culture was subcultured into 30ml o f YEPD and 
grown until a cell count o f lx l0 7cells/ml was reached. 10ml o f this culture was 
harvested at 3000xg for 3 minutes and the supernatant was discarded. The pellet was 
washed in 10ml o f distilled water and centrifuged for a further 3 minutes. The wash 
was discarded and the pellet was resuspended in 10ml o f 1M sorbitol. The 
suspension was centrifuged for a further 3 minutes. Again, the supernatant was 
discarded and the pellet was resuspended in 10ml o f 1M sorbitol containing 20mM 
HEPES (Sigma-Aldrich). The suspension was centrifuged for another 3 minutes. 
The supernatant was again discarded and the pellet was resuspended in 50pl 1M 
sorbitol containing 20mM HEPES. The suspension was transferred to an ice-cold 
1.5ml Eppendorf tube and placed on ice. To this suspension 5pl of plasmid DNA 
was added. The cells were transferred to an ice-cold electroporation cuvette. The 
cells were electroporated using the following conditions: 1.5kV, 25pF and 200fL 
Immediately the cells were resuspended in lm l of cold YEPD and incubated at room 
temperature for 1 hour. The cells were then washed twice in lml o f distilled water 
and resuspended in 500pl o f distilled water. The suspension was spread onto a YM 
agar plate containing 5pg/ml histidine (Acros Organics).
2.2.9 Plasmid Sequencing
Plasmid DNA was sent for sequencing to Eurofins MWG Operon (London) at a 
concentration o f 50-100ng/pl in a total volume of 15pi. Primers were sent with the 
plasmid for sequencing (see table 2.1) at a conce*itration o f 2pmol/pl in a minimum 
volume of 15pi.
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2.2.10 SDS-PAGE
3.6ml of the resolving gel was pipetted into the gel forming equipment, immediately 
followed by lm l o f water saturated with butanol, which was used to remove any 
bubbles that may have formed in the gel. The resolving gel was left for 90 minutes 
to set. Once set the butanol saturated water was removed and the gel was washed 
twice with distilled water. Any remaining traces o f the water were removed before 
the stacking gel was then pipetted on top o f the resolving gel and left to set for 30 
minutes.
The protein samples were prepared by adding cracking buffer and incubated at 100°C 
in a heat block for 5 minutes. The cracking buffer was added at a ratio of 1:1 to 
purified protein and 5:1 with unpurified protein samples. The samples were then 
centrifuged for 2 minutes at 13,000rpm. 5pi of the sample was then loaded into one 
o f the wells o f the gel. 7pl o f protein marker was also added. The gel was run at 
150V for 70 minutes.
Following electrophoresis, the stacking gel was removed and the remaining part o f 
the gel was stained for 10 minutes in Coomassie Blue stain. The gel was then 
destained overnight in Coomassie Blue destain.
2.2.11 Reconstitution Assays
The truncated S. cerevisiae NADPH-cytochrome P450 reductase (ScA33:CPR) 
protein used in these assays was a gift from Dr. Andrew Warrilow, Swansea 
University.
2.2.11.1 Micelle Formation
lOpl o f 2mg/ml o f substrate (dissolved in chloroform) was added to lOOpl of 
chloroform and lOOpl of 1 mg/ml dilaurylphosphatidylcholine (DLPC -  dissolved in 
chloroform). The solution was thoroughly mixed prior to the addition of 200pl of 
distilled water. This solution was then thoroughly mixed producing a white 
emulsion. The chloroform was evaporated under a nitrogen stream until a clear 
solution o f aqueous substrate-DLPC micelles was produced.
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2.2.11.2 Reconstitution System
Added to 200pl o f the aqueous micelles (section 2.2.11.1) was 50(xl o f 40mM 
glucose-6-phosphate, 50pl of lOU/ml glucose-6-phosphate dehydrogenase and lOOpl 
1M Tris-HCl (Melford), pH6.4. Various concentrations o f purified cytochrome P450 
protein and purified CPR protein were also added to the system (see chapters 5 and 6 
for details). The final volume o f this solution was made up to 900pl with the 
addition of distilled water. The solution was mixed thoroughly and pre-incubated at 
37°C for 5 minutes. The reaction was initiated by the addition o f lOOpl of lOmM 
NADPH dissolved in 0.2% (w/v) sodium bicarbonate. The solution was mixed 
thoroughly before incubation at 37°C for 1 hour.
After incubation the reaction was either terminated on ice, extracted with 5ml o f a 
chloroformimethanol (2:1, v/v) solution and evaporated to complete dryness in a 
SpeedVac or the reaction was subjected to saponification (section 2.2.11.3).
2.2.11.3 Saponification
The reaction was terminated by the addition o f lm l o f 15% (w/v) potassium 
hydroxide dissolved in ethanol. The stopped reactions were mixed and then 
incubated at 85°C for 90 minutes. The samples were then extracted three times with 
lm l of hexane. The extracted fractions were evaporated to complete dryness in a 
SpeedVac.
2.2.12 Silvlation of Samples
To the dried sample (in a GC vial), lOOpl o f pyridine (Sigma-Aldrich) and one vial 
o f V,0-bis(trimethylsilyl)trifluoroacetamide-trimethylchlorosilane (BSTFA-TCMS 
[90:10]) was added. The lid was crimped onto the GC vial and the sample was 
heated to 70°C on a hotblock for 1 hour.
2.2.13 GCMS
To determine the products o f reconstitution assays using hydrocarbons and sterols as 
substrates, the extracted samples require analysis by GCMS (Gas Chromatography - 
Mass Spectrometry).
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For separation by gas chromatography, the extracted sample is suspended in an 
organic solvent, such as methanol, which is injected into a mobile phase, in this case 
the inert gas, helium. The sample is carried to a column (known as the stationary 
phase) where it is separated and eluted. The products which interact with the column 
the quickest are eluted first, whereas those that take the longest time to interact, elute 
the slowest. This separation can be aided by ramping (increasing) the oven 
temperature (where the column resides) so that the products can be separated by 
boiling point. Therefore, products with lower boiling points are eluted from the 
column faster than those with higher ones. The eluted products then enter a detector 
producing a signal, which can be used to identify the point/time at which the product 
was eluted from the column. This is known as the retention time. Using a software 
program, such as MSD Enhanced ChemStation, a chromatograph can be produced 
plotting retention time against abundance (signal intensity). If the conditions used 
remain constant, then the retention time can be used to identify the product eluted as 
this will remain almost constant. However, different products may have similar or 
very close retention times, which require more analysis to correctly determine the 
product. This can be done using mass spectrometry.
Following elution from the GC column, the product can enter a mass spectrometer 
detector where it is fragmented by a cascade o f electrons. These charged fragments 
are separated by electromagnets and are recorded as a graph, known as the mass 
spectrum. This mass spectrum shows the reproducible fragmentation pattern for a 
given product/chemical, allowing for accurate identification when used in 
conjunction with the retention time produced by the GC.
Figure 2.1 shows a schematic overview o f the GCMS.
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Figure 2.1 -  Schematic overview of the GCMS.
Analysis of the products of reconstitution assays using hydrocarbons and sterols as 
substrates were performed using a 7890A GC system (Agilent Technologies), 5975C 
mass spectrometer (Agilent Technologies) and MSD Enhanced ChemStation 
software. A DB-5MS fused silica column with a 30m x 0.25mm x 0.25pm film 
thickness (J & W Scientific) was used to separate the products on the GC. Samples 
were injected in lp l volumes in the splitless mode using helium as the carrier gas.
2.2.13.1 GCMS Method for the Analysis of Alkanes, Fatty Acids and their 
Derivatives
The GCMS method used was adapted from the methods of He et al., 2005 and 
Basconcillo & McCarry, 2008.
The oven program used was as follows. The oven temperature was held at 70°C for 
4 minutes and then ramped, 20°C/min, to a final temperature of 300°C. The oven 
w'as held at fhis temperature for 5 minutes and a solvent delay of 5 minutes was used.
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2.2.13.2 GCMS Method for the Analysis of Sterols
The GC oven program was initially set at 70°C for 4 minutes. The temperature was 
then ramped, 25°C/min, to a final temperature of 280°C. This temperature was held 
for 25 minutes.
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Chapter 3: Identification of Cytochrome P450 Genes in Candida albicans Using
a Bioinformatic Approach
3.1 Introduction
Bioinformatics is an interdisciplinary field combining biological sciences with 
mathematics (including statistics) and computer sciences (Golding, 2003). It allows 
biological data, such as sequence data, to be collated and accessed, as well as 
enabling the user to search through vast collections o f data, using bioinformatic tools 
(discussed in detail in section 3.1.5). The user can look for sequence data (nucleotide 
or protein) that is a homologue, orthologue or paralogue o f another gene/protein. A 
homologue is a DNA sequence or protein molecule that has the same function as 
another and is related by a common ancestor (Westhead et al., 2002). Paralogues 
and orthologues are different types o f homologues. An orthologue is a homologue, 
that has arisen after speciation (Westhead et al., 2002), for example CYP51. CYP51 
is a member o f the cytochrome P450 family and is involved in sterol production. It 
can be found in a plethora of species including yeast, mycobacteria and humans 
(Kelly et al, 2001). A paralogue however, is a homologue with a different function, 
which has arisen after gene duplication, e.g. trypsin and haptoglobin. Trypsin is an 
enzyme involved in the breakdown and digestion o f proteins and shares a common 
ancestor with haptoglobin. However, haptoglobin has a completely different 
function to trypsin and is involved in the prevention o f unrequired protein 
aggregation by acting as a chaperone (Lesk, 2005). Enzymes belonging to the 
CYP52A subfamily o f cytochromes P450 are examples o f paralogues. Proteins in 
this subfamily are only found in yeast and share homology, but they preferentially 
hydroxylase different hydrocarbon molecules. For example, CYP52A3 can catalyse 
the hydroxylation o f both alkanes and fatty acids to their respective alcohols and 
diacids (Zimmer et al., 1996; Scheller et al., 1998) whereas CYP52A4 can only 
hydroxylate fatty acids (Zimmer et al., 1995; Zimmer et al., 1996). Bioinformatics is 
an excellent tool for discovering new genes, including those that make up the 
cytochrome P450 family, as it can be used to identify putative orthologous genes.
The objective o f this chapter is to identify all possible cytochrome P450 genes in 
Candida albicans and to find which o f these genes has the greatest homology to the 
alkane-hydroxylating gene from C. maltosa, CYP52A3 (Ohkuma et al., 1991).
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CYP52A3 is o f interest as CYP52 genes and proteins o f yeasts and fungi are 
associated with the terminal hydroxylation o f alkanes where the alcohols produced 
are further converted to fatty acids and then subjected to p-oxidation. Alternatively, 
fatty acids can be converted to diacids, which can then either be subjected to p- 
oxidation or be extracted to form the chemical basis of many industrial products, 
such as perfumes, plastics, lubricants, hot-melting adhesives and antibiotics 
(Eschenfeldt, et al., 2003; Liu, et al., 2003).
3.1.1 Genome Databases
In 1976, Walter Fiers et a l  from the University o f Ghent, Belgium published the first 
complete RNA genome sequence from bacteriophage MS2 (Fiers et al., 1976). This 
was quickly followed by the publication o f the first complete DNA genome from 
phage (p-X174 in 1977 by Fred Sanger and his team (Sanger et al., 1977). Since then 
there has been an explosion in the number o f genome sequences published. These 
have included Haemophilus influenza (the first genome to be published from a living 
organism, (Fleischmann et al., 1995)), Escherichia coli (Blattner et al., 1997), 
Genlisea margaretae (Greilhuber et al., 2006), Sacchromyces cerevisiae
(http://veastgenome.org/) and Homo sapiens (draft version in 2001 (International 
Human Genome Sequencing Consortium, 2001); completed in 2003 (Collins et al., 
2003)). It is important to note this is not an exhaustive list and many other genome 
projects have been completed or are currently being undertaken.
Large-scale genomic sequencing, such as those mentioned above, can be undertaken 
using robot-fed capillary sequencers, which produces sequence data in the form of 
chromatographs (Golding, 2003). Alternatively, next-generation sequencing (NGS) 
technologies can be used to produce sequence data. NGS permits an entire genome 
to be sequenced by breaking it down into fragments, which can be read and 
assembled to produce a whole genome sequence (Zhang et al., 2011). This 
technology is rapidly developing and utilisation o f high-throughput techniques (such 
as microarray analysis) has led to advancements in the understanding and 
identification of genes involved in human disease as multiple human genomes can 
now be sequenced (Zhang et al., 2011).
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Genome sequences that are nearly or completely sequenced can be found in their 
own specific database as well as in nucleotide databases (which are described in 
section 3.1.2). Genomic databases contain genetic and molecular biological 
information for a particular species. They contain DNA sequences, protein 
sequences (to a lesser extent), descriptions and classifications o f biological roles, 
molecular functions, subcellular localisations, links to literature, links to functional 
genomic datasets (e.g. expression arrays) and bioinformatic tools for the analysis and 
comparison o f sequences.
An example of such a genome database is the Candida Genome Database (CGD, 
www.candidagenome.org) (see figure 3.1). As the name implies, this archive 
provides data on the Candida genome sequence, particularly C. albicans. It provides 
the user with helpful resources, such as those mentioned above, as well as 
information on biochemical pathways and comparisons to the S. cerevisiae genome. 
The database also provides researchers with the latest news from the Candida 
research community. The CGD is funded by the National Institute o f Dental and 
Craniofacial Research, US National Institutes o f Health and is based on the 
Saccharomyces Genome Database (SGD, http://veastgenome.org/). which was set-up 
to provide researchers within the yeast community fast and easy access to 
information relating to the S. cerevisiae genome. This collaboration has enabled 
CGD to offer improved bioinformatic tools, such as advanced search, batch 
download, pattern matching and primer design (www.candidagenome.org).
66
Searches database. Second search box at the 
bottom o f  the screen (not show n) Searches outside  
the database and is powered by G oogle
I he Candida Genome D atabase Microsoft
* »''-http canddagencre or*
Ffe E<* V»* Fiwortti Took Met
'ai 4* f-TTieC«nAia«kvKM*e DetaLase
Available
analytical
tools
txp lorer provided by Swansea University
- m  * . • ‘’v  * J  Took -
Candida Genome Database
I'**— IjD Outclc Scam *■ J SHe Map I (■ u# Searcti | Help | Contact CGO | Home
cQOTTOWttirtp Supmnpaa blast Pramre P#*»cn Q»^S«9.P«P>J»s f*t3g£&JiS*& WBugLgaa
Search Options
V m w  ■«. Advanced Search. 
O f  Sequence. BLAST. 
QBrowse (A21). Pathvwys. 
»PatMatcft. Prtmers. Futt-text 
5SH^ .SJ.»!!S!!S3Sl Search COD wet) pages Qtobal Gene Hunter. 
SM®LL5ta«!l3. Bndjnon
Help Resources
Vtow sH Gettmo Started. 
Sitemap. FAQ, and more
GO Resources
V W r—. SOD GO Tutorial. 
What»  GO?.
GO Slim Mapper.
GO Term Finder, and more
This is The home of Jhe Candida Genome Database, a  resource lor genomic sequence data and gene 
and protein Information tor Candida a& cans CGD is based on toe Saccfiarom vces Genome 
Database and is fcmded by toe National Institute of Dental & Craniofacial Research at the US National 
Institutes of Health.
CGD News
Latest Candida 
new s
•  10th ASM Conference on Candida and Candidiasis
The 10th ASM Conference on Candida and CandkJtesis *A  take ptace from March 22-26,2010, at the 
Hyatt Regency in Miami Florida. Absfract submissions wti open In Fal 2009. Please see the meeting 
web site tor detafts (Posted May 10.2009)
•  Search full text of Candida journal articles with Textpresso
A futi-texl literature search caoabititv has now been added to CGD. The Iterature search tool is 
powered by 7extpresso, a  text-mining tool developed at Wormbase (Mtdter H. et al. (20041 PLoS Biol.
Database resources listed 
dow n the page
Quick links
Figure 3.1 -  View of the Candida Genome Database (CGD) homepage.
3.1.2 Nucleotide Databases
Nucleotide databases are repositories for nucleic acid sequences (and to less extent 
translated protein sequences). They have become a more popular medium in recent 
years as fewer and fewer journals are publishing new nucleotide sequence data 
(Ashbumer & Goodman, 1997). There are three primary databases, which store raw 
nucleic acid sequence data: GenBank (NCBI, www.ncbi.nlm.nih.gov/Genbank), the 
Nucleotide Sequence Database (EMBL, www.ebi.ac.uk/embl) and the DNA 
Databank of Japan (DDBJ, www.ddbi.nig.ac.ip). Collectively they are known as 
“The International Nucleic Acid Sequence Data Library.” The data in these archives 
come from genome projects, scientific publications and patent applications (Lesk, 
2005). This information is shared between the three databases on a daily basis, 
meaning that all three archives contain a lot of the same raw data (Lesk, 2005). 
However, this information is said to have a lifespan due to the fact most entries are 
added before they have been fully annotated and checked by library staff (Ashbumer 
& Goodman, 1997). Tne quality of the information submitted is not the
67
responsibility o f the database but o f the researcher/research group who submitted the 
original sequence (Ashbumer and Goodman, 1997). Therefore, once reviewed, 
many o f the sequences may be discarded due to a number o f reasons, including 
sequence errors, mislabelling, contamination and sequence duplication. These are 
big problems as they cause a needless increase in the size of the archive making the 
database redundant (Ashbumer & Goodman, 1997). Those sequences that remain 
are extensively annotated and the important properties o f each sequence are 
highlighted, e.g. name and origin, protein attributes, sequence similarities, ontologies 
and literature reference(s).
Figure 3.2 shows a screen shot from the Nucleotide Sequence Database (EMBL, 
www.ebi.ac.uk/embl). The database was searched for sequences relating to the 
alkane-hydroxylating cytochrome P450 from C. maltosa, CYP52A3. It was able to 
identify 2 nucleotide sequences, 1 protein sequence and 5 related articles. This 
information is sufficient to be used, for instance, to produce primers or to be used in 
a BLAST search (discussed in more detail in section 3.1.5). Other genes searched 
will yield more or less information than CYP52A3 depending on the level o f 
annotation and information available (from the database).
68
Search criteria
- P a g r  -  } lo o b
N* Uk *rw Nw*« Took mfe 
W *? |  5Mrth far C VP52A3 n  Al th» tW | EBI
t u a .  e j
Ca&ftases re**? [ 3  ‘> n * n  frsn tn j
O ption to access the drop 
dow n box, w hich  
identifies w here data is 
archived/available from
Search for CYP62A3 m  AM tfm E B I
Available results» ttpdndcfl <r Cottpsea*
r i
One Lanssm
0 99n*cr*n *0**
aajttut emm i
C « n g  S e o ^ e o c r s  « i  F U B i- A » r #
Search lor CVP52AJ mAMOrt LBi
•rith Vie toHowvig ke^ ottJs [
Second search box to allow the user to refine 
the original search criteria
Figure 3.2 -  Entry page from the nucleotide sequence database (www.ebi.ac.uk).
CYP52A3 was entered into the search box at the top of the homepage (not shown) 
and Go was pressed generating the page shown in this figure. The user is able to 
identify the gene, the DNA sequence (as well as the protein-coding sequence), 
information about the protein and any relevant literature.
3.1.3 Prim ary Protein Databases
Like nucleotide sequences, raw protein sequences are initially collated into 
databases, such as SWISS-PROT and TrEMBL. SWISS-PROT is the result of a 
collaboration between the Swiss Institute o f Bioinformatics (http://www.isb-sib.ch/) 
and the European Bioinformatics Institute (http://www.ebi.ac.uk), and contains 
protein sequences, from published scientific articles, that are actively monitored and 
annotated manually by curators (Apweiler et al., 2004; Lesk, 2005). Unlike 
nucleotide sequence databases, primary protein sequence databases are non- 
redundant (Apweiler et al., 2004). As mentioned previously, nucloetide databases 
can contain many of the same or similar sequences (Ashbumer & Goodman, 1997), 
however, SWISS-PROT contains very little repeated data ensuring the database is 
not unnecessarily large, thus reducing the time the user has to spend searching for a 
particular sequence. Data in the SWISS-PROT database is extensively annotated and 
the biological information used includes protein function, post-translational
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modifications, the identification o f sites and domains, protein similarities and 
biological pathways involving the protein (Apweiler et al, 2004).
TrEMBL, on the other hand, contains sequences derived from translated protein 
sequences found in the Nucleotide Sequence Database (EMBL, 
www.ebi.ac.uk/embl), which are not already integrated into SWISS-PROT (Lesk, 
2005). By using translated protein sequences the rate at which new protein 
sequences are made available is constantly increasing (Ashbumer & Goodman, 1997; 
Apweiler et al, 2004). However, TrEMBL is not just made up of translated protein 
sequences as it also contains some sequences from published journals and 
experimental data (Apweiler et al, 2004).
Due to the redundancy associated with primary nucleotide databases, many o f the 
sequences in the TrEMBL database may have to be removed or merged to produce a 
single entry. The annotations used for many o f these sequences are from the 
nucleotide database (Apweiler et a l , 2004). However, the remaining unannotated 
sequences require annotation. Information for these seqeunces comes from InterPro 
(an integrated protein database) (Apweiler et a l , 2001, www.ebi.ac.uk/interpro/), 
which is made up of other databases such as PROSITE, PRINTS and Pfam (descibed 
in more detail in section 3.1.4) (Apweiler et al, 2004). Despite this the sequences in 
TrEMBL are not as extensively annotated as those in SWISS-PROT (Ashbumer & 
Goodman, 1997). However, these sequences, once completed, are eventually moved 
to the SWISS-PROT database where they undergo more extensive annotation (Lesk, 
2005).
It has been established that SWISS-PROT and TrEMBL are the main repositries of 
primary protein sequence data, and this recognition led to the formation of a single 
database in 2003 named UniProt (www.uniprot.org) (Apweiler et al, 2004b, Lesk, 
2005). This database not only combines biological data from SWISS-PROT and 
TrEMBL, but also from a third database, PIR (Protein Information Resource, 
http://pir.georgetown.edu/) (Apweiler et al, 2004). The PIR database provides 
UniProt with sequences found in neither the SWISS-PROT nor TrEMBL databases 
(Apweiler et al, 2004). Therefore, the UniProt database provides the same data as 
the other primary protein databases, but is split into two parts: those sequences that
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are fully annotated (continuing to be called SWISS-PROT) and those sequences 
waiting to be annotated (referred to as TrEMBL) (Apweiler et al, 2004).
3.1.4 Secondary Protein Databases
In contrast to nucleotide databases, there is a second generation o f protein databases 
available. The secondary protein sequence databases allow an unknown protein to be 
determined (within the archive) by noting the existence o f a particular pattern, motif, 
signature or fingerprint within the sequence. For instance, cytochromes P450 contain 
a conserved sequence relating to the haem-binding region, FxxGxxxCxG (Nelson et 
al, 1993; Nelson et al., 1996). Using this conserved sequence to search against 
sequences from the database related protein families can be identified (Lesk, 2005). 
Examples o f secondary protein databases are PROSITE (Hofmann et al., 1999, 
www.expasv.ch/prosite/), PRINTS (Attwood et al., 2000,
http://www.bioinf.man.ac.uk/ dbbrowser/PRINTS/) and Pfam (Bateman et al., 2000, 
http://pfam.sanger.ac.uk/). Each o f these databases use a different methodology to 
determine an unknown protein and these are described below.
PROSITE (Hofmann et al., 1999) is the oldest sequence-motif database (Kriventseva 
et al, 2001) and it identifies proteins by sequence domains or motifs (see figure 3.3) 
(Ashbumer & Goodman, 1997). The motifs come from published articles and are 
linked to annotations in the SWISS-PROT database (Liu & Rost, 2003), which 
means sites and patterns that are biologically significant can be identified so the 
protein’s family can be determined rapidly. However, the identification o f new 
members from diverse families is less reliable because if  the information/motif 
required is not matched in SWISS-PROT then PROSITE is unlikely to be able to 
match that motif to unidentified proteins (Liu & Rost, 2003).
An example is the FxxGxxxCxG m otif associated with cytochrome P450 proteins. 
This m otif contains areas between the conserved residues that can be occupied by 
any one o f the twenty-two amino acids available. PROSITE identifies the 
defined/highly conserved residues and ignores the amino acids in between by using 
position-dependent profiles or weight matrices (Bork & Koonin, 1996; Kriventseva 
et a l , 2001). These matrices define the residues o f interest so that any insertions or 
positions that are not part of the motif can be tolerated (Kriventseva et a l, 2001).
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Figure 3.3 shows an example o f a results page from PROSITE. It has been generated 
using the protein sequence o f Alkl (accession number: Q5A8M1) from C. albicans 
(for more details on this protein see section 3.3). PROSITE identifies this protein as 
being a member o f the cytochrome P450 group and gives a short description o f the 
recognized motif (“Cytochrome P450 cysteine heme-iron ligand signature”). The 
m otif is highlighted on a linear graphic o f the protein sequence and there is a legend 
accompanying these graphic identifying generalised sites. In this case the motif is 
classified as “other sites”. Finally, the region the motif is situated in within the 
protein sequence is also identified. In this case, it is found between residues 467 and 
476 and is identified as FNgGPRICLG.
A second secondary database is PRINTS (Attwood et al., 2000). PRINTS like 
PROSITE is made up o f motifs extracted from searches undertaken in SWISS-PROT 
(Kriventseva et al., 2001). However, unlike PROSITE, PRINTS uses a technique 
called “fingerprinting” (Lesk, 2005). Fingerprints are groups of motifs that indicate 
specific protein families (Attwood et al., 2003). This means rather than searching its 
archive for one particular sequence m otif like PROSITE, PRINTS can search for 
several by examining multiple alignments (Liu & Rost, 2003). This method is more 
flexible than the single-motif methods and it has the ability to identify a greater 
number o f relative proteins (Attwood et al., 2003).
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Figure 3.3 -  Results page from PROSITE (Hoffman et a l 1999). Results were 
obtained by searching the database with the protein sequence for Alkl (in FAST A 
format). These results show that Alkl contains a motif associated with cytochromes 
P450.
Thirdly, Pfam (Bateman et al., 2000) (see figure 3.4) searches for conserved domains 
in the SWISS-PROT database (Kriventseva et al., 2001) and uses Hidden Markov 
Models (HMMs) to identity these conserved regions in other protein sequences 
(Bateman et al., 2002). HMMs are sophisticated systems that take their name from 
the fact that although the sequences are shown to the user the path through the 
models (or states) used to identify them are not seen. The HMMs depict the protein 
domain family by producing sequences from that particular family with a very high 
probability along with other sequences that produce a less variable probability. This 
method makes identification of new family members more reliable (Lesk, 2005).
Figure 3.4 shows a results page from Pfam. It was produced using the Alkl protein 
sequence. A generated graphic shows the motif identified within the sequence, in 
this case the motif is cytochrome P450. By clicking on this domain graphic the user 
is redirected to a second webpage (not shown), which provides information on the 
protein family the motif belongs to, related references, gene ontology and links to 
external databases including other secondary protein databases, such as PROSITE 
and PRINTS. Immediately below there is a table noting the domain boundaries of 
the identified motif. For Alkl, this is 316 to 525. This is a far greater length of
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sequence than was quoted by PROSITE, which identified the motif for cytochrome 
P450 as being between residues 467 and 476 (see above). A reason for this is that 
some of the domains identified by Pfam may be obscuring/overlapping other 
domains giving the entry sequence a larger domain boundary. The alignment of the 
motif to the protein entry may be observed by pressing the “Show” button (not 
shown). Finally, the Pfam results also indicate motifs that are deemed less important 
than the other motifs it deems “significant” (in this case a Nupl33 N terminal like 
motif and a second cytochrome P450 domain). Significance is determined by the 
bits score and E-value, which are related to sequence homology. The greater the 
score and the lower the E-value, the higher the homology is (this is described in 
greater detail in section 3.1.5). Therefore a significant Pfam match is classified as 
having a very high bits score and a very low E-value.
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Fi2ure 3.4 - Results page from Pfam (Bateman et a l 2000). Results were 
obtained by searching the database with the protein sequence for Alkl (in FASTA 
format). These results show that Alkl contains a domain associated with 
cytochromes P450 and where it is located within the sequence.
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Due to these differing approaches, each database has a particular area o f expertise. 
For instance, PROSITE focuses much of its attention on functional sites, whereas 
Pfam is used primarily to search for divergent domains and PRINTS can identify 
sub-families. These are just a small subsection o f the secondary databases (and 
methods) available but they convey the notion that there is no one ideal 
method/database to use. To combat this issue an integrated archive, entitled the 
InterPro database (Apweiler et al., 2001, www.ebi.ac.uk/interpro/), was formed. 
InterPro initially allowed quick and easy access to information in PROSITE, 
PRINTS, Pfam and ProDom (Apweiler et al, 2001, Kriventseva et al., 2001, Lesk. 
2005). (ProDom (Corpet et al., 2000, http://www.toulouse.inra.ff/prodom.html) is a 
sequence cluster database, that unlike the aforementioned databases is produced 
using clustering algorithms directly from sequence databases (Apweiler et al., 2001, 
Kriventseva et al., 2001)). However, since 2001 other protein databases have been 
incorporated into the InterPro database. These include: PIRSF (provides information 
on protein sequence hierarchies) (Nikolskaya et al., 2007, 
http://pir.georgetown.edu/pirwww/dbinfo/pirsf.shtml). PANTHER (proteins are 
classified by function) (Mi et al., 2007, http://www.pantherdb.org/). SMART 
(involved in domain architecture analysis) (Letunic et al., 2006, http://smart.embl- 
heidelberg.de/). TIGRFAMs (protein family database) (Haft et al., 2003, 
http://www.isvi.org/cms/research/proiects/tigrfams/overview/). Gene3D (produces 
theoretical 3D images o f protein domains) (Yeats et al., 2008, 
http://gene3d.biochem.ucl.ac.uk/Gene3D/) and SUPERFAMILY (archives protein 
functions and structures for completely sequenced genomes) (Wilson et al., 2007, 
http://supfam.cs.bris.ac.uk/SUPERFAMILY/) (Hunter et al, 2009).
InterPro entries are annotated with information correlating to function, related 
published articles and links to the original secondary protein database from which 
they were generated (e.g. PROSITE, PRINTS, Pfam or ProDom) (Apweiler et al., 
2001). The future aim o f this database is to make it truly integrated by linking 
information from one database to another enabling the user to identify how motifs 
from different databases correlate to one another (Hunter et al., 2009).
The different types o f databases mentioned above are excellent collections o f 
nucleotide and protein sequences. As described, they provide the user with quick
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and easy access to a constantly increasing volume o f biological data. However, the 
data needs to be analysed and interpreted to obtain scientific answers o f use. This 
can be done using a growing number o f bioinformatic tools that have become 
available in recent years, some o f which are mentioned below.
3.1.5 Bioinformatics Tools
Bioinformatic tools can be used, for instance, to find comparisons between new 
sequences and characterised sequences from the aforementioned databases, to 
determine the degree o f homology between sequences and to evaluate evolutionary 
relationships. One important bioinformatic tool is BLAST (or Basic Local 
Alignment Sequence Tool) (Altschul et al., 1997). BLAST compares a given 
(nucleotide or protein) sequence against every entry in a database to find (other) 
sequences with varying degrees o f homology to the original search sequence. There 
are many different BLAST programs and most use amino acid sequences as the 
query sequence against databases containing protein or translated nucleotide 
sequences. Protein sequences are preferred to nucleotide ones as the query sequence 
because they allow homology (of sequences and characteristics through evolution) to 
be assessed (Rehm, 2001). Table 3.1 shows a sample o f various BLAST programs 
available and the types o f query and database sequences they use. The BLAST 
program checks each query sequence for short adjoining regions found in each 
sequence within the database (Lesk, 2005). A substitution scoring matrix 
(BLOSUM62) is used, but no gaps are permitted (Lesk, 2005). This means that a list 
o f potential sequences can be produced quicker than it would take to generate the 
results manually. Each sequence in this list is given a bit score and an E-value. The 
bit score is given relating to the sequence similarity, so the greater the score the 
higher the homology (Lesk, 2005). A bit score is better than a raw score, which is 
the same as a bit score, except a bit score also takes the statistical parameters o f the 
scoring system into consideration (Karlin & Altschul, 1990; Altschul, 1991; Altschul 
& Gish, 1996; Rehm, 2001). The E-value describes the probability o f homology 
between the query sequence and the BLAST results, the greater the homology the 
lower the E-value (Rehm, 2001; Lesk, 2005). For instance, if  the E-value is less than 
0.02 then the sequences are probably homologous, but if  the E-value is greater than 1 
then the probability o f the sequence being homologous is very slim (Lesk, 2005). 
The E-value is calculated as follows:
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E-value = P-value x Database size
Where the P-value is the probability o f the alignment being better than random 
(Lesk, 2005). The P-value does not depend on the size o f the database, unlike the E- 
value. P-values lower than 10'100 are deemed an exact match, with anything below 
10'1 being classified as probably insignificant (Lesk, 2005).
This bioinformatic tool can be used to find sequences with homology to, for instance, 
CYP52A3. The results are ranked according to homology so the sequence with the 
highest bit score and lowest E-value is at the top o f the page. Usually, this is the 
query sequence itself. The user can identify sequences o f interest by choosing 
sequences in the list depending on the species o f interest (e.g. C. albicans), the 
family o f interest, the bit score and the E-value. An example o f a BLAST results 
page is shown in figure 3.7, which is in the results section (3.3) o f this chapter.
Program  Name Query Sequence Database Type
PSI-BLAST Amino Acid Protein
BLASTN Nucleic Acid Nucleic Acid
BLASTX Translated Nucleotide Protein
TBLASTN Amino Acid Translated Nucleotide
Table 3.1 -  Exam ple of some of the different BLAST program s available. Each 
program uses a different type o f query sequence to search the different types o f 
database.
Another bioinformatic tool involves sequence alignment. Using the same basic 
principle as BLAST (but on a smaller scale), pairwise alignments can be used to 
match identical amino or nucleic acids (depending on the sequence used) in pairs or 
in multiple arrangements. Usually, a program such as ClustalX (Thompson et al.,
1997) is used. This utility not only allows sequences to be matched, but also places 
the sequences with the greatest homology at the top of the list during multiple 
alignments. Alignments from ClustalX can then be viewed as a .aln file in a separate 
program, such as BioEdit (Hall, 1999), where identical units o f the sequences can be 
shaded the same colour to allow conserved regions of interest to be quickly 
identified. Following alignment in ClustalX (Thompson et al., 1997) a .dnd file is
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also produced, which allows the alignment to be viewed as a phylogenetic tree in a 
separate program, such as TreeView (Hall, 2001).
A phylogenetic tree shows graphically the ancestral relationships o f different 
sequences. Homology can be inferred using this method because sequences with 
much similarity will share a common ancestor (Westhead et al., 2002). A 
phylogenetic tree is made up o f branches and nodes (external and internal). External 
nodes are the tips o f the tree (e.g. the name o f the sequence/gene/organism), whereas 
the internal nodes are the points where two (or more) nodes intersect (Hall, 2001). A 
branch connects two (or more) nodes together (Hall, 2001). The distance between 
two nodes can be calculated by counting the number o f amino or nucleic acid 
changes that have occurred along that branch (Hall, 2001). This means the greater 
the homology between the two sequences, the easier it is to convert one of the 
sequences into the other as fewer mutations are required (Westhead et al., 2002). 
Phylogenetic trees that relate branch length to distance usually have a legend 
corresponding to this. An example o f this is shown in figure 3.10 (which can be 
found in the results section 3.3).
Such databases and bioinformatic tools can be used to discover new cytochrome 
P450 genes. These methods will be used to quantify how many cytochrome P450 
genes there are in C. albicans and which o f these has the greatest homology to 
CYP52A3, a known alkane-hydroxylating P450 gene from C. maltosa (Ohkuma et 
al,  1991).
3.2 Methods
3.2.1 The Cytochromes P450 of C. albicans
The ExPASy website (www.expasv.org) was searched for potential cytochromes 
P450 in C. albicans using the query “P450 Candida albicans.” The fungal 
cytochrome P450 database (http://p450.riceblast.snu.ac.kr) was also searched.
The nomenclature for cytochromes P450 is based upon amino acid identity. 40% 
identity and above place a CYP in the same family and more than 55% identity 
places them in the same subfamily (Nebert, et al., 1987; Nelson, et al., 1996). 
Families are designated a CYP number based on those reserved for different
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taxonomic groups (http://dmelson.utmem.edu/CvtochromeP45Q.html)., for lower 
eukaryotes (including fungi) these are CYP51-CYP69, CYP501-CYP699 and 
CYP5001-CYP6999. Sequences were collated and scoured for the presence of 
consensus amino acid sequences associated with cytochromes P450. These 
conserved regions include the PER(W) domain, the haem binding domain and ExxR 
of the K-helix. The haem-binding domain is characterised as FxxGxxxCxG, where 
the cysteine (highlighted) acts as the fifth ligand o f the haem iron (Werck-Reichhart 
& Feyereisen, 2000). The ExxR motif is found in the K-helix, which is known to 
provide core structure stability (Werck-Reichhart & Feyereisen, 2000).
The search data was refined by undertaking a TBLASTN (Gish, 1996-2000) search 
using the protein sequence of each potential cytochrome P450 in the Candida 
Genome Database (see figure 3.5). Sequences not found within the C. albicans 
genome were easily identified and discarded, along with any duplicated sequences. 
The remaining duplicates were identified by aligning the remaining sequences in 
ClustalX (Thompson et al., 1997) and viewed in BioEdit (Hall, 1999).
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Figure 3.5 -  TBLASTN page of the Candida Genome Database. The TBLASTN 
was undertaken using the protein sequence o f Alkl (in FASTA format).
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3.2.2 Homologue of CYP52A3
A BLAST search was undertaken using the CYP52A3 protein sequence (accession 
number: P I6496) (See figure 3.6). As a result, a list of homologous CYP52A3
proteins was produced and the C. albicans genes with the highest homology were
noted. Search results are given a score relating to the degree of sequence similarity, 
and an E-value pertaining to the probability of the sequences being a match, 
therefore, the higher the score the greater the degree o f similarity, and the lower the 
E-value the better the match. This means a gene with high/great homology would 
have as a result a high score and a low E-value.
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Figure 3.6 -  BLAST (Altschul et al., 1997) page of ExPASy (www.expasv.ch).
The BLAST search was undertaken using the C. maltosa cytochrome P450, 
CYP52A3 (accession number: P I6496).
To ensure the C. albicans genes identified were full cytochrome P450 sequences and 
not partial or duplicated ones, the accession numbers of each gene was compared 
with those cytochromes P450 known to be in the C. albicans genome (see section
3.3.1 for a comprehensive list). Any partial or duplicated sequences were then 
removed from the list. Finally, the (remaining) sequences were fully aligned with
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CYP52A3 using ClustalX (Thompson et al., 1997) and viewed in BioEdit (Hall, 
1999). Phylogenetic trees were produced in TreeView (Page, 2001).
3.3 Results
3.3.1 The Cytochromes P450 of C. albicans
There are 10 putative cytochrome P450 genes/proteins in C. albicans, o f which five 
are potential alkane and/or fatty acid hydroxylating genes or CYP52s. The proteins 
encoded by these genes (ALK1, ALK2, ALK3, ALK6 and ALK8) have been 
highlighted in table 3.2.
Name O therName
Accession
No. ORF No. Species K-Helix
PER(W )
Domain
Haem-Binding
Domain
Protein
Length
(AA)
M olecular
Weight
(Da)
CYP52A3 P I6496 - C. maltosa ETLR PERW FNGGPR1CLG 523 59,840
Alkl Q5A8M1 ORF19.5728 C. albicans ETLR PDRW FNGGPRICLG 526 59,738
Alk2 Q5AAH6 ORF] 9.7513 C. albicans ECLR PERW FNGGPRICLG 522 59,820
Alk3 Q5AAH7 ORF19.7512 C. albicans ESLR PERW FNGGPRICLG 538 61,849
Alk6 Q5AGW4 ORF19.6574 C. albicans ESLR PERW FCTGPRLCLG 507 58,293
Alk8 CYP52A21 Q59K96 ORF19.10 C. albicans ETLR PERW FNGGPRICLG 515 59,332
Dit2 Q5A6K0 ORF19.55 C. albicans ETLR PERW FHGRKRACLG 387 44,342
Ergl 1 CYP51F1 P10613 ORF19.922 C. albicans ESLR PERW FGTGPHVCLG 528 60,675
Erg5 094016 ORF! 9.5178 C. albicans ETLR PTRW FGGGRHRCIG 517 59,652
PAH1 CYP501 Q59PA5 ORF19.1411 C. albicans ETLR PDRW FGAGSRMCSG 600 69,012
Tri4 Q5A0Z1 ORF19.3105 C. albicans ENGR PERW FGKGVRMCLG 519 60.064
Table 3.2 -  The 10 putative cytochromes P450 in C. albicans. The conserved 
regions are highlighted (the PER(W) domain, the haem binding domain and K-helix).
3.3.2 Homologue of CYP52A3
Results from the BLAST query showed that the potential alkane/fatty acid 
hydroxylating cytochromes P450 highlighted in the search o f the Candida genome 
had varying degrees o f homology to CYP52A3. Alkl was shown to have the 
highest homology to C. maltosa CYP52A3 because it had the highest score and the 
lowest E value o f all the C. albicans genes meaning the probability o f this homology 
being a coincidence was low (see figure 3.7).
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To ensure ALK1 was in fact the gene with the greatest homology to CYP52A3, the 
protein sequences of CYP52A3, A lkl, Alk2, Alk3, Alk6 and Alk8 were all aligned 
using ClustalX (Thompson et al., 1997) and viewed in BioEdit (Hall, 1999) (see 
figure 3.8). Again, Alkl was shown to have the greatest homology to CYP52A3, 
which was confirmed visually and by comparing the percentage identities of all the 
potential CYP52s (see table 3.3).
Final confirmation came in the form of a phylogenetic tree (see figure 3.9). This 
showed that Alkl does in fact have the highest homology of all the potential C. 
albican CYP52s to CYP52A3 as Alkl shares a closer evolutionary history to 
CYP52A3 than the other potential C. albican CYP52s do.
CYP52A3 
sequence from 
Candida maltosa
Score E-Value
ALK1
S e q u e n c e s  p r o d u c in g  s i y u f i c a n c  a l ig n m e n ts :
sp iP lM » 4 !C P S 2 C _ C B N l»  C y to c h r a w  P450 52E3 (EC 1 1 4  14 - )  (CYPLI 
094080_CANMA C y to d ira m e  P4S0 52 (EC 1 . 1 4 . 1 4 . - )  (C a n d id a  m a l t o . 
s p ! P 2 4 4 5 8 ! CP52E CANMA. C y tochrom e P450 52A5 (EC 1 . 1 4 . 1 4 . - )  (CYPLI. 
Q SM U I CMTOL C y to c h ro m e * 450  52 (EC 1  14 14 -> [M A I ]  [C a n d id
*P
Q8 7 4 J5_CANTR C ytochrom e P450 52 <KC 1 .1 4 .1 4  
P 30608! CP52F_CANTR C y to ch ro m e P450 52A6 (EC 
A5E5R8_L0DEL C ytochrom e P450 52 (EC 1 .1 4 .1 4
A3LRT5_PICST C y tochrom e P4S0 S2A13 (A1Aan* h y d r o x y la s e  2) ( A l . 
A3LR60_PICST C y tochrom e P4S0 52 (EC 1 . 1 4 . 1 4 . - )  (CP52C) ( P i c h i .  
0 9Y7 5 8 I CPS2M_DEBHA C y to ch ro m e P4S0 S2A13 (EC 1 . 1 4 . 1 4 . - )  (A lk a
- )  (PCUG_058SS) [ .  
- )  (D EHAOCO 298 lg )  . 
- )  (DKHA0K19635g] .
A£DPF4_PICCU C ytochrom e P4S0 52 (EC 1 .1 4 .1 4
Q6BVH7_DEBHA C ytochrom e P4S0 52 (EC 1 .1 4 .1 4
Q6ENV8_DEBHA C ytochrom e P 450 52 (EC 1 .1 4 .1 4
Q9Y7S7!CPS2L_DEBHA C ytochrom e P4S0 S2A12 (EC 1 . 1 4 . 1 4 . - )  (A lk a
ASDD87_PICGU C ytochrom e P4S0 52 (EC 1 .1 4 .1 4
Q874J4_CANTR C y to d rro m e P4S0 52 (EC 1 .1 4 .1 4
Q5WUK OkNDL C y to c A n m e  * 450  52 (EC 1 .1 4  14
ASDQW9~PICGU C ytochrom e P4S0 52 (EC 1 .1 4 .1 4
Q8 7 4 J3_CANTR C ytochrom e P450 52 (EC 1 .1 4 .1 4
Q8 7 4 18_CANTR C ytochrom e P4S0 52 (EC 1 .1 4 .1 4
Q1 2 5 81_CANMA C ytochrom e P450 52 (EC 1 .1 4 .1 4
Q8 7 4 19_CANTR C ytochrom e P450 52  (EC 1 .1 4 .1 4
P30607! CPS2B_CAUTR C y to ch ro m e P450 S2A2 (EC 
Q6BNV9_DEBHA C ytochrom e P4S0 52 (EC 1 .1 4 .1 4
A5E1L9_LQDEL C ytochrom e P4S0 52  (EC 1 .1 4 .1 4
Q6BNW0DEBHA C ytochrom e P4S0 52  (EC 1 .1 4 .1 4
Q5A8US_CANAL P o t e n t i a l  a lk a n e  h y d r o x y l a t i n g  
ASDRQ8_L0DEL C ytochrom e P4S0 52 (EC 1 .1 4 .1 4
A3LS01_PICST C y tochrom e P4S0 52 (EC 1 .1 4 .1 4
Q59K96CRNEL C y to c h r m *  *450 52 (EC 1 .1 4  14
A5E1 L8_LQDBL C ytochrom e P4S0 52  (EC 1 .1 4 .1 4
074626_CANAL C ytochrom e P4S0 52 (EC 1 .1 4 .1 4
Q12S89ICPS2K CAMHA C ytochrom e P4S0 S2A11 (EC 1 . 1 4 . 1 4 . - )  (CYPL. 
Q 5M X7 CMNHL C y to c k rx x *  * 450  52 (EC 1 .1 4  1 4 . - )  [A IA 3] [C a n d id . 
A3LSP0_PICST C y tochrom e P4S0 52  (EC 1 . 1 4 . 1 4 . - )  (CP52LJ ( P i c h i .
- )  (CYP52A12) (Ca. 
1 . 1 4 . 1 4 . - )  (CYPLI. 
-)  [LELG 0 4 9 5 7 ) [ .
- )  (PCUG_01238) I .  
- )  (CYP52A13) [Ca. 
- )  D U K 2] [C a n d id  
- )  (PCT)G_0S670) | .  
- )  ICYPS2A14) (Ca. 
- )  (CYPS2A18) (Ca. 
- )  [AIA2-A] [C and. 
- )  (CYPS2A17) (Ca. 
1 . 1 4 . 1 4 . - )  (CYPLI. 
- )  [D EHA0E19 6 1 3g]  . 
- )  (LBLG_03S06) ( .  
- )  [D EHA0E1959 lg ]  . 
m o n o o x y g en a se  P 4 5 . 
- )  (LELG_00044) ( .  
- )  1ALK2] ( P i c h i a .  
-> [M A S ] [C a n d id  
- )  ILELG__03505J [ . 
- )  l a lk S ]  (C a n d id .
( b i t s )
1062
1041
984
•66
834
823
763
652
652
640
640
635
625
617
617
617
617
617
615
612
612
610
608
607
607
603
601
593
589
509
588
587
579
579
576
0.0  
0.0 
•  0 ^ .  
0.0  
0.0  
0.0  
0.0  
0.0  
0.0  
0.0  
1 80  
177  
-1 7 5  
-1 7 5  
175 
-1 7 5  
-1 7 5  
174 
-1 7 3  
-1 7 3  
-1 7 3  
-1 7 2  172 172 
171 
170 
-1 6 8  
r-166 
166 
166 
166 
163 
-1 6 3  
-1 6 2
Highest Score -  
Lowest E-value of 
the potential 
Candida albican 
genes, therefore 
greatest homology 
to CYP52A3
Some results have been omitted
tr!Q 2TZU 9_A SP0R C ytochrom e P4S0 52 (EC 1 . 1 4 . 1 4 . - )  [A 0090011 0 0 0 7 1 . . .  353 Z e-9S
tr!05SG W 4 CKOUj C y to c h ro m e * 450  52  (EC 1  1 4 . 1 4 . - )  CM A6] [C a n d id  352 4 e - 9 5
tr!Q0CYT4_ASPTX C ytochrom e P4S0 52 (EC 1 . 1 4 . 1 4 . - )  [ATEGJDllSOl ( . . .  351 6 e - 9 5
Lowest Score -  
H ighest E-value 
of the potential 
Candida albican 
genes, therefore 
lowest homology
Figure 3.7 - BLAST query results. Results are listed in order of homology to the 
queried CYP52A3 amino acid sequence, with the sequences with the highest score 
and lowest E-value at the top, and the lowest score and highest E-value at the bottom. 
The first result is CYP52A3 itself and is highlighted in blue. The sequences 
highlighted in red are the potential alkane/fatty acid hydroxylating c^lochromes P450 
found in the C. albicans genome.
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Figure 3.8 -  Section of the alignment involving CYP52A3 and the potential C. 
albican alkane hydroxylating cytochromes P450 (from residue 361 to the end).
The alignment was undertaken in ClustalX (Thompson et al., 1997) and viewed in 
BioEdit (Hall, 1999). Threshold for shading was set at 80%. Identical residues are 
highlighted in black and similar residues are coloured grey. The haem-binding site, 
K-helix and PER(W) domain are indicated on the alignment.
Protein Name Accession Name Identities
Alk2 Q5AAH6 314/521 60%
Alk8 Q59K96 306/507 60%
Alk3 Q5AAH7 302/529 57%
Alk6 Q5AGW4 195/447 43%
Table 3.3 -  Potential alkane/fatty acid hydroxylating CYP52s identified in C. 
albicans (http://www.expasv.org/cgi-bin/blast.pl). All proteins compared to 
CYP52A3. Alkl is shown to have the highest identity (to CYP52A3) o f all the 
potential CYP52s identified in this table.
Alk8
Alk6
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Figure 3.9 - Phylogenetic tree showing the relationship between CYP52A3 from  
C. maltosa and the potential CYP52s from  C. albicans. This phylogenetic tree
shows that A lkl and CYP52A3 share a close evolutionary history, suggesting that
Alkl has a greater homology to CYP52A3 than the other potential alkane/fatty acid 
hydroxylating proteins. The distance between Alkl and CYP52A3 is minimal, 
which indicates there are few amino acid changes between the two sequences 
showing relatively high homology.
3.4 Discussion
There is no doubt that since the conception of bioinformatics it has become an 
integral tool in the biological sciences. However, it is still in its infancy and it is still 
evolving. More attention needs to be focused on the nucleotide databases as 
currently they are relatively redundant. A second generation of nucleotide databases 
need to be developed primarily dealing with the sequence duplication, 
contamination, mislabelling, sequence errors, etc. that make these databases 
redundant. This will reduce the size o f the databases, making it quicker and easier 
for the user to access biological data. However, bioinformatics is still an excellent 
tool and is integral in the discovery o f new cytochrome P450 genes.
Using a bioinformatic approach, it has been shown that there are 10 putative 
cytochrome P450 genes in C. albicans. These are ALK1, ALK2, ALK3, ALK6, ALK8, 
TRI4, DIT2, PAH1, ERG5 and ERG11. Tri4, according to UniProt, has weak 
similarity to trichodiene oxygenase, a member o f the CYP58 family, which is
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involved in the biosynthesis o f mycotoxin trichothecene 
(http://www.uniprot.org/uniprot/Q5A0Zl). However, a BLAST search showed that 
Tri4 shares homology with several uncharacterised proteins, as well as a putative N- 
formyltyrosine oxidase (Dit2) from C. dubliniensis (B9WF59, bit score = 933, E- 
value = 0.0, identities = 86%). Dit2 from C. albicans shares sequence homology 
with N-formyltyrosine oxidases (CYP56s) from, amongst others, C. dubliniensis, S. 
cerevisiae, Aspergillus clavatus, A. fumigatus, Neosartorya fiocheri and 
Paracoccidioides brasiliensis. This means Dit2 potentially has a similar function to 
other CYP56 proteins, which are known to be involved (in conjunction with D itl) in 
the biogenesis o f the meiotic spore wall o f S. cerevisiae (Briza et al., 1994; Briza et 
al., 1996; Melo et al., 2008). PAH1 is a phenylacetate hydroxylase, which is 
homologous to putative genes from C. dubliniensis, Penicillium marneffei, 
Talaromyces stipitatus, Ajellomyces dermatitidis and Neosartorya flscheri and is 
identified as CYP501 on the Cytochrome P450 Homepage 
(http://dmelson.uthsc.edu/CvtochromeP450.html). E rg ll (also called CYP51 and 
lanosterol 14a-demethylase) from C. albicans shares homology with CYP51s from 
C. glabrata, C. dubliniensis, C. krusei, S. cerevisiae, S. elongisporus, Kluyveromyces 
polysporus and Pichia stipitis. CYP51s are associated with sterol production and are 
the main target o f azole antifungal drugs (Kelly et al., 2001). Erg5 (also called 
CYP61 and sterol 22-desaturase), on the other hand, shows homology to putative 
CYP61 proteins from P. stipitis, P. pastoris, S. cerevisiae, Symbiotaphrina buchneri, 
S. kochii, Microsporium canis, A. clavatus, A. fiocherianus, A. fumigatus, A. niger 
and A. terreus. Like CYP51, CYP61 is involved in sterol production, but is a sterol 
C-22 desaturase rather than a lanosterol 14a-demethylase (Kelly et al., 1997). The 
remaining five putative cytochromes P450 in C. albicans:; A lkl, Alk2, Alk3, Alk6 
and Alk8 are potentially involved in alkane and/or fatty acid hydroxylation. O f these 
Alkl has been shown to have the greatest homology to a known alkane 
hydroxylating cytochrome P450 from C. maltosa, CYP52A3 and is, therefore, of 
interest for the studies that follow.
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Chapter 4 : Cloning and Protein Expression of A lkl. its Truncations and
NADPH-Cvtochrome P450 Reductase (CPR) from Candida albicans and
CYP52A3 from C. maltosa
4.1 Introduction
In chapter 3 it was shown that Alkl from C. albicans shares homology with 
CYP52A3, the archetypal alkane-hydroxylating cytochrome P450 in C. maltosa, 
suggesting Alkl has the ability to hydroxylate alkanes. However, homology does 
not necessarily result in the same protein function. This has been shown with the 
CYP52A subfamily, of which CYP52A3 is a member. CYP52A3 and CYP52A4 
from C. maltosa have been shown to hydroxylate both mid-to-long chain alkanes and 
fatty acids (Zimmer et al., 1995; Zimmer et al., 1996; Scheller et al., 1998), whereas 
CYP52A13 and CYP52A17 from C. tropicalis have only been shown to hydroxylate 
fatty acids (Eschenfeldt et al., 2003). All these genes share greater than 55% identity 
as they are all part o f the same subfamily, but they cannot all hydroxylate alkanes, 
thus showing differences in activity between the proteins does exist. These 
differences are not exclusive to the CYP52A subfamily as similar occurrences have 
been shown to arise between other cytochromes P450. CYP77A4 and CYP77A6, 
from Arabidopsis thaliana, are both able to catalyse the in-chain hydroxylation o f 
lauric acid (C l2:0) (Li-Beisson et al., 2009; Sauveplane et al., 2009). However, only 
CYP77A4 has been shown to be involved in the epoxidation of unsaturated fatty 
acids, such as oleic acid (C l8:1) (Sauveplane et al., 2009). This again shows that 
exact function cannot be conferred from homology. Therefore, to study the 
substrates o f Alkl and the reactions it is involved in the protein needs to be 
expressed for in vitro studies.
Cytochromes P450 can be expressed in a number o f host organisms, most commonly 
Escherichia coli and yeast cells.
4.1.1 Expression in E. coli
E. coli is a preferred host for protein expression as the method is relatively quick and 
easy (Waterman et al., 1995). The initial transformation o f DNA into E. coli only 
requires a small amount o f DNA to be successful and is thought to be r elatively easy 
when compared to other host organisms, such as mammalian and insect cells (Verma
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et al., 1998). Plasmid vectors used for the cloning and expression o f individual 
genes in E. coli contain an origin of replication (ori) allowing for efficient replication 
in the host and multiple restriction cleavage sites for insertion o f the gene fragment 
into the vector. The vector usually contains an antibiotic resistance gene, such as 
Ampr (which conveys resistance to ampicillin) allowing E. coli colonies containing 
the plasmid to grow in media containing the antibiotic. Those cells that do not 
contain this plasmid will not grow in this media, meaning the antibiotic can be used 
as a selectable marker. Cloning vectors, such as pUC and pGEM-T easy, can also be 
used for blue/white selection of colonies when complemented with an E. coli strain 
that contains a partial lacZ gene deletion (lacZAM15), such as the XL-1 blue strain. 
The lacZ gene, which is also present in these vectors, makes up part of the lac 
operon. The lac operon is involved in the transport and metabolism of lactose in E. 
coli and requires the enzyme, p-galactosidase to digest lactose to glucose (Mtiller- 
Hill, 1996). LacZ encodes for p-galactoside, which is induced in the presence of 
isopropyl-p-D-thio-galactoside (IPTG). IPTG is a thio-galactoside, which is a 
compound that acts as a P-galactosidase inducer, but does not itself become 
hydrolysed by the enzyme (Muller-Hill, 1996). Unlike 5-bromo-4-chloro-3-indolyl- 
P-D-galactoside (X-Gal), which is converted to galactose by P-galactosidase (Muller- 
Hill, 1996). The resultant galactose is then broken down further to produce an 
insoluble blue-indigo dye (Muller-Hill, 1996). This dye is produced if  the lacZ gene 
o f the vector is undisrupted during cloning thus producing colonies, which appear 
blue in the presence o f X-Gal and IPTG. However, if  the lacZ gene is disrupted by 
the insertion of another gene, e.g. the gene fragment, the p-galactosidase is no longer 
induced by IPTG so X-Gal is not broken down and this blue-dye is not produced. 
This results in the production o f white colonies, thus giving rise to blue/white 
selection.
For protein expression, the gene o f interest requires ligation into an expression 
vector. An expression vector is a vector that has been designed so that the gene 
fragment can be inserted at a particular site (within the vector sequence) enabling it 
to be transcribed and translated into protein (Alberts et al., 2002). Expression 
vectors usually contain a strong promoter, which can be regulated by the addition of 
a regulatory chemical, such as IPTG, to initiate expression. Examples include: the 
lac promoter (Miller et al., 1968), the trp promoter (Zubay et al., 1972) and the tac
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promoter (Amann et al., 1983; de Boer et al., 1983). The lac promoter is found 
upstream of the cloning site and can be induced by the addition of IPTG. The trp 
promoter is involved in tryptophan synthesis and, unlike the lac promoter, can be 
both induced and repressed. The addition of 3-P-indoleacrylic acid can induce the 
promoter and result in the transcription o f the gene o f interest. Alternatively, the 
addition o f tryptophan represses the promoter so transcription cannot take place. The 
tac promoter is a trp/lac promoter hybrid making it a stronger promoter than the 
other two. However, like the lac promoter, it is induced by IPTG, leading to the 
expression o f the down-stream gene o f interest. The use o f an expression vector with 
a strong promoter, along with the fast rate o f growth o f E. coli means that protein can 
be expressed in high yields and in a much shorter time than in other systems, such as 
mammalian cells (Verma et al., 1998). However, the use o f IPTG, particularly in 
large-scale protein expression, can increase the costs of this technique as the 
chemical is relatively expensive to purchase. Furthermore, the cost to express 
cytochrome P450 protein is increased by the need to add 5-aminolevulinic acid (Ala) 
to the media as it is a haem precursor required for cytochrome P450 function 
(Richardson et al., 1995; Gillam et al., 1995).
The gene sequence of the hydrophobic N-terminus o f an individual membrane-bound 
cytochrome P450 can be altered to enhance the amount o f protein produced by 
expression in E. coli (Barnes et al., 1991). These alterations were first shown to aid 
protein expression of the bovine 17a-hydroxylase, CYP17A1 (Barnes et al., 1991). 
In the gene sequence o f this cytochrome P450, the second codon was altered to GCT 
(which encodes for alanine) as it is the preferred second codon for lacZ gene 
expression in E. coli (Looman et al., 1987; Barnes et al., 1991). Furthermore, 
codons three to eight were made AT-rich to prevent the formation o f GC hairpins 
(Barnes et al., 1991). Collectively, these alterations resulted in an increase in the 
concentration o f cytochrome P450 produced. The yield o f CYP17A1 protein 
(expressed in pCW vector and the E. coli strain JM109) increased to 750nmoles/L 
(using this method) from Onmoles/L, which was produced using the native sequence 
and same growth/expression conditions (Barnes et al., 1991; Waterman et al., 1995). 
Therefore, modifying the sequence is a useful tool for enhancing protein expression 
in E. coli.
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However, the overexpression o f protein in E. coli can lead to the formation of 
inclusion bodies, which occur if  expression exceeds the cells capability for 
production (Barnes, 1996). These inclusion bodies are the result o f incorrectly 
folded/unfolded protein and lead to the formation o f inactive cytochrome P450 
protein (Williams eta l., 1982; Barnes, 1996).
4.1.2 Expression in Yeasts
Yeasts are also a common choice o f host organism for protein expression. 
Saccharomyces cerevisiae, Schizosaccharomyces pombe and Pichia pastoris have all 
been used to express cytochrome P450 protein, with S. cerevisiae AH22 being the 
most commonly used strain (Guengerich et al., 1991).
Yeasts, unlike E. coli, contain native cytochrome P450 genes. For example, S. 
cerevisiae contains three cytochromes P450: CYP51, CYP61 and CYP56. Although, 
these are not spectrally detectable, allowing the organism to be used for protein 
expression experiments. However, this is an advantage as the presence of 
cytochromes P450 in the organism means NADPH-cytochrome P450 reductase 
(CPR) is also present as it is required for electron transport during cytochrome P450 
activity (see section 1.2.1). This means that any microsomal fractions produced as a 
result o f protein expression in this organism could be used for metabolism studies as 
CPR would be present in the fraction (Pompon et al., 1996). However, in some cases 
(e.g. CYP3A4) additional CPR would be required for functional metabolism 
(Pompon et al., 1996).
There are two types o f vectors used for cloning and expression in S. cerevisiae’. 
integrative and autonomous. Integrative vectors require integration into the 
chromosome o f the yeast for replication, whereas autonomous vectors are able to 
replicate independently o f the chromosome as they contain an autonomously 
replicating sequence (ARS), which contains a yeast origin o f DNA replication. 
Autonomous vectors are the most commonly used and many are known as “shuttle 
vectors” as they also contain an E. coli origin o f replication. This means these 
shuttle vectors are able to replicate in E. coli, as well as yeast, allowing manipulation 
and high-copy numbers of the plasmid to be undertaken quickly. These vectors also 
contain an antibiotic resistance gene (e.g. Ampr or Tetr) to allow selection on that
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antibiotic (e.g. ampicillin or tetracycline). Yeast vectors usually contain a selectable 
gene marker, which allows colonies containing the plasmid to grow in the absence of 
certain amino acids that would normally be added to the media. These gene markers 
include: LEU2 (Beggs, 1978), TRP1 (Tschumper & Carbon, 1980), H1S3 and URA3 
(Struhl et al., 1979). Presence of one o f these genes on the vector (e.g. LEU2) means 
that the amino acid (e.g. leucine) does not need to be added to the media as the amino 
acid can be synthesised independently o f the cell. Therefore, using this plasmid with 
a complementary strain (i.e. a strain that is unable to synthesis that particular amino 
acid) means only cells containing this plasmid can grow in the absence o f that amino 
acid allowing for the selection and growth of cells containing the gene o f interest.
Yeast expression vectors require promoters for transcription. The most commonly 
used are the GAL promoters GAL1 and GAL 10, which are induced by the addition of 
galactose to the media (Broach et al., 1983). Yeast preferentially grows on media 
containing sugars, most notably glucose, which can be used directly by glycolysis 
(conversion o f sugar to pyridine producing ATP and NADH as by-products) for 
growth (Romanos et al., 1992). However, if  cells containing plasmids carrying such 
a promoter (such as YEp51 containing a GAL 10 promoter) are grown in glucose-rich 
media expression cannot be induced until all the glucose has been exhausted. This is 
because glucose represses the promoter involved in transcription thus preventing 
protein expression until all the glucose has been consumed (Romanos et al., 1992). 
Using the GAL10 promoter also means expensive chemicals, such as IPTG are not 
required to be added to the media as IPTG is not needed to induce transcription. 
Furthermore, the yeast cells are able to synthesise their own haem without the need 
for the addition o f Ala, which E. coli cells are unable to do for high level expression. 
However, ferric chloride (F eC y  can be added to the media to enhance haem 
production.
There are many advantages and disadvantages to using E. coli and yeasts as host 
organisms for protein expression, but they remain the most commonly used 
expression systems to date. Table 4.1 outlines these advantages and disadvantages. 
Other organisms have also been used, to a lesser extent, for the heterologous 
expression of cytochromes P450. These include mammalian and insect cells.
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Host Organism Advantages Disadvantages
E. coli
• Relatively quick
• Vector manipulation is 
relatively easy
• The amount o f membrane- 
bound protein produced can 
be increased by altering the 
N-terminus (e.g. making it 
AT-rich)
• Requires Ala as a haem 
precursor
• Overexpression can lead to 
the formation o f inclusion 
bodies
• Lack of post-translational 
modifications
Yeast
• Does not require Ala as a 
haem precursor (ferric 
chloride (FeCl3) can be 
added to enhance haem 
production instead)
• Contains native 
cytochromes P450 and CPR
• Post-translation 
modifications
• Slower growth than E .  c o l i
• Cell wall is difficult to break
• Vector manipulation is more 
difficult than with E .  c o l i
Table 4.1 -  Overview of the advantages and disadvantages of using E. coli and 
yeast as host organisms for protein expression.
4.1.3 Expression in Mammalian Cells
The use o f the mammalian expression system is uncommon as it is relatively 
expensive and expresses protein at low levels compared to the E. coli and yeast 
systems (Guengerich et al., 1991). However, there are two types o f this expression 
system available (COS cells and the vaccinia virus) and they have both been used to 
express cytochromes P450.
COS cells are the most commonly used mammalian expression system and are 
produced by integrating SV40 viral DNA into kidney cells (CV-1) from the African 
Green Monkey (Gluzman, 1981). This cell line has been used to express a number of 
human cytochromes P450 including CYP1A1 (McManus et al., 1990), CYP3A4 
(Ball et al., 1992) and CYP4A11 (Imaoka et al., 1993). However, because o f the low 
expression levels associated with this expression system, it is difficult to properly
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measure the cytochrome P450 protein content so this system is primarily used for the 
screening of cytochrome P450 activity (Gonzalez & Korzekwa, 1995).
The vaccinia virus has also been used to express a number of cytochrome P450 
proteins, including the human genes CYP4B1 (Nhamburo et al., 1989) and CYP2A6 
(Yamano et al., 1990). However, this expression system is not widely used as the 
production of the recombinant virus is time-consuming and its availability is quite 
low (Gonzalez & Korzekwa, 1995). There is also a safety concern with this system 
as the vaccinia virus is derived from the cow pox virus and there are fears o f human 
infection despite the virus being attenuated (Gonzalez & Korzekwa, 1995).
4.1.4 Expression in Insect Cells
Insect cells have been used as a host for the expression o f insect cytochrome P450 
proteins, such as CYP6B33 (Mao et al., 2008). However, at present only a limited 
number o f cytochromes P450 from other organisms have been expressed in this 
system. These include CYP4A11 (Imaoka et al., 1993), CYP3A4 (Buters et al.,
1994), CYP19A1 (Sigle et a l, 1994), CYP2A13 (Zhou et al., 2010) and CYP2A25 
(Zhou et al., 2010). However, higher levels of protein have been produced using an 
insect cell system when compared with expression in mammalian cells (Verma et al.,
1998). The most common type o f expression system in insect cells is the baculovirus 
system as there are over 500 species available, which unlike the vaccinia virus, are 
not potentially harmful to humans as they are restricted to use in insect cells (Groner, 
1986; Gonzalez et al., 1991; Verma et al., 1998). As with the vaccinia virus, the 
process to produce recombinant bacluovirus is time-consuming (Gonzalez & 
Korzekwa, 1995) thus putting the systems at a disadvantage when compared to other 
expression systems, such as E. coli and yeast.
O f the cytochrome P450 protein expression systems described above, E. coli and 
yeast cells are the most commonly used host organisms. However, E. coli is the 
preferred host organism for protein expression as it is readily available and relatively 
quick and easy to use (Waterman et al., 1995). Therefore, in this chapter ALK1 will 
be cloned and expressed in E. coli as the gene o f interest, as in chapter 3 it was 
shown to have the greatest homology to the archetypal alkane-assimilating 
cytochrome P450, CYP52A3 from C. maltosa. Expressing the protein will allow
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further studies to be undertaken to identify potential substrates through substrate 
binding and reconstitution assays thus potentially deorphanising A lkl. Truncations 
o f this gene will also be designed to aid the heterologous expression of Alkl and to 
be potentially used for crysatillisation studies. The production o f a crystal o f this 
protein would increase the understanding o f its structure. As Alkl is a membrane- 
bound protein it would first need to be truncated as the hydrophobic N-terminus 
would interfere in crystal production. CYP52AS will also be cloned and expressed as 
will CPR from C. albicans (CaCPR). CYP52A3 will be used as a positive control in 
reconstitution assays and CaCPR will be used in these assays to transfer electrons 
from NADPH during the monooxygenase cycle (i.e. insertion of an oxygen atom into 
the substrate). Therefore, the objectives o f this chapter are to clone and express the 
proteins o f ALK1 and CaCPR from C. albicans and CYP52A3 from C. maltosa. Also 
attempts to design an active truncated form of ALK1 and to clone and express its 
protein are described.
4.2 Materials and Methods
4.2.1 Media
4.2.1.1 Terrific Broth (TB) for Protein Expression in E. coli 
Based on the recipe o f Tartoff & Hobbs, 1987.
12g of tryptone, 24g o f yeast extract and 8ml o f 50% (v/v) glycerol were added to 
900ml o f distilled water and autoclaved.
4.2.1.2 Minimal Media for Protein Expression in S. cerevisiae
4.2.1.2.1 Minimal Media Containing Glucose as the Initial Carbon Source
0.67% (w/v) yeast nitrogen base (without amino acids) (Difco) and 2% (w/v) glucose 
were added to 1 litre o f distilled water and autoclaved.
4.2.1.2.2 Minimal Media Containing Raffinose as the Initial Carbon Source
Based on the recipe o f Zimmer et al., 1995.
0.67% (w/v) yeast nitrogen base (without amino acids), 2% (w/v) raffinose and 
ling/L FeCh (Sigma) were dissolved in 1 litre o f distilled water and autoclaved.
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4.2.2 Buffers
4.2.2.1 Lysozyme Buffer for Protein Preparation (E.coli)
0.25M sucrose, 50mM Tris HC1 (Melford) pH7.4, 0.5mM EDTA (Sigma-Aldrich) 
and 1 mg/ml lysozyme (Sigma-Aldrich). Stored at 4°C.
4.2.2.2 Sonication Buffer for Protein Preparation (E.coli)
50mM potassium phosphate pH7.4, 20% (v/v) glycerol, 0.1 mM DTT, 0.1 mM EDTA, 
0.5M sodium acetate (Sigma-Aldrich) and 2% (w/v) sodium cholate (Acros 
Organics). Stored at 4°C.
4.2.2.3 Equilibration Buffer for Ni2+-NTA Agarose Purification
0.1M potassium phosphate pH7.4 (19.8ml of 1M KH2PO4 and 80.2ml of 1M 
K2HPO4) and 20% (v/v) glycerol. Stored at 4°C.
4.2.2.4 W ash Buffer for Ni2+-NTA Agarose Purification
0.5M sodium chloride, dissolved in equilibration buffer. Stored at 4°C.
4.2.2.5 Elution Buffer for Ni2+-NTA Agarose Purification
60mM L-Histidine (Acros Organics), dissolved in wash buffer. Stored at 4°C.
4.2.3 Methods
4.2.3.1 Design of Alkl Truncations
Alkl truncations were designed using the following web-based software programs: 
TMHMM (http://www.cbs.dtu.dk/services/TMHMM) (figure 4.1), HMMTOP 
(http://www.enzim .hu/hmmtop/) (figure 4.2) and SignalP
(http://www.cbs.dtu.dk/services/SignalP/) (figure 4.3). TMHMM and HMMTOP use 
HMM-driven algorithms based on compiled datasets to predict the membrane anchor 
region of a protein, whereas SignalP predicts signal peptide cleavage sites rather than 
the membrane anchor region. Together the results from each of these programs can 
be used to indicate residues, which may be omitted from the Alkl protein to produce 
a truncated version lacking the hydrophobic N-terminus.
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“ S u b m it” is  p ressed  to  g e n e r a te  th e  re su lts
Figure 4.1 -  TM HM M  (http://www.cbs.dtu.dk/services/TM HM M ). TMHMM is 
a web-based program, which can be used to predict the membrane anchor region of a 
protein.
95
The sequence is pasted 
into this box
“Submit" is pressed to 
generate the results
The “Subm it” button is 
pressed to reach the sequence  
subm ission screen
[ < tl K. y r'*r* ■
HMMTOP
Figure 4.2 -  HM M TOP (http://www.enzim.hu/hmmtop/). HMMTOP can be used 
to predict the potential topology and membrane anchor regions of the protein.
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The protein sequence 
(in FASTA format) is 
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11 — I
The “Submit” button is pressed to generate the 
results
Figure 4.3 -  SignalP (http://www.cbs.dtu.dk/services/SignalP). SignalP can be 
used to predict the signal peptide cleavage sites in a protein sequence.
4.2.3.2 PCR
The complete open reading frames (ORF) of ALK1, its truncations, CaCPR and 
CYP52A3 were amplified from extracted genomic or plasmid DNA using primers 
that flank the 5’ and 3’ end of the coding sequence (see table 4.2). Each primer 
contains a region coding for a restriction enzyme that enables the gene to be cut and 
ligated into the expression vector of choice (i.e. pCWori+). For this study, the coding 
sequence of each gene was flanked by Nde I and Hind III restriction sites, which 
allows the gene to be ligated into the vector pCWori . These flanking regions of the 
primer do not bind to the template DNA, but during PCR they are replicated 
producing PCR products that have incorporated terminal restriction sites (Brown,
1995). Both the forward and reverse primers for each gene also contain a GC clamp 
to aid with PCR (Abrams et al., 1990; Traystman et al., 1990). The reverse primers 
have a four codon histidine tag to support protein purification by affinity
• 2 “hchromatography (using N f  -NTA) followed by a stop codon (TAA). Both are 
incorporated into the terminal ends of the PCR product in the same way as the 
restriction sites (described above). The CaCPR primers used were produced based 
on the design of Park et al., 2010 (table 4.2).
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ALK1 was amplified by PCR from extracted C. albicans DNA using the proof­
reading enzyme, Platinum® Pj5c DNA polymerase (Invitrogen). The reaction mixture 
was made up to a final volume of 50pl by mixing together 27pi o f distilled water, 
5 pi o f lOx Pfx amplification buffer (Invitrogen), 1.5 pi of lOmM dNTP mix 
(Promega), 3pl of 50mM MgSC>4 (Invitrogen), 1.5pl o f the forward primer, 1.5pl of 
the reverse primer, 0.5pi o f Platinum® Pfx DNA polymerase (1 Unit) (Invitrogen), 
5pi of C. albicans genomic DNA and 5pi of lOx PCRX Enhancer solution 
(Invitrogen). The PCR program was set-up with an initial step at 94°C for 2 minutes. 
This was followed by 25 cycles o f denaturation set at 94°C for 15 seconds, the 
annealing temperature set at 45°C for 30 seconds and elongation temperature set at 
68°C for 2 minutes. Lastly, a 4°C ad infinitum step was added.
To optimise PCR product formation, ALK1 was titrated against different 
concentrations of magnesium and genomic DNA (see table 4.3b). The thermal 
cycling conditions were also altered to try and optimise the reaction (see table 4.3a). 
Initially, the number o f cycles was increased from 25 to 35 cycles. The elongation 
time was then increased from 2 minutes to 4 minutes with an extra cycle o f 2 minutes 
added on at the end. The duration o f the denaturation stages was also increased. The 
initial cycle was increased from 2 minutes to 5 minutes and the denaturation stage as 
part o f the 35 cycles was doubled from 15 seconds to 30 seconds. The amount of 
each primer was also increased from 1.5pl to 3pl. The optimisation steps described 
above are shown in table 4.3b.
The final optimised PCR parameters for the amplification o f ALK1 are as follows. 
The reaction mixture was made up to a final volume o f 50pl by mixing together 22pl 
o f distilled water, 5 pi o f lOx Pfx amplification buffer, 1.5 pi of lOmM dNTP mix, 3pl 
o f MgSC>4, 3pl of the forward primer, 3pl o f the reverse primer, 0.5pl o f Platinum® 
Pfx DNA polymerase, 7pl of C. albicans genomic DNA and 5pi o f lOx PCRX 
Enhancer solution. The PCR program was set-up with an initial step at 94°C for 5 
minutes. This was followed by 35 cycles o f denaturation set at 94°C for 30 seconds, 
the annealing temperature set at 45°C for 30 seconds and the elongation temperature 
set at 68°C for 4 minutes. Lastly, a single elongation step at 68°C for 2 minutes was 
added with a final, ad infinitum, step at 4°C.
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ALK1 truncations; A33:ALK1, A69.ALK1, modifiedA50:ALKl and 
modifledA44:ALKl were amplified from pCWori+:AlklL456S plasmid DNA using 
the primers detailed in table 4.2 and Expand High Fidelity polymerase (Roche). The 
reaction mixture was made up to a final volume of 50pl by mixing together 23.25pl 
of distilled water, lpl of lOmM dNTP mix (Promega), 3 pi of the forward primer, 3 pi 
of the reverse primer, 5pl of lOx Expand High Fidelity buffer (Roche), 7pl o f 25mM 
magnesium (Roche), 7pl o f pCWori+:AlklL456S plasmid DNA and 0.75pl of 
Expand High Fidelity polymerase (Roche). The thermal cycling conditions were set­
up with an initial denaturation step at 94°C for 5 minutes. This was followed by 35 
cycles o f denaturation at 94°C for 15 seconds, the annealing temperature at 55°C for 
30 seconds and the elongation temperature at 68°C for 2 minutes. An additional 1 
cycle elongation step o f 68°C for 7 minutes was added before a final 4°C ad 
infinitum step.
CYP52A3 was amplified from C. maltosa genomic DNA using the same method as 
described for the Alkl truncations above.
CaCPR was amplified from C. albicans genomic DNA using Expand High Fidelity 
DNA polymerase. The reaction mixture was made up as follows: 2pM of lOmM 
dNTP mix, 3pi of the forward primer, 3pi of the reverse primer, 5pi o f lOx Expand 
High Fidelity buffer, 3pl o f 25mM magnesium and 7pl o f C. albicans genomic DNA. 
The mixture was made to a final volume o f 50pl with distilled water. The thermal 
cycling conditions were set up as follows. An initial denaturation step o f 94°C for 5 
minutes was followed by 35 cycles of denaturation at 94°C for 15 seconds, the 
annealing temperature at 45°C for 30 seconds and elongation at 68°C for 2 minutes. 
A final elongation step o f 68°C for 7 minutes was added before a final 4°C ad 
infinitum step.
In all cases the PCR product was visualised on a 1 % (w/v) agarose gel.
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Step T em perature D uration
N o. O f  
C ycles
#1
Denaturation 94°C 2 mins x l
Denaturation 94°C 15 secs
x25Annealing 45°C 30 secs
Elongation 68°C 2 mins
Cooling 4°C 00 x l
#2
Denaturation 94°C 2 mins x l
Denaturation 94°C 15 secs
x35Annealing 45°C 30 secs
Elongation 68°C 2 mins
Cooling 4°C oo xl
#3
Denaturation 94°C 5 mins x l
Denaturation 94°C 30 secs
x35Annealing 45°C 30 secs
Elongation 68°C 4 m ins
Elongation 68°C 2 m ins x l
Cooling 4°C 00 x l
b)
1 2 3
R eaction Num ber 1 2 3 4 5 6 7 8
Water 27pl 24pl 25 |il 22pl 22pl 25pl 22pl 8pl
1 Ox Pfx Amplification Buffer 5pl 5pl 5 pl 5 pi 5pl 5pl 5pl 5pl
50mM M g S 0 4 3 pi 6pl 3pl 6pl 3pl 3pl 3 pi 3pl
1 OmM dNTP Mixture 1.5pl 1.5pl 1.5pl 1.5pl 1.5pl 1.5pl 1.5pl 1.5pl
Forward Primer 1.5pl 1.5pl 1.5 pi 1.5pl 1.5pl 1.5pl 3pl lOpl
Reverse Primer 1.5pl 1.5pl 1.5pl 1.5pl 1.5pl 1.5pl 3pl lOpl
Platinum® Pfx D N A  Polymerase 0.5pl 0.5pl 0.5pl 0.5pl 0.5pl 0.5pl 0.5pl 0.5pl
D N A 5pl 5pl 7 |il 7pl lOpl 7pl 7pl 7 pi
1 Ox PCRX Enhancer Solution 5pl 5pl 5pl 5pl 5pl 5pl 5pl 5pl
Thermal Cycling Conditions #1 #2 #3
Table 4.3 -  ALK1 PCR methods, a) Shows the thermal cycling conditions used for 
each PCR reaction; b) The PCR reaction mixtures set-up.
4.2.3.3 A-Tailing and Ligation into pGEM®-T Easy Vector (Promega)
Blunt-ended ALK1 PCR product was A-tailed as follows: lp l o f 15mM magnesium 
chloride (Promega), lp l o f 2mM dATP (Promega), lp l o f Taq polymerase 
(Promega) and lp l of magnesium free Taq buffer (Promega) was added to 6pl of 
PCR product. This was placed in the thermal cycler for 30 minutes at 37°C. The 
mixture was then immediately incubated on ice in preparation for ligation into the
pGEM®-T easy vector. However, CYP52A3, CaCPR, A33.ALK1, A69.ALK1, 
modifiedA50:ALKl and modifiedA44:ALKl PCR products did not require A-tailing 
as the polymerase used for PCR (High Fidelity) contains Taq, which adds adenosine 
to the ends at the gene during PCR.
For ligation into the pGEM®-T easy vector system (Promega) reactions were made 
up containing 3pi o f the (A-tailed) DNA product, lp l o f the pGEM®-T easy vector 
(Promegag), 5 pi o f the 2x rapid ligation buffer (Promega) and lp l o f T4 DNA ligase 
(Promega). A control was also set up with 1 pi of the control insert DNA (Promega), 
lp l of pGEM®-T easy, 2pl of water, 5pi of 2x rapid ligation buffer and lp l o f T4 
DNA enzyme. All reactions were incubated overnight at 4°C.
The ligations were then transformed into competent XL-1 E. coli cells and grown on 
LB ampicillin plates containing X-Gal and IPTG for blue/white selection.
4.2.3.4 Ligation into pCWori+ and YEp 51
Isolated vector DNA for ligation into pCWori+ was double digested with Nde I and 
Hind III (section 2.2.6.2), visualised on a 1% (w/v) agarose gel (section 2.2.3) and 
the DNA was extracted (section 2.2.4). For ligation o f DNA into YEp51 the DNA 
was double digested with Sal I and Hind III (section 2.2.6.2).
For ligation into the pCWori+ or YEp51 vectors reactions were made up containing 
lp l of T4 DNA ligase (Roche), lp l of lOx T4 ligation buffer (Roche) and various 
ratios of vector to insert to make a final volume of lOpl. All reactions were 
incubated overnight at 4°C.
The ligations were then transformed into DH5a E. coli cells and spread onto LB agar 
plates containing ampicillin, which were incubated overnight at 37°C.
4.23.5 Cloning Strategies
Overview of the cloning strategies used to express the protein o f A lkl, its 
truncations, CaCPR and CYP52A3 using E. coli and S. cerevisiae as the host 
organisms.
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4.2.3.5.1 Summary of Cloning Strategy Used for the Expression of Protein in E.
coli
Figure 4.4 shows the cloning strategy used to express ALK1, its truncations and 
CaCPR from C. albicans and CYP52A3 from C. maltosa into E. coli in preparation 
for protein expression.
A -Tailing
PCR product
PCR product 
ligated into 
pGEM-T easy 
vector pGEM-T easy
vecto r
Figure 4.4 -  Cloning strategy used for the 
expression of ALK1, its truncations, 
CaCPR and CYP52A3 in E. coli. These 
genes were amplified from genomic or 
plasmid DNA to be cloned into E. coli, the 
host organism for the expression of protein.
Transform ation  into XL-1 
ce lls fo r blue/white 
Poly-T e n d s  se lec tion
Ndel and H ind lll 
restnctionenzym es DNA w ithsticky
used to  remove gene ends (Ndel and
Hindlll restriction  
sites)
PCR product 
ligated into 
pCWori+ vector
pCWori* vector with Ndel 
and Hindlll restriction  
s ites  (sticky ends)
Transform ed 
into DH5a cells
DH5a C hrom osom e
P c w or>+ T > [g e |
gene
DH5a cell -  Ampicillin is used  
to se lect transform ants
Genomic DNA was extracted from C. albicans and C. maltosa (section 2.2.2) and 
used as the template for PCR of ALK1, CaCPR and CYP52A3 (section 4.2.3.2). 
A33.ALK1, A69.ALK1, modifiedA50:ALKl and modifiedA44:ALKl were amplified 
by PCR from pCWori+:Alkl L456S plasmid DNA. Following PCR, the PCR product 
was visualised on a 1% (w/v) agarose gel (section 2.2.3). The expected size o f each 
gene (shown in table 4.2) was compared with the DNA marker. Correct size 
amplicons were isolated from the gel and the DNA was extracted (section 2.2.4). 
The extracted DNA was A-tailed (depending on the PCR polymerase used) and 
ligated into the vector, pGEM-T easy (section 4.2.3.3). The plasmids were then 
transformed into XL-1 E. coli cells and spread onto LB plates containing ampicillin, 
IPTG and X-Gal for blue/white selection (section 2.2.7). Individual white colonies
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were picked and used to inoculate 10ml o f LB broth containing ampicillin for 
overnight culturing. Plasmid DNA was isolated from 1ml o f the culture (section 
2.2.5) and digested with the restriction enzyme, Not I to check for the gene of interest 
(section 2.2.6.1) and visualised on a 1% (w/v) agarose gel. Plasmids containing 
inserts o f the correct size were then subjected to a Nde UHind III double digest
(E)(section 22.6.2) to release the gene from the pGEM-T easy vector and to prepare 
the gene with sticky ends for ligation into pCWori+. A 1% (w/v) agarose gel was 
used to visualise the band o f interest and the correct sized amplicon was isolated 
from the gel and the DNA was extracted. The DNA sequence o f the gene of interest 
in the pGEM-T easy plasmid was verified by sequencing (section 2.2.9).
The extracted DNA was ligated into pCWori+ (section 4.2.3.4) and transformed into 
DH5a cells and spread onto LB plates containing ampicillin. Individual colonies 
were picked and used to inoculate 10ml o f LB broth containing ampicillin for 
overnight culturing. Plasmid DNA was isolated from 1ml o f the culture and digested 
with the restriction enzymes, Nde I and Hind III to check for the presence o f the 
insert (section 2.2.6.3). This was visualised on a 1% (w/v) agarose gel. The gene of 
interest was verified by sequencing (section 2.2.9).
4.2.3.5.2 Summary of Cloning Strategy Used for the Expression of Protein in S.
cerevisiae
YEp51:CYP52A3_yeast plasmid was a kind gift from Dr. Wolf-Hagen Schunck, 
Max Delbriick Centre for Molecular Medicine, Berlin, Germany. The plasmid was 
transformed into S. cerevisiae (AH22 strain) cells and spread onto YM plates 
containing histidine (section 2 .2 .8).
4.2.3.6 Synthetic Genes -  ALK1L456S, ALK1L456S yeast and A6S:ALK1
The synthetic genes, ALK1L456S and A65:ALK1 were produced by GeneCust. and 
optimised for expression in E. coli. ALKl_yeast was optimised for expression in S. 
cerevisiae. All genes were designed to contain a codon encoding for serine at 
residue 456.
The ALK1L456S and A65.ALK1 were designed as follows (see figure 4.5). The 
serine in the second position o f both the protein sequences was altered to alanine and
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the first six codons were made AT rich as these changes are thought to enhance 
protein expression in E. coli (Barnes et al., 1991). The sequence for each gene was 
also designed to be flanked by two sets o f restriction sites. At the 5’ end, the protein 
sequence was flanked by restriction sites encoding for Not I and Nde I. These were 
complemented at the 3’ end by restriction sited for Not I and Hind III. Nde I and 
Hind III were incorporated at either end o f the sequence to allow ligation o f the 
genes into the expression vector, pCWori+, which had already been prepared with 
those restriction enzymes. However, the ALKlL456_yeast gene was designed to be 
flanked by a Sal I restriction site rather than Nde I to allow ligation into the yeast 
expression, vector, YEp51 (see figure 4.6).
Incorporated into both of these sequences at the 3’ end was the stop codon TAG and
9+a six codon histidine tag to aid with Ni -NTA purification (see figures 4.5 and figure 
4.6).
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Nde I
I
Not I
>AlklL45 6S
rGCGGCCGCCATATG@STTFNDIIDSVLPYLTKWYTILIGAGLIFVLSTNLKNA  
YYSYKLGCKNPVHLKRAGWTGIPALIDAIKAKNSGKLAEFGGDTFDELNSKNF 
YLNVAGVLKIIFTIEPENIKAVLATQFN DFSLGTRHAHFY PLLGDGIFTLDGE 
GWKHSRAMLRPQFAREQIAHVKSLEPHIQILAKQIKLNKGETFDLQELFFRFT 
VDTATEFLFGESVHSLYDDKLGIPPPNDIPGRDNFATAFITSQHYLATRSYSQ  
TFYWLTNNKEFRDCNAKVHHLAKYFVDKALNSTEKEIEEKSQGGYVFLYELVK 
QTKNPKVLQDQLLNIMVAGRDTTAGLLSFAMFELARNPKVWNKLREEIEANFG 
VGEEARVEDITFENLKKCEYLKAILNETLRLYPSVPINFRTSTKDTTLPTGGG  
PNGTSPIFVPKGSTVAYTVFKTHRLEEYYGKDSHDFRPDRWFEPSTKKLGWAY 
L P FNGGPRICLGQQFALTEASYVISRLAQLFPVLESRDEQYPPNKCIHLTMNH 
DEGVFVSMNCATCACCATCACCATCACTAGAAGCTTGCGGCCGC.._______
Not I
Histidine Tag Stop Codon “ wd III
N de I
> A65:A1k1 /
'GCGGCCGCCATATC^IDAIKAKNSGKLAEFGGDTFDELNSKNFYLNVAGVLKI  
N o  j IFTIEPENIK AVLA TQFND FSLGTR HA HFYPLLG DG IFTLDG EG W KH SR AM LR  
P Q F A R E Q IA H V K SL E P H IQ IL A K Q IK L N K G E T FD L Q E L F F R FT V D T A T E FL F G  
E SV H SL Y D D K L G IPP P N D IPG R D N FA T A F IT SQ H Y L A T R SY SQ T F Y W L T N N K E  
FRDCNAKVHHLAKYFVDKALNSTEKEIEEKSQGGYVFLYELVKQTKNPKVLQD  
Q LLNIM VAGRDTTAGLLSFAMFELARNPKVW NKLREEIEANFGVGEEARVEDI  
T F E N L K K C E Y L K A IL N E T L R L Y P S V P IN F R T S T K D T T L P T G G G P N G T S P IF V P  
KGSTVAYTVFKTHRLEEYYGKDSHDFRPDRWFEPSTKKLGWAYLPFNG GPRIC  
LGQQFALTEASYVISRLAQLFPVLESRDEQYPPNKCIHLTM NHDEGVFVSM NC  
A TC ACC ATCA CCA TCAC TAG AAG CTTG CG G CCG C^
\  Not I
H istidine Tag
Stop Codon
Figure 4.5 - Synthetic genes, ALK1L456S and A65:ALK1. The protein sequence 
was optimised for expression in E. coli. The first A (alanine) in the protein sequence 
is also highlighted because in the original, native sequence it is a serine but this has 
been changed to enhance protein expression in E. coli (Barnes et al., 1991). The 
haem-binding site is underlined and the amino acid of interest (serine) is in bold. 
This protein sequence is flanked by nucleotide sequences, which do not require 
optimisation for expression in E. coli and are highlighted as follows. The 6 codon 
histidine tag is orange. The Not 1 restriction sites are highlighted in blue and the Nde 
1 and Hind III sites are green. The stop codon is yellow.
1 0 6
Not I
>AlklL456S_yea^ 
GCGGCCGCGTCGACATcJSjiTFNDIIDSVLPYLTKWYTILIGAGLIFVLSTNLK 
N A Y Y S Y K L G C K N P V H L K R A G W T G IP A L ID A IK A K N S G K L A E F G G D T F D E L N S K N  
F Y L N V A G V L K I I F T I E P E N I K A V L A T Q F N D F S L G T R H A H F Y P L L G D G I F T L D G E  
G W K H S R A M L R P Q F A R E Q IA H V K S L E P H IQ IL A K Q IK L N K G E T F D L Q E L F F R F T V  
D T A T E F L F G E S V H S L Y D D K L G I P P P N D I P G R D N F A T A F I T S Q H Y L A T R S Y S Q T F  
Y W L T N N K E FR D C N A K V H H L A K Y FV D K A L N ST E K E IE E K SQ G G Y V F L Y E L V K Q T K  
N P K V L Q D Q L L N IM V A G R D T T A G L L S F A M F E L A R N P K V W N K L R E E IE A N F G V G E E  
A R V E D I T F E N L K K C E Y L K A I L N E T L R L Y P S V P I N F R T S T K D T T L P T G G G P N G T S  
P IF V P K G S T V A Y T V F K T H R L E E Y Y G K D S H D F R P D R W F E P S T K K L G W A Y L P FNGG  
P R IC L G Q Q F A L T E A S Y V I S R L A Q L F P V L E S R D E Q Y P P N K C IH L T M N H D E G V F V S
M NCATCACCATCACCATCACTAGAAGCTTGCGGCCGC7
HiStidineT3g S.op Codon Hini III
Not
Figure 4.6 - Synthetic gene, ALKlL456S_yeast. The protein sequence was 
optimised for expression in S. cerevisiae. The haem-binding site is underlined and 
the amino acid of interest (serine) is in bold. This protein sequence is flanked by 
nucleotide sequences, which do not require optimisation for expression in E. coli and 
are highlighted as follows. The 6 codon histidine tag is orange. The Not 1 restriction 
sites are highlighted in blue and the Sal I and Hind III sites are green. The stop 
codon is yellow.
pUC57:Alkl L456S, pUC57:Alkl L456S_yeast and pUC57:A65:Alkl were 
transformed into DH5a cells (section 2.2.7) and spread onto LB agar plates 
containing ampicillin. Individual colonies were grown overnight at 37°C in LB 
ampicillin broth and the plasmid was purified (section 2.2.5). ALK1L456S and 
A65:ALK1 were liberated using a Nde l/Hind III digest (section 2.2.6.2). The DNA 
was extracted using the QIAquick Gel Extraction kit (section 2.2.4) and ligated into 
the expression vector pCWori4 for protein expression (section 4.2.3.4). 
pCWori+:AlklL456S and pCWori+:A65:Alkl were transformed into DH5a cells and 
grown on LB + ampicillin agar plates (section 2.2.7). Individual colonies were 
grown overnight at 37°C in LB ampicillin broth and the plasmid DNA was extracted 
and purified (section 2.2.5). A Nde MHind III restriction enzyme digest (section 
2.2.6.3) was used to screen for the presence of the ALK1L456S and A65.ALK1 genes 
in each plasmid.
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The ALKlL456S_yeast gene was ligated into the yeast expression vector, YEp51 and 
transformed into DH5a cells, which were grown on LB + ampicillin agar plates. 
Individual colonies were grown at 37°C overnight in LB ampicillin broth and the 
plasmid DNA was extracted and purified. A Sal l/Hind III restriction enzyme digest 
was used to screen for the presence of the gene in the plasmid. The 
YEp51:AlklL456S_yeast plasmid was then transformed into S. cerevisiae cells and 
grown at 30°C on YM plates containing histidine (section 2.2.8).
All genes were verified by DNA sequencing (section 2.2.9).
4.2.3.7 Protein Expression
4.2.3.7.1 Protein Expression using E. coli as the Host Organism
To 900ml of TB, 100ml of a solution comprising of 0.17M KH2PO4 and 0.72M 
K2HPO4, 1ml of ampicillin (lOOpl/ml) and 10ml o f overnight E. coli (LB + 
ampicillin) culture were added. Cultures were incubated at different temperatures 
and for different durations and these conditions are shown in tables 4.4, 4.5, 4.6, 4.7 
and 4.8. After growth, ImM Ala and IPTG were added and the culture was 
incubated further (see tables 4.4, 4.5, 4.6, 4.7 and 4.8). However, the expression o f 
CaCPR required IPTG to be added to the media at the start o f the experiment (based 
on the Park et al., 2010 method).
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E x p e r im e n t G r o w th E x p r e ss io n
1
230rpm  
37°C 
7 hours
Ala 85mg 
IPTG 120mg
190rpm 
25°C 
18 hours
2
190rpm
30°C
Overnight
Ala 170mg 
IPTG 240m g
160rpm
20°C
Overnight
3
230rpm
37°C
Overnight
Ala 170mg 
IPTG 240m g
200rpm  
28°C  
23 hours
4
230rpm 
37°C 
5 hours
Ala 85mg 
IPTG 120mg
200rpm  
28°C  
21 hours
5
230rpm  
37°C 
6 hours
Ala 85mg 
IPTG 120mg
200rpm  
28°C  
18 hours
Table 4.4 -  Protein expression of native A lk l. The table shows the amendments 
made to the growth and expression conditions whilst trying to express active 
cytochrome P450. Each attempt resulted in a peak at 420nm, indication of protein 
that was not folded correctly. Arase et al., 2006 method used.
E x p e r im e n t G r o w th E x p r e ss io n
1
230rpm  
30°C 
7 hours
Ala 170mg 
IPTG 240m g
190rpm 
20°C  
48 hours
2
230rpm  
30°C 
7.5 hours
Ala 170mg 
IPTG 240m g
190rpm 
20°C  
40.5 hours
3
230rpm  
37°C 
7.5 hours
Ala 170mg 
IPTG 240m g
190rpm 
20°C  
40  hours
Table 4.5 -  Protein expression of A lklL456S. The table shows the changes made 
to the growth and expression conditions during optimisation. Arase et al., 2006 
method used.
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Experim ent G row th E xpression M ethod
1
230rpm 
37°C 
7.5 hours
Ala 170mg 
IPTG 240m g
190rpm 
20 °C 
17 hours
Arase et al., 2006
2
230rpm  
37°C 
7.5 hours
Ala 170mg 
IPTG 240m g
190rpm 
20°C  
40 hours
Arase et al., 2006
3
230rpm  
37°C 
7.5 hours
Ala 170mg 
IPTG 240m g
190rpm 
30°C  
17 hours
Arase et al., 2006
4
230rpm  
37°C 
7.5 hours
Ala 170mg 
IPTG 240m g
190rpm 
30°C  
40  hours
Arase et al., 2006
5
230rpm  
37°C 
7.5 hours
Ala 170mg 
IPTG 240m g
190rpm 
20°C 
17 hours
Isolation o f  Membranes and Cytosol
6
230rpm  
37°C  
7.5 hours
Ala 170mg 
IPTG 240m g
190rpm 
20°C 
40  hours
Isolation o f  Membranes and Cytosol
7
230rpm  
37°C  
7.5 hours
Ala 170mg 
IPTG 240m g
190rpm 
30°C 
17 hours
Isolation o f  Membranes and Cytosol
8
230rpm  
37°C 
7.5 hours
Ala 170mg 
IPTG 240m g
190rpm 
30°C 
40  hours
Isolation o f  Membranes and Cytosol
Table 4.6 -  Protein expression of A33:Alkl, A65:Alkl, A69:Alkl, 
modifiedA50:Alkl and modifiedA44:Alkl. The table shows the changes made to 
the growth and expression conditions, along with the methods used, to try and 
express active protein.
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Experim ent G row th Expression M ethod
1
230rpm
37°C 
5 hours
Ala 170mg 
IPTG 240m g
190rpm
25°C 
22 hours
Arase et al., 2006
2
230rpm
37°C 
7 hours
Ala 170mg 
IPTG 240m g
190rpm
25°C 
17 hours
Arase et al., 2006
3
230rpm
30°C 
7.5 hours
Ala 170mg 
IPTG 240m g
190rpm
20°C 
40 hours
Arase et al., 2006
4
230rpm
35°C 
18 hours
Ala 170mg 
IPTG 240m g
190rpm
25°C 
24 hours
Arase et al., 2006
5
230rpm
37°C 
5 hours
Ala 170mg 
IPTG 240m g
190rpm
25°C 
22 hours
Isolation o f  Membranes and Cytosol
Table 4.7 -  Protein expression of CYP52A3. The table shows the changes made to 
the growth and expression conditions, along with the methods used, to try and 
express active protein.
G row th E xpression M ethod
200rpm
37°C 
5 hours
200rpm
28°C  
19 hours
Isolation o f  Membranes and Cytosol
Table 4.8 -  Protein expression of CaCPR. The table shows the growth and 
expression conditions used, as based on the method o f Park et al., 2010.
I l l
4.2.3.7.1.1 Arase et al.* 2006 M ethod for Protein Isolation
Figure 4.7 shows an overview of the method used for protein isolation based on 
Arase et al., 2006.
Added:
•Overnight culture 
•100pg/ml Ampicillin
1L Terrific BrothI
A ,
37°C, 230rpm, c.7.5 hours
Added:
•Ala(1mM) 170mg 
•IPTG (1mM) 240mg
20°C, 190rpm, c.40 hours
Cells
Harvest cells at 
5000rpm and 4°C 
for 10 minutes
Lysozyme buffer
r i o t  I ''i iv i; /
A — U  0
Cells
Resuspend cells in 
lysozym e buffer gently 
and leave on ice for 30 
minutes
Ultracentrifuge at 
40000 rpm fo r i  
hour at 4°C
Cells
Sonicate at 50% power 
for 30 seco n d s, 4 bursts 
(1 minute resting 
periods on ice)
y
R esuspend  
spheroblasts in 
sonication buffer
Centrifuge at 16000rpm  
for 15 minutes (4°C)to  
get spheroblasts
Supernatant
Pour off supernatant 
containing solubilised  
membrane bound protein
CO difference spectra on 
supernatant
Fiuure 4.7 -  Schematic diagram  of the experimental approach used to express 
Alkl protein. The figure shows an overview of the method used to express 
cytochrome P450.
Cells were harvested at 5000rpm (Beckman JLA8.1000 rotor) and 4°C for 10 
minutes. The supernatant was discarded and the cells were gently resuspended in 
lysozyme buffer before being incubated on ice for 30 minutes. The resuspended 
cells were then centrifuged for 15minutes at 16000rpm (Beckman JA25.5 rotor) and 
4°C to obtain spheroplasts. The spheroblasts were resuspended in sonication buffer 
and sonicated at 50% for 30 seconds in 4 bursts (with a rest period of 1 minute 
between bursts). The sonicated cells were then placed in the ultracentrifuge for 1 
hour at 4°C and 40000rpm (Beckman type 50.2Ti ultracentrifuge rotor). The 
supernatant was then removed and the carbon monoxide (CO) difference spectrum 
was determined using the cytochrome P450 assay (section 4.2.3.10.1).
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4.2.3.7.1.2 Isolation of Membranes and Cytosol
Cells were harvested as in method 4.2.3.7.1.1, except the spheroplasts were 
resuspended in 0.1 M Tris HC1 pH8.1 buffer instead o f sonication buffer. Following 
sonication, the sonicated cells were then centrifuged at 16000rpm (Beckman JA25.5 
rotor) for 10 minutes. The pellet was discarded and the supernatant was centrifuged 
again for 10 minutes at 16000rpm (Beckman JA25.5 rotor). The supematent was 
then place in the ultracentrifuge for 1 hour at 40000rpm (Beckman type 50.2Ti 
ultracentrifuge rotor). The supernatant was removed and the membranes were 
resuspended in 0.1 M Tris HC1, pH8.1 containing 25% (w/v) glycerol using a Potter- 
Elvehjeim glass homogenizer. The CO difference spectrum was determined for both 
the membranes and supernatant using the cytochrome P450 assay method (section 
4.2.3.10.1). The CaCPR membranes were solubilised (section 4.2.3.8) prior to Ni2+- 
NTA agarose purification (section 4.2.3.9).
4.2.3.7.2 Protein Expression using S . cerevisiae as the Host Organism
Based on the methods o f Zimmer et al., 1995; Shyadehi et al., 1996 and Lamb et al., 
1999.
To 1 litre of minimal media (containing 2% (w/v) sugar (see table 4.9)), 10ml o f 
lOOmg/ml histidine (Acros Organics) and 20mls o f overnight AH22 (YM + histidine) 
culture was added. Cultures were grown under different conditions, which are 
shown in table 4.9.
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E xperim ent Sugar Source G row th Expression
1 2% (w/v) Glucose
200rpm 
28°C 
48 hours
G lucose exhausted 
(5 x l0 7cells/m l)
Induced with 3% 
(w /v) galactose
2 2% (w/v) Glucose
200rpm  
30°C  
48 hours
G lucose exhausted 
(6x107cell s/ml)
Induced with 3% 
(w /v) galactose
3
2% (w/v) 
Raffinose
220rpm
28°C  
48 hours
Cells grown to 
8.6x10 7cells/ml
Induced with 2% 
(w /v) galactose
Table 4.9 -  Protein expression of CYP52A3 in AH22 yeast cells. The table shows 
the changes made to the growth and expression conditions and the sugar used as the 
initial carbon source in the media. In all experiments expression lasted 24 hours.
Cells grown in minimal media containing 2% (w/v) glucose (section 4.2.1.2.1) were 
induced with a final concentration o f 3% (w/v) galactose (Acros Organics) following 
glucose exhaustion. Glucose exhaustion was tested using Clinistix reagent strips for 
urinalysis (Bayer). Alternatively, cells grown in minimal media containing 2% (w/v)
n
raffinose (section 4.2.1.2.2) were grown to a cell density o f 8.6x10 cells/ml before 
induction with 2 % (w/v) galactose (final concentration).
The protein was isolated from yeast using the following method. Yeast cells were 
harvested at 5000rpm (Beckman JLA8.1000 rotor) and 4°C for 10 minutes. The 
supernatant was discarded and the cells were resuspended in distilled water. The 
suspension was centrifuged at 3000xg and 4°C for 3 minutes. The supernatant was 
discarded and the cells were resuspended in 0.1 M potassium phosphate, pH7.4 buffer 
containing 20% (w/v) glycerol. The yeast cells were mechanically disrupted using a 
Braun homogeniser with six 30 second bursts. Cells were cooled during 
homogenisation by liquid carbon dioxide. The homogenised mixture was 
centrifuged for 30 minutes at 4000xg and 4°C. The cell debris was discarded and the 
supernatant was centrifuged for a further 15 minutes at 16000rpm (Beckman JA25.5 
rotor) and 4°C. The cell debris was again discarded and the supernatant 
centrifugation step was repeated. The supernatant was then ultracentrifuged for 1 
hour at 40000rpm (Beckman type 50.2Ti ultracentrifuge rotor) and 4°C. The 
supernatant was removed and the microsomes were resuspended in 0.1M potassium
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phosphate, pH7.4 containing 20% (w/v) glycerol using a Potter-Elvehjeim glass 
homogenizer. The CO difference spectrum was determined for the microsomes 
using the cytochrome P450 assay method (section 4.2.3.10.1).
4.2.3.8 Solubilisation of CaCPR Membranes for Ni2+-NTA Agarose Purification
After expression o f CaCPR in E. coli, the CaCPR membranes were diluted in 0.1 M 
potassium phosphate, pH6.8  containing 25% (w/v) glycerol to a final volume of 
50ml and stirred at a steady pace with a magnetic flea at 4°C. To the mix 0.5g of 
sodium cholate (Acros Organics) was added and the mixture was left to stir for 2 
hours. The mixture was ultracentrifuged for 90 minutes at 4°C and 40000rpm 
(Beckman type 50.2Ti ultracentrifuge rotor). The supernatant was decanted to be
94-used for Ni -NTA agarose purification (section 4.2.3.9).
4.2.3.9 Ni2+-NTA Agarose Purification of Protein
Ni -NTA agarose (Qiagen) was washed prior to use with equilibration buffer 2-3 
times until all traces o f ethanol were removed and resuspended in 15ml o f 
equilibration buffer and added to the protein sample and left to mix overnight (using 
a magnetic flea and stirrer) at 4°C. The solution was then centrifuged for 1 minute.
9 4-The Ni -NTA agarose-bound protein was retained and washed twice in equilibration 
buffer. The agarose/protein was resuspended in 15ml o f equilibration buffer and 
poured into the column. The resin was washed in 2 column volumes o f wash buffer. 
The protein was then eluted from the agarose using elution buffer and collected in 
lml fractions. The fractions were assayed to determine the concentration of 
cytochrome P450 or CPR protein (see section 4.2.3.10).
4.2.3.10 Determination of Protein Concentration
4.2.3.10.1 Assay to Determine Cytochrome P450 Concentration
The amount o f cytochrome P450 protein in the sample was determined using the 
method o f Omura & Sato, 1964.
The protein sample was diluted to lm l using lOOmM Tris HC1 pH8.1, containing 
25% (w/v) glycerol. CO was gently bubbled through the sample for lm in before it 
was split between the reference and sample cuvettes (in equal volumes). The 
baseline was then recorded between 400 and 500nm. A few grains o f sodium
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dithionite were added to the sample cuvette and mixed thoroughly by inversion. The 
spectrum was then recorded. The extinction coefficient, 91M cm"1 was used to 
calculate the concentration o f cytochrome P450 in the sample (Omura & Sato, 1964).
4.2.3.10.2 Assay to Determine CaCPR Concentration
The absolute spectra o f the protein sample was recorded by diluting the sample five 
fold in 0.1M potassium phosphate, pH6.8  containing 25% (w/v) glycerol to a final 
volume o f lml. The baseline was recorded between 295nm and 705nm using buffer 
filled cuvettes. In the sample cuvette, the buffer was removed from the chamber and 
was replaced with the diluted sample (lm l). The spectrum was then recorded. The 
8Amax o f the peak at 462nm and the extinction coefficient 21.4M cm ' 1 (Vermilion & 
Coon, 1978) were used to calculate the concentration o f CaCPR in the sample.
4.3 Results
4.3.1 Design of A lkl Truncations
To design truncations of A lkl, TMHMM, SignalP and HMMTOP were used to 
predict the hydrophobic N-terminal region o f the protein. The results generated 
using TMHMM suggested that the membrane anchor region o f Alkl begins at 
residue 13 and ends at residue 35 (see figure 4.8). This was also shown with SignalP 
(see figure 4.9). The results from HMMTOP, however, predicted the end of the 
membrane anchor region at residue 33 (see figure 4.10). These results were used to 
form the basis o f the A33: Alkl truncation designed in this study.
The truncations A65:Alkl and A69:Alkl were designed based on the topology of 
CYP52A3, which is believed to have two predicted hydrophobic regions in its N- 
terminus (Menzel eta l ., 1996).
ModifiedA50:Alkl and modifiedA44:Alkl were designed according to the method 
used to produce truncated versions o f CYP2C3 and CYP2C5 where the amino acids 
prior to a proline-rich region o f the sequence were deleted (Richardson et al., 1993; 
von Wachenfeldt et al., 1997; Cosme & Johnson, 2000; Wester et al., 2002). The N- 
termini o f these two truncations were also modified to MAKKTSSKGKL as this 
sequence was previously shown to aid the expression o f full-length and truncated 
CYP2C3 in E. coli (Li & Chiang, 1991; Karam & Chiang, 1994).
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Each truncation is described in further detail in section 4.4.2.
$ Alkl Length: 525
t  Alkl Number of predicted THHs: 1
$ Alkl Exp number of AAs in THHs: 22.14645
$ Alkl Exp number, first 60 AAs: 21.60348
# Alkl Total prob of N-in: 0.88388
# Alkl POSSIBLE N-term signal sequence
Alkl THHMM2.0 inside 1 12
Alkl TMHMM2.0 THhelix 13 35
Alkl THHHM2.0 outside 36 526
TMHMM p o ste r or probabilities for Alkl 
1.2      ,-------------------
0 1 0 0  20 0  3 0 0  4 0 0  5 0 0
transm em brane -------  in s id e ----------  outside
Figure 4.8 -  TM HMM  (http://www.cbs.dtu.dk/services/TM HM M /) results 
showing the potential A lkl m em brane anchor region. This plot indicates that the 
membrane anchor region starts at residue 13 and ends at 35 with the cytosolic region 
starting at residue 36.
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S i g n a l P - H N  p r e d i c t i o n  (eule n e t w o r k s ) !  A l k l
C score 
S score0
0 . 4
0.0
M S S T T F N D I I D S V L P Y L T K W Y T I L I G A G L I F V L S T N L K N A Y Y S Y K L G C K N P V H L K R A G U T G I P A L I D A I
30 5 0 6 0 7 00 4 0
P o s i t i o n
U data
> A lk l  
U
l e n g t h  = 70
M eas u re P o s i t i o n V a l u e C u t o f f s i g r
m a x . C 27 0 . 0 8 5 0 . 3 2 NO
m a x . Y 35 0 . 1 9 0 0 . 3 3 NO
max . S 27 0 . 9 3  6 0 . 8 7 YES
mean S 1 -3 4 0 . 4 1 8 0 . 4 8 NO
D 1 -3 4 0 . 3 0 4 0 . 4 3 NO
U H o s t  l i k e l y  c l e a v a g e  s i t e  b e t w e e n  p o s .  34  a n d  3 5 :  VLS-TN
S i g n a l P - H M M  p r e d i c t i o n  ( e u k  m o d e l s ) :  A l k l
C l e a v a g e  p r o b  
n - r e g i o n  p r o b  
h - r e g i o n  p r o b
c-region prob
6
6
4
8
0
M S S T T F M D I I D S V L P Y L T K U Y T I L I G A G L I F V L S T N L K N A Y Y S Y K L G C K N P V H L K R A G U T G I P A L I D A I
0 30 5 0 6 0 7 0
P o s i t i o n
U data
> A lk l
P r e d i c t i o n :  N o n - s e c r e t o r y  p r o t e i n  
S i g n a l  p e p t i d e  p r o b a b i l i t y :  0 .0 0 2  
S i g n a l  a n c h o r  p r o b a b i l i t y :  0 . 4 7 7
Max c l e a v a g e  s i t e  p r o b a b i l i t y :  0 . 0 0 1  b e t w e e n  p o s .  34  a n d  35
Figure 4.9 -  SignalP (http://www.cbs.dtu.dk/services/SignalP/) results showing 
the signal peptide cleavage site of A lkl. The plot indicates that the signal peptide 
cleavage site of Alkl is at residue 34.
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Length: 52 6
N-terminus: IN
Number of transmembrane helices: 1 
Transmembrane helices: 12-33
Total entropy of the model: 17.0231
Entropy of the best path: 17.0239
The best path:
seq MASTTFNDII DSVLPYLTKU YTILIGAGLI FVLSTNLKNA YYSYKLGCKN 50
pred Iiiiiiiiii iHHHHHHHHH HHHHHHHHHH HHHooooooo ooooooooOO
seq PVHLKRAGUT GIPALIDAIK AKNSGKLAEF GGDTFDELNS KNFYLNVAGV 100
pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO
seq LKIIFTIEPE NIKAVLATQF NDFSLGTRHA HFYPLLGDGI FTLDGEGUKH 150
pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO
seq SRAMLRPQFA REQIAHVKSL EPHIQILAKQ IKLNKGETFD LQELFFRFTV 200
pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO
seq DTATEFLFGE SVHSLYDDKL GIPPPNDIPG RDNFATAFIT SQHYLATRSY 250
pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO
seq SQTFYWLTNN KEFRDCNAKV HHLAKYFVDK ALNSTEKEIE EKSQGGYVFL 300
pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO
seq YELVKQTKNP KVLQDQLLNI MVAGRDTTAG LLSF AHFELA RNPKVWNKLR 350
pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO
seq EEIEANFGVG EEARVEDITF ENLKKCEYLK AILNETLRLY PSVPINFRTS 400
pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO
seq TKDTTLPTGG GPNGTSPIFV PKGSTVAYTV FKTHRLEEYY GKDSHDFRPD 450
pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO
seq RUFEPSTKKL GWAYLPFNGG PRICLGQQFA LTEASYVISR LAQLFPVLES 500
pred OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO OOOOOOOOOO
seq
pred
RDEQYPPNKC
OOOOOOOOOO
IHLTMNHDEG
OOOOOOOOOO
VFVSMN 52 6
000000
Figure 4.10 -  HM M TOP (http://www.enzim.hu/hmmtop/) results for A lkl 
showing the potential mem brane anchor region of the protein. These results 
predict the membrane anchor region of Alkl ends at residue 33.
4.3.2 Cloning of ALKL  its Truncations, CaCPR and CYP52A3
ALK1 was amplified from C. albicans genomic DNA (optimal conditions were 
reaction 7 (see table 4.3b) and thermal cycling conditions #3 (see table 4.3a)). 
CaCPR was also amplified from C. albicans and CYP52A3 from C. maltosa genomic
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DNA by PCR. The ALK1 truncations: A33.ALK1, A69.ALK1, modifiedA50:ALKl 
and modifiedA44:ALKl, were all amplified by PCR from pCWori+:Alkl L456S 
plasmid DNA. The genes of interest were visualised on a 1% (w/v) agarose gel and 
verified by comparing the expected size of that gene (see table 4.2) (see figure 4.11).
lOOOObp 
I500bp
250bp
lOOOObp 
I500bp
250bp
Fieure 4.11 -  1% (w/v) agarose gel showing gene fragments following PCR.
Each amplicon was isolated from the gel and the DNA was extracted before ligation 
into pGEM-T easy and transformation into E. coli XL-1 cells. Colonies were 
screened for the presence of each gene using a Not I restriction enzyme digest, which 
was visualised on a 1% (w/v) agarose gel. The presence of each gene was verified 
by DNA sequencing.
A Nde \/Hind III double digest was used to release each gene from pGEM-T easy 
and prepare the genes with the appropriate sticky ends for ligation into pCWorT. 
The genes were visualised on a 1 % (w/v) agarose gel Each band was isolated from 
the gel and the recovered DNA of each gene, plus A65. ALK1 and ALK1L456S, was
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then ligated into pCWori+. The ligations were then transformed into DH5a cells. 
Colonies were screened for each gene using Nde MHind III digest and visualised on a 
1% (w/v) gel. The presence of each gene was verified by sequencing.
4.3.3 Protein Expression of A lkl, AlklL456S, its Truncations, CaCPR and 
CYP52A3 Usinu E. coli as a Host Organism
Methods described in section 4.2.3.7.1 were used to express the proteins of A lkl, its 
truncations and CYP52A3. The Arase et al., 2006 method for the isolation of protein 
(section 4.2.3.7.1.1) for each gene resulted in the production in a peak at 420nm (see 
figure 4.12) in the presence of carbon monoxide and sodium dithionite. This is 
characteristic of the inactive form of cytochrome P450, P420.
Expressing the proteins of the Alkl truncations using the isolation of membranes and 
cytosol method (section 4.2.3.7.1.2) also resulted in the production of inactive 
cytochrome P420 in both the membrane and cytosol fractions.
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Figure 4.12 -  Difference spectra of the reduced/CO-bound forms of A lkl, its 
truncations and CYP52A3. The spectra produced show peaks at 420nm, which is 
indicative of the inactive form of cytochrome P450, cytochrome P420.
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Using methods described earlier in table 4.5 (section 4.2.3.7.1) it was demonstrated 
that protein expression of AlklL456S yielded a peak at 447nm in the presence of 
carbon monoxide and sodium dithionite, indicating that the protein expressed was a 
member of the cytochrome P450 superfamily and produced in a correctly folded 
form (see figure 4.13).
0.10
<D(J
CC3
X>
i-i
0.05
o 0.00
< -0.05
- 0.10  :
400 450 500
Wavelength (nm)
Figure 4.13 -  Difference spectrum  of the reduced/CO-bound form of AIklL456S 
showing a 447nm peak. A peak at 447nm indicates cytochrome P450 protein.
Table 4.10 shows the protein yields obtained from the protein expression 
experiments undertaken. Increasing the growth temperature from 30°C to 37°C 
produced almost 2.5 fold more protein.
Experiment Growth Expression Results
1
2 3 0 rpm 
3 0 °C  
7 hours
Ala 170mg 
IPTG 2 4 0 m g
190rpm 
2 0 °C 
48  hours
8 0 n m oles/L
2
2 3 0 rpm 
3 0 °C 
7 .5  hours
Ala 17()mg 
IPTG 2 4 0 m g
19 0 rpm 
2 0 °C 
4 0 .5  hours
5 4 nm oles/L
3
2 3 0 rpm 
3 7 °C 
7 .5  hours
Ala 170mg 
IPTG 2 4 0 m g
19 0 rpm
2 0 °C 
4 0  hours
19 3 nm oles/L
Tabic 4.10 -  Protein expression of AlklL456S. The table shows the changes made 
to the growth and expression conditions during optimisation and the protein yield 
obtained.
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2 +
The AlklL456S protein was purified using Ni -NTA agarose. Initially when the 
protein fractions were run out on a SDS-PAGE gel, it was found that there were still 
other proteins in the sample. The AlklL456S protein was further purified using
94 -N f -NTA agarose, but the resin was washed an additional time using 1 column 
volume of wash buffer containing lOmM of L-histidine, prior to the elution of the 
protein (see section 4.2.3.9). This extra wash was used to remove the unwanted
• 2"fproteins that were non-specifically bound to the Ni" -NTA agarose (see figure 4.14) 
(Wester et al., 2002). The concentration of AlklL456S protein following 
purification was 25pM.
1% Histidine Wash Fractions
0.1% Histidine 
Wash Fractions
Purified 
A lkl 1.456S 
Protein
Figure 4.14 -  SDS-PAGE gel showing AlklL456S protein following optimised 
Ni +-NTA agarose purification. lOmM histidine step incorporated into the 
purification method.
CaCPR protein was expressed in E. coli using the method in table 4.8 (section 
4.2.3.7). Following the solubilisation of the membranes and protein purification 
(figure 4.15), an absolute spectra of the protein showed peaks at 453nm and 382nm 
indicating the presence of CaCPR (figure 4.16). The concentration was 19pM.
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M205
115
Purified
|  CPR
66 Protein
45
29
Figure 4.15 -  SDS-PAGE gel showing CaCPR following Ni2+-NTA agarose 
purification.
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Figure 4.16 -  Absorption spectrum  of CaCPR, showing peaks at 453nm and 
382nm indicating the presence of CPR protein.
4.3.4 Protein Expression of CYP52A3 yeast Using S. cerevisiae as the Host 
Organism
Protein expression of CYP52A3 using E. coli as the host organism failed to result in 
the production of cytochrome P450 protein. Therefore, CYP52A3_yeast was 
expressed in AH22 cells. Growth in media containing glucose as the initial carbon 
source before addition of galactose failed to produce microsomes containing 
cytochrome P450 protein. The expression of CYP52A3_yeast in media containing 
raffinose (induced with galactose) yielded a peak at 450nm indicating the presence of
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cytochrome P450 in the microsomes (figure 4.17). The yield o f cytochrome P450 
protein was 38nmoles/L.
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Figure 4.17 -  Difference spectrum of the reduced/CO-bound form of 
CYP52A3_yeast. A peak at 449nm is an indication o f the presence o f cytochrome 
P450 protein in the microsome preparations.
4,4 Discussion
4.4.1 Expression of A lkl
All genes were designed to be expressed as protein in E. coli because this host 
organism produces large quantities o f protein and is relatively quick and easy to use. 
However, the expression o f Alkl in E. coli resulted in a reduced carbon monoxide 
difference peak at 420nm rather than a peak at 450nm (which is characteristic of 
cytochrome P450 (Omura & Sato, 1964)). Initially, this was thought to be due to the 
formation o f insoluble aggregates called inclusion bodies (Sorenson & Mortensen,
2005), which can form during protein expression in E. coli (Verma et al., 1998). 
Inclusion bodies are misfolded proteins, which are formed when cells are open to 
environmental stresses, such as extremes in temperature, and are generally inactive 
(Sorenson & Mortenson, 2005; Arie et a l , 2006). These inclusion bodies could form 
if  the temperatures used for the protein expression protocol were too harsh or were 
held for too long. One method to prevent the formation o f these protein aggregates is 
to alter the temperature and duration o f expression (Ventura & Villaverde, 2006). 
However, changes in the temperature and duration o f both the growth and expression
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phases o f Alkl protein expression (see table 4.4) continued to result in a peak at 
420nm, which corresponds to the inactive form of cytochrome P450, P420.
Other approaches that can be employed to prevent the formation o f inclusion bodies 
include the use o f chaperones (to aid with the folding o f the protein) and alterations 
to the protein sequence (as altering the amino acids used can alter the 
integrity/folding o f the structure) (Ventura & Villaverde, 2006). With these 
approaches in mind, the translated nucleotide and protein sequences o f Alkl were 
aligned for comparison (see figure 4.18). At residue 456, it was shown that the 
nucleotide sequence (CUG) encodes for the amino acid leucine, but the protein 
sequence shows a serine. This is because in C. albicans there is an alteration in the 
universal genetic code in which the triplet CUG encodes for serine instead o f the 
expected leucine (Santos & Tuite, 1995). A deviation in the genetic code such as this 
is not exclusive to Candida spp. as other species also show alterations.
a) b)
gctattttgaacgaaactttaagattatacccatcagtcccaattaatttcagaacttca 
A I L N E T L R L Y P S V P I N F R T S  
accaaagacactactttaccaaccggtggtggtccaaatggtacttctccaattttcgtt 
T K D T T L P T G G G P N G T 8 P I F V  
cctaaaggttctactgttgcttacactgttttcaagactcatagattagaggaatattat 
P K G S T V A Y T V F K T H R L E E Y Y  
ggtaaagattctcatgattttagaccagacagatggtttgaacct^^accaagaaattg 
G K D S H D F R P D R B F E P  Q  T K K L 
ggatgggcttacttgccattcaatggtggtccaagaatttgtttgggfcaacaatttgct 
G R A Y L P F N G G P R I C L G Q Q F A  
ttaactgaagcttcttatgttattagtagattggcacaattgttcccagtgttggaatca 
L T E A S Y V I S R L A Q L F P V L E S  
agagatgaacaataccctccaaataaatgtattcatttgactatgaatcacgatgaaggg 
R D E Q Y P P N K C I H L T M N H D E G  
gtctttgtttcaatgaactaa 
V F V 3 M N *
>Alkl
MSSTTFNDIID3VLPYLTKBYTILIGAGLIFVLSTNLKNAYYSY 
KLGCKNPVHLKRAGWTGIPALIDAIKAKNSGKIAEFGGDTFDEL 
NSKNFYLNVAGVLKIIFTIEPENIKAVLATQFNDFSLGTRHAHF 
YPLLGDGIFTLDGEGHKHS RAMLRPQFAREQIAHVK 3 LE PHIQI 
LAKQIKLNKGETFD1QELFFRFTVDTATEFLFGE3VHSLYDDKL 
GIPP PNDIPGRDNFATAFITSQHYLATRS YS QTFYWLTNNKEFR 
DCNAKVHHLAKYFVDKALNSTEKEIEEKSQGGYVFLYELVKQTK 
NPKVLQDQLLNIMVAGRDTTAGLLSFAMFELARNPKVWNKLREE 
IEANFGVGEEARVEDITFENLKKCEYLKAILNETLRLYPSVPIN 
FRT3TKDTTLPTGGGPNGTSPIFVPKGSTVAYTVFKTHRLEEYY 
GK D S HDFRPDRBFE E^TKKLGBAYLPFNGGPRICLGQQFALTEA 
3YVI3RLAQLFPVLESRDEQYPPNKCIHLTONHDEGVFVSMN
Figure 4.18 - Comparison of the nucleotide and protein sequences of A lkl. a) C-
terminal ALK1 nucleotide sequence with 1 letter amino acid translation (beginning at 
nucleotide position 1141); b) Alkl protein sequence. The haem binding domain is 
highlighted in red. Amino acid differences highlighted by a black box.
The first deviation in the universal genetic code was identified in 1979 in vertebrate 
(human) mitochondria (Barrell et al., 1979). AUA was shown to encode for the start 
codon methionine rather than isoleucine and UGA for tryptophan instead o f a stop 
codon as in the universal genetic code (Barrell et al., 1979). This revelation seemed 
to cast doubt on Crick’s “Frozen Accident Theory,” which suggests that any 
changes/alterations in the code could cause potentially lethal mutations in the
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organism (Crick, 1968). However, as this codon deviation was in a structure within 
the organism/cell, it was thought that any possible changes would remain within the 
organelle and not affect the cell as a whole, i.e. not lead to cell death. This theory 
was shattered in 1985 when the first organism was shown to have codon deviations 
within its genetic code (Yamao et al, 1985). This was Mycoplasma capricolum, a 
goat pathogen, which exhibited a deviation in the translation o f the UGA codon from 
a stop codon to a tryptophan codon (Yamao et al., 1985). Since then the genetic 
codes o f other organisms have been shown to contain codon deviations, including 
Euplotes spp. (stop codon UGA reassigned as cysteine) (Moura et al., 2010) and 
Candida spp. (Ohama et al., 1993; Pesole et al., 1995).
Several Candida spp. have been shown to contain a deviation in the CUG codon 
whereby it encodes for serine rather than leucine (as in the “universal” genetic code). 
This deviation was first identified in C. cylindracea (Kawaguchi et al., 1989; 
Yokogawa et al., 1992) before being identified in other species in the Candida 
genus, such as C. maltosa (Ohama et al., 1993; Pesole et al., 1995; Sugiyama et al., 
1995), C. albicans, C. tropicalis and C. parapsilosis (Ohama et al., 1993; Pesole et 
al., 1995). Such deviations are thought to arise due to the loss o f tR N A ^C A G  
corresponding to CUG along with the codon itself (Osawa & Jukes, 1989). This 
could possibly be due to AT pressure, which can cause CUG to be converted to other 
codons encoding leucine (e.g. CUA, UUG and UUA) (Jukes & Osawa, 1996). This 
means neutral changes occur ensuring protein sequences remain unchanged and the 
codon is completely lost from the organism’s genome (Jukes & Osawa, 1996).
Initially, following the loss o f CUG and its tRNA, the CUG codon may act as a 
nonsense (stop) codon, thereby terminating translation (Osawa & Jukes, 1989; Jukes 
& Osawa, 1996). This indicates there is a transitional period between the loss o f the 
codon and its recapture. During evolution, the codon is recaptured by a newly 
developed tRNA with the correct anticodon (Osawa & Jukes, 1989). In the case of 
Candida, this is tRNASerCAG. These recaptured CUG codons are then 
reincorporated into genes via mutations (Jukes & Osawa, 1996). This process is 
known as the “Codon Reassignment (Codon Capture) Theory” (Osawa & Jukes, 
1989).
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The deviations in the “universal” genetic code such as the one described above may 
have a detrimental effect on active gene and protein expression. Leucine is a non­
polar, hydrophobic amino acid, whereas serine is polar and hydrophilic. Such a 
difference in the properties o f the amino acids could cause an alteration in the way 
the protein folds, leading to inactive expression. An example o f the affect of CUG 
on expression was demonstrated by Sugiyama et al. (1995) using URA3 from S. 
cerevisiae. This gene contains one CUG codon, which is usually translated as 
leucine in S. cerevisiae (Sugiyama et al., 1995). Upon transformation into C. 
maltosa the gene was found to be inactive i.e. it would not complement (Sugiyama et 
al., 1995). Following mutation o f the codon to CTC, which codes for leucine in both 
S. cerevisiae and C. maltosa, the gene was found to be active (Sugiyama et al.,
1995). Not only does this show that C. maltosa encodes CUG as serine, but it also 
suggests that genes containing CUG in Candida need to be altered to a different 
serine codon for active expression in other organisms. Inactive expression has also 
been shown to occur within a number o f cytochromes P450 from Candida. They 
include: CYP52A4 (residues 99 and 389) (Scheller et al., 1996; Zimmer et al., 1996), 
CYP52A5 (residue 499) and CYP52A9 (position 249) from C. maltosa (Zimmer et 
al., 1996), CYP52A17 (residues 261 and 490) and the reductase, NCPA from C. 
tropicalis (Eschenfeldt et al., 2003).
In ALK1, the CUG codon can be found in close proximity to the haem-binding site 
(see figure 4.18) suggesting any changes in the protein structure that may occur may 
affect access to or incorporation o f the haem. To rectify this problem in ALK1, the 
gene was synthesised to express UCU (which encodes for serine) in place o f the 
CUG codon. UCU was used because ALK1 was to be expressed in E.coli and this 
species has a bias towards this particular codon, therefore, giving it greater efficiency 
when translating (Sharp & Li, 1987).
Expression of AlklL456S resulted in a peak at 450nm, which is indicative of 
correctly folded cytochrome P450 (Omura & Sato, 1964). This showed that the 
problems with protein expression, which occurred with the native ALK1 gene were 
due to the amino acid change associated with CUG in C. albicans. With this in 
mind, the sequences o f the other (potential) cytochrome P450 genes identified in C. 
albicans (chapter 3) were aligned to check for the codon CUG and the translated
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amino acid. O f the remaining cytochrome P450 genes, three did not contain this 
leucine/serine alteration. These genes are ALK2, ALK3 and TR14. CYP61 (residue 
43), ALK8 (residue 40) and DIT2 (residue 122) all contained single changes, whereas 
multiple alterations were identified in PAH1 (four -  residues 3, 391, 392 and 565) 
and ALK6 (three -  residues 163, 206 and 491). Thus suggesting these cytochromes 
P450 may require replacement o f the CUG codon with another coding for serine if  
active protein was not expressed using the native sequence.
After altering CUG to another serine-encoding codon and modifying the N-terminus 
for optimised expression in the synthesised gene, ALK1L456S resulted in the 
production o f 193nmoles/L o f protein. Similar modifications that were made to 
ALK1L456S (i.e. alanine at the second position and the first six codons made AT 
rich) were made to the human CYP17 sequence. This resulted in 40nmoles/L of 
protein being expressed (Waterman et al., 1995), which is 5 fold less than 
AlklL456S. However, by using the exact N-terminal sequence o f modified bovine 
CYP17A1 (ATG GCT CTG TTA TTA GCA GTT TTT (Barnes et al., 1991)), 
400nmoles/L o f CYP17 protein was expressed, which is 10 fold more than what was 
previously produced, but still almost half the yield o f the modified bovine CYP17A1 
protein (750nmoles/L (Barnes et al., 1991)) (Waterman et al., 1995). This difference 
in protein yields could be due to the fact the rest o f the sequence also plays a part in 
the level o f protein expression, not just that o f the N-terminus alone (Waterman et 
al., 1995). Other cytochromes P450 have also shown high levels o f protein 
expression by using the modified bovine CYP17A1 N-terminal sequence. These 
include rabbit CYP2C3 (400nmoles/L (Richardson et al., 1993)) and human 
CYP1A2 (700nmoles/L (Fisher et al., 1992) and 245nmoles/L (Sandhu et al., 1994) 
-  differences in yield are potentially due to differences in the E. coli strains used 
(JM109 and DH5a respectively)). This suggests that if  the exact bovine CYP17A1 
N-terminal sequence was used in ALK1L456S, the level o f protein expressed may 
have been increased.
4.4.2 Expression of A lkl Truncations
As alluded to in section 4.4.1 modifications can occur in the N-terminus without any 
effect on the activity o f the cytochrome P450 protein, suggesting truncated forms of 
membrane-bound enzymes can be produced without any detrimental effect on
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function. Versions o f Alkl missing various parts o f the N-terminus were designed 
for heterologous expression in E. coli. They were designed using the web-based 
programs: TMHMM, SignalP and HMMTOP. The results of these programs 
predicted that the membrane anchor region terminated between residues 33 and 36. 
The decision was made to delete the first 33 amino acids o f the Alkl sequence to 
produce the truncation A33: A lk l. Expression of this protein in E. coli resulted in the 
production of inactive cytochrome P450 protein. This same method was used for the 
production o f a truncated version o f CYP2E1 from rabbit liver (Larson et al., 1991). 
Truncation following the first hydrophobic region o f CYP2E1 resulted in the 
production o f active cytochrome P450 protein, which was still membrane-bound (i.e. 
the protein was found bound to the membrane o f the cell rather than soluble in the 
cytosol) (Barnes et al., 1991; Larson et al., 1991). However, this protein contains 
two transmembrane loops (Larson et al., 1991) and truncation following this second 
region may have resulted in a soluble protein expressed in the cytosol (Pemecky et 
al., 1993; von Wachenfeldt et al., 1997). Another cytochrome P450 with a second 
hydrophobic membrane anchor region is CYP52A3 (see figure 4.19) (Menzel et al.,
1996). Therefore, the second and third truncations were based on the topology of 
CYP52A3 (figure 4.19).
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Segment found in 
the ER lumen
First hydrophobic 
region -  spans the 
membrane
/
Second hydrophobic 
region -  found on the 
cytoplasmic side
/> C Y P 5 2 A 3
MAIEQIIEEVLPYLTKWYTILFGAAVTYFLSIALRNKFYEYKLKCENPVYFEDAGLFGIPAL
I D I I K V R K A G Q L A D Y T D T T F D K Y P N L S S Y M T V A G V L K I V F T V D P E N I K A V L A T Q F N D F A L G A  
R H A H F D P L L G D G I F T L D G E G W K L S R A M L R P Q F A R E Q I A H V K A L E P H V Q I L A K Q I K L N K G K T F  
D L Q E L F F R F T V D T A T E F L F G E S V H S L Y D E K L G I P A P N D I P G R E N F A E A F N T S Q H Y L A T R T Y S  
Q IF Y WL TN PK E FR D CN A K V H K L A Q Y F V N T A L N A T E K E V E E K S K G G Y V F L Y E L V K Q T R D P K V L  
Q D Q L L N I M V A G R D T T A G L L S F A M F E L A R N P K I W N K L R E E V E V N F G L G D E A R V D E I S F E T L K K  
C E Y L K A V L N E T L R M Y P S V P I N F R T A T R D T T L P R G G G K D G N S P I F V P K G S S V V Y S V Y K T H R L K  
Q F Y G E D A Y E F R P E R W F E P S T R K L G W A Y L P F N G G P R I C L G Q Q F A L T E A S Y V I A R L A Q M F E H L E  
S K D E T Y P P N K C I H L T M N H N E G V F I S A K
Cytosolic Domain
Figure 4.19 -  M em brane topology of CYP52A3 (Menzel et al., 1996).
Highlighted in red is the portion of gene found in the lumen of the endoplasmic 
reticulum. The first hydrophobic region is highlighted in blue and the second is in 
brown. The purple sequence is the cytosolic domain.
A69:Alkl was designed to begin at the end of the second predicted hydrophobic 
region (and prior to the hydrophilic lysine residue), thus deleting the first 69 residues 
of the sequence. This region of Alkl was deleted because an alignment o f the 
CYP52A3 and Alkl protein sequences showed similarity between the second 
predicted membrane anchor region of CYP52A3 and Alkl (figure 4.20).
Second Hydrophobic 
Region
50 \  70
|  |  | . | . . . . | .
CYP52A3 NPVYFEDAGLF GIPALIDIIKVRK
A U c l NPVHLKRAGWTGIPALIDAIKAKN
C X u s t C o  * * * ■ • •  *  *  * * * * * * *  * *  • •
Figure 4.20 -  Sequence alignment of CYP52A3 and A lkl. Similarity shown 
between the second hydrophobic region of CYP52A3 (which is highlighted in red) 
and A lk l.
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A65:Alkl was truncated prior to the end of the membrane anchor region (highlighted 
in figure 4.20). In CYP52A3, this region was used to create a site-specific region for 
factor Xa digestion in the production o f an active soluble CYP52A3 protein (Scheller 
et al., 1994). In A lkl, this region was used to create the truncation A65:Alkl as 
adding four hydrophobic residues to the beginning of the A69:Alkl sequence may act 
to stabilise the Alkl protein during protein expression.
However, these truncations resulted in the production o f inactive proteins. The 
production o f cytochrome P420 truncated protein with this and the previous method 
was not due to the CUG problem that plagued the native ALK1 gene expression as 
the truncations were amplified from the ALK1L456S synthesised sequence or the 
sequence o f the truncation was synthesised. Therefore, the truncated genes contained 
the required alteration (TCT for CTG (as explained in section 4.4.1)).
The reason for the expression o f inactive protein could be due to the instability o f the 
folded structure. A truncated version of the bovine 17a-hydroxylase, CYP17, 
missing its N-terminal anchor, was shown to be expressed in its inactive form (Clark 
& Waterman, 1991; Sagara et al., 1993). Insertion o f an anchor sequence into this 
protein resulted in the production o f correctly folded, active protein (Sagara et al.,
1993). Thus suggesting the N-terminus anchor region is required for correct folding 
and, therefore, stability of the protein, which is lacking in the truncated versions 
(Clark & Waterman, 1992; Sagara et al., 1993). This problem can be overcome by 
designing truncations with regard to the proline-rich regions o f the N-terminus as in 
CYP2C3 (Richardson et al., 1993; von Wachenfeldt et al., 1997) and CYP2C5 
(Cosme & Johnson, 2000; Wester et al., 2002). Proline residues are required for the 
correct folding o f the protein, as they are important in the formation o f turns and the 
disruption/formation of a-helices and P-sheets in secondary structure (Kusano et al., 
2001; Kusano et al., 2001b). Rabbit CYP2C3 was shown to be successfully 
expressed in its truncated form using this method o f introducing the truncation after 
the proline rich region following the hydrophobic membrane anchor (von 
Wachenfeldt et al., 1997). This version o f CYP2C3 was associated with the 
membrane, but could be found in the cytosol following treatment with a high salt 
buffer (von Wachenfeldt et al., 1997) suggesting the truncated protein produced was 
not membrane-bound (and did not require detergents for its release). Similar results
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were seen with CYP2C5 (von Wachenfeldt et al., 1997). Due to this success, two 
truncations were designed for Alkl using this method (although Alkl does not 
contain a defined proline-rich region within its protein sequence). 
ModifiedA50:Alkl was designed using the same N-terminus sequence as CYP2C3. 
This sequence MAKKTSSKGKL has been shown to maintain folding stability 
without affecting the cytochrome P450 function and was optimised for the 
expression of (full-length) CYP2C3 in E. coli (Li & Chiang, 1991; Karam & Chiang,
1994). ModifiedA44:Alkl was designed using the CYP2C3 N-terminal leader 
sequence and more of the Alkl protein sequence prior to the proline rich region to 
promote correct folding.
Both modifiedA50:Alkl and modifiedA44:Alkl resulted in inactive cytochrome 
P420 following expression. Unlike CYP2C3, CYP2C5 and other microsomal P450s 
(e.g. CYP2D6), Alkl does not contain a defined proline-rich region, PPGPXPXP 
(see figure 4.21) (von Wachenfeldt et al., 1997; Kusano et al., 2001b). However, 
this method was used to see if truncating the sequence near a proline may result in 
the production of an active, truncated version of A lk l. Therefore, the proline used in 
the design of the Alkl truncations was chosen by aligning the Alkl sequence with 
the amino acid sequences for CYP2C3 and CYP2C5 (figure 4.21). However, this 
resulted in the production of inactive cytochrome P420 protein. This indicates that 
the proline identified may not have been the important residue for folding stability 
and the truncations of Alkl may require re-designing at other prolines to produce 
more soluble, active cytochrome P450 protein.
50
CYP2C3 GKGKdPPGPTPLP^VG 
CYP2C5 GRGKqPPGPTPFPJlG 
A l k l  SYKL<jCKNPVHLK^AG 
CYP52A3 E YKL I£C ENPVYFE ij AG
Figure 4.21 -  Sequence alignment showing the proline-rich region. Sequence 
alignment of rabbit CYP2C3, rabbit CYP2C5, CYP52A3 and Alkl. The dashed blue 
line indicates the proline-rich region of the sequence. Highlighted in red are the 
proline residues conserved in all four sequences.
134
Active soluble CYP52A3 protein was produced using sequence-specific proteolysis 
at a specially designed cleavage site (Scheller et al., 1994). The full-length 
membrane-bound CYP52A3 protein was expressed in S. cerevisiae containing the 
recognition sequence Ile-Glu-Gly-Arg for factor Xa (Scheller et al., 1994). Upon 
treatment o f the protein with this protease, the cytosolic domain was released from 
the N-terminus producing a soluble CYP52A3 protein with spectral properties 
similar to the full-length version, with only a decrease seen in the catalytic activity of 
the truncation (Scheller et al., 1994). A similar method was used with human 
CYP1A2 (Dong et al., 1996). In this method, a thrombin-sensitive region was 
incorporated into the full-length sequence to allow release o f the cytosolic domain 
from the N-terminus upon treatment with thrombin (Dong et al., 1996), thus 
producing an active, soluble cytochrome P450 protein. This may be an alternative 
method that could be used to produce active soluble Alkl protein.
The production of active cytosolic cytochromes P450 is difficult as it depends upon 
the hydrophobic profile o f the protein, the method o f design used and the cytochrome 
P450 protein itself. Many attempts at producing a variety o f different cytochromes 
P450 (e.g. CYP2B6 from human livers) by different laboratories have resulted in 
either the formation o f inactive cytochrome P450 or an active truncated version o f 
the full-length protein, which is still membrane-bound (Scott et al., 2001). 
Therefore, the difficulties in producing an active truncated protein as seen in this 
study are not exclusive to A lkl.
4.4.3 Expression of CYP52A3
Using E. coli as a system for the expression o f CYP52A3 resulted in the production 
o f inactive cytochrome P420 protein. As Alkl was also unable to express in its 
native form in this organism a similar approach (as discussed in section was 4.4.1) 
was implemented to try and produce CYP52A3 in its active form. Alterations in the 
temperature and duration o f both the growth and expression phases o f CYP52A3 
protein expression continued to result in the production o f cytochrome P420 protein, 
suggesting the formation o f inclusion bodies was not the reason for the production of 
inactive CYP52A3 protein. The protein and translated nucleotide sequences for 
CYP52A3 were aligned to ascertain whether CYP52A3, like A lkl, had a deviation in 
the translation o f CUG. The CYP52A3 nucleotide sequence did not contain this
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codon and there were no other differences identified between the two sequences. 
Therefore, the deviation in the “universal” genetic code, which was problematic in 
the protein expression of native A lkl, was not the reason for the production of 
inactive CYP52A3 protein.
Previously, CYP52A3 was expressed in its active cytochrome P450 form by Scheller 
and co-workers (1996) when S. cerevisiae was used as the host organism. Therefore, 
S. cerevisiae AH22 cells were used to express CYP52A3_yeast protein in this study. 
This resulted in the production o f protein with a reduced carbon monoxide difference 
spectrum at 449nm, suggesting the presence o f cytochrome P450 protein in the 
microsomes. This might suggest that CYP52A3 requires eukaryotic posttranslational 
modifications for it to be expressed in its active cytochrome P450 form or it could be 
other aspects o f eukaryote biology, such as appropriate chaperones.
Despite the expression of proteins in E. coli resulting in high yields (compared to 
other systems described in section 4.1) and being relatively quick and easy, this 
expression system can result in the production o f instable and inactive proteins. 
This can be due to the inability o f E. coli to undertake posttranslational modifications 
on the protein (such as phosphorylation or glycosylation), which are required for the 
correct folding o f the protein and for enzymatic activity (Gonzalez & Korzekwa,
1995). Yeast such as S. cerevisiae, are able to perform these posttranslational 
modifications and are, therefore, ideal host organisms for the expression o f proteins 
that are unable to express in their active form in E.coli.
In conclusion, ALK1L456S, CaCPR and CYP52A3_yeast were all shown to produce 
a reduced carbon monoxide cytochrome P450 spectrum upon expression o f the 
protein in either E. coli or S. cerevisiae. The AlklL456S protein will be used in 
further studies to identify possible substrates o f this protein through substrate binding 
and reconstitution assays. CYP52A3_yeast will be used as a control in these assays. 
CaCPR will be used in these reactions for the transfer o f electrons from NADPH.
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Chapter 5: AlklL456S Binding and Metabolism Studies Using Alkanes and
Fatty Acids as Substrates
5.1 Introduction
Cytochromes P450 produce a Soret peak at 450nm when carbon monoxide binds to 
the sodium dithionite reduced protein (Omura & Sato, 1964) and exhibit other 
spectral peaks in the native state. Cytochromes P450 also exhibit other spectra on 
binding with potential substrates and the spectral changes which occur can be 
classified into two types: type I and type II depending on the spectra produced 
(figure 5.1).
425-435nm385nm
4 1 8-420nm 390-4 lOnm
T y p e  I B i n d in g T y p e  II  B i n d in g
Fiuure 5.1 -  Schematic overview of the two classes of binding spectra: type I and 
type II. Indicated on each spectrum is the wavelength at which the peak and trough 
occur, characterising the type of spectra shown.
In its substrate-free (resting) state, the cytochrome P450 haem iron is in its ferric 
low-spin form (figure 5.2). In this state, water acts as the sixth ligand and an 
absolute spectra of 416-418nm is produced (Yoshida, 1988). In the presence of 
substrate, the substrate coordinates with the haem iron at the sixth coordination 
position, but does not adhere as the sixth ligand. This prevents water accessing the 
haem causing a spin shift change from low- to high-spin (figure 5.2) (Yoshida, 
1988). This shift is characteristic of type I binding and is represented as a peak at 
385nm and a trough at 418-420nm (Schenkman, 1970; Schenkman et al., 1972).
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Figure 5.2 -  Alterations in the spin-state of the cytochrome P450 haem iron 
(caused by substrate interaction) and the binding spectra produced. Type I 
binding is caused by a shift in the spin-state o f the haem iron from low to high, 
which occurs when the substrate prevents the water molecule binding as the sixth 
ligand (black arrows). Type II binding occurs when the substrate coordinates with 
the haem iron acting as the sixth ligand. Type I la binding spectra occurs when the 
haem iron remains in a low-spin state (red arrows). Type lib binding spectra is 
produced when there is a shift in the spin-state from high to low (blue arrows).
However, if a substrate interacts with the haem iron acting as the sixth ligand, then 
the cytochrome P450 acquires an artifical hexa-coordinated low-spin configuration 
(figure 5.2). This results in the formation of type II binding spectra, o f which there 
are two types: type Ila and type lib. Type Ila binding occurs when the substrate-free 
form of the cytochrome P450 is in a high-spin state resulting in a high- to low-spin 
state shift when the substrate binds as the sixth ligand (figure 5.2) (Yoshida, 1988). 
This type of binding is characterised by a peak at 427-430nm and trough at 410nm 
(Schenkman, 1970; Schenkman et al., 1972; \osh ida, 1988). Type lib binding
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occurs when the substrate-free form is already in a low-spin state and is represented 
as a peak at 425-427nm and a trough at 390nm (figure 5.2) (Schenkman, 1970; 
Schenkman et al., 1972; Yoshida, 1988). Type II binding can be indicative of 
cytochrome P450 inhibition. However, some substrates containing nitrogen or 
sulphur atoms can bind as the sixth ligand producing weak type II binding spectra as 
these atoms can readily interact with the haem iron (Locuson et al., 2007).
Binding studies are important to identify potential substrates o f a cytochrome P450 
enzyme. These substrates can then be used in in vivo and in vitro experiments to 
identify how the cytochrome P450 enzyme catalyses their metabolism.
Reconstitution assays are a common method to evaluate the in vitro activity o f a 
purified cytochrome P450 protein on a substrate. To allow the cytochrome P450 
monooxygenase cycle to progress and for metabolites to be produced redox partners 
need to be added to the assay (see sections 1.2.1 and 1.2.2). In this chapter, purified 
AlklL456S protein was used to catalyse substrate metabolism and as this is a 
membrane-bound eukaryotic protein, it belongs to the class II group o f cytochrome 
P450 proteins (see section 1.2.2.2). Cytochromes P450 belonging to this class 
require NADPH-cytochrome P450 reductase (CPR) for the transfer of electrons from 
the electron donor NADPH to the haem centre o f the protein (Werck-Reichhart & 
Feyereisen, 2000; Paine et al., 2005). CPR is a flavoprotein consisting o f equal 
amounts o f the cofactors ferredoxin reductase (FAD - flavin adenine dinucleotide) 
and flavodoxin (FMN - flavin mononucleotide), which are required for the transfer o f 
electrons (He & Chen, 2005; van Bogaert et al., 2007). The hydride ion o f NADPH 
transfers electrons to the FAD domain of the CPR, as FAD has a lower oxidation 
potential than NADPH (van Bogaert et al., 2007). A single electron is then 
transferred from FAD to the FMN domain, which is then transferred to the 
cytochrome P450 to reduce the haem centre (Groves, 2005; van Bogaert et al., 2007). 
A second electron is then transferred to cleave oxygen for incorporation into the 
substrate (Groves, 2005). Therefore, these components need to be added to the 
reconstitution assay to aid AlklL456S activity.
However, not all cytochromes P450 require CPR and NADPH for the transfer o f 
electrons to the haem centre, so alternative components may need to be added to the
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reconstitution assay for functional enzymatic activity to occur. For instance, 
CYP101D1 from Novosphingobium aromaticivorans belongs to the class I o f 
cytochromes P450 and requires ferredoxin reductase and iron sulphur redoxin (as 
well as NADH) to catalyse the conversion o f camphor to 5-exo-hydroxycamphor 
(Bell et al., 2010). Alternatively, CYP102A1 from Bacillus megaterium is a 
naturally occurring cytochrome P450-CPR fusion protein (Warman et al., 2005), 
which requires the addition o f NADPH to the assay, but not an additional redox 
partner.
A regeneration system can also be added to ensure an adequate supply o f the cofactor 
in the assay. For example, glucose-6-phosphate and glucose-6-phosphate 
dehydrogenase can be added to the assay to regenerate NADPH (Urlacher & Eiben,
2006). The transfer o f electrons to the cytochrome P450 results in the reduction o f 
NADPH to NADP+, which can no longer be used to drive the cytochrome P450 
monooxygenase cycle. NADP+ can be regenerated in the presence o f glucose-6- 
phosphate and glucose-6-phosphate dehydrogenase as the dehydrogenase catalyses 
the removal o f hydrogen (dehydrogenation) from the glucose-6-phosphate molecule. 
The hydrogen released can react with NADP+ to form NADPH, which can then be 
used to drive the reaction. The addition o f a regeneration system is not necessary for 
cytochrome P450 activity to occur. However, NADPH is an expensive compound to 
purchase and a continuous supply to the assay would prove costly so the addition o f a 
regenerating system is not only beneficial in regenerating consumed NADPH, but 
also reducing the overall cost o f the reaction (Urlacher & Eiben, 2006).
A lipid component can also be added to the reconstitution assay mix if  a membrane- 
bound cytochrome P450 protein is used. This is required for protein stability and to 
ensure the cytochrome P450 and CPR proteins are at the required orientation for 
electron transfer by ensuring the N-terminus o f the protein is attached to the 
membrane and the C-terminus is facing the cytoplasm (Paine et al., 2005; van 
Bogaert et al., 2007). Phospholipids, dilaurylphosphaticholine (DLPC) and yeast 
microsomes have all been used as the lipid component in reconstitution assays 
(Guengerich et al., 1991; Reed et al., 2006). However, if  yeast microsomes are used 
then purified cytochrome P450 protein does not need to be added to the assay as 
microsomes can be produced containing the protein o f interest. These microsomes
140
also contain their own CPR and so additional reductases are not required to be added 
to the assay (Guengerich et al., 1991). However, some cytochromes P450 are not 
able to utilise the yeast CPR for electron transfer in the reaction and, therefore, 
require the addition of CPR protein to the assay (Pompon et al., 1996).
Each o f the components described above can be added in different concentrations to 
the reconstitution assay mix to aid the enzymatic activity o f the cytochrome P450 
protein and to enhance product formation, thus making reconstitution assays a 
favourable method for evaluating cytochrome P450 activity. However, 
reconstitution assays require a quantifiable amount o f cytochrome P450 protein for 
experiments to be undertaken. Expressed cytochrome P450 protein can be difficult 
to obtain (see chapter 4), therefore, in vivo, whole-cell experiments can be 
undertaken as alternatives to reconstitution assays. Not only do these experiments 
not require the addition o f protein, they do not require the addition o f expensive 
cofactors, such as NADPH, and they also contain additional proteins, which may be 
required for enzymatic activity and stability (Urlacher & Eiben, 2006). However, 
these experiments can be limited by poor substrate uptake and potential substrate 
toxicity as well as the possibility that the products formed could be subjected to 
further metabolism by other enzymes occurring naturally in the cell (Urlacher & 
Eiben, 2006). These limitations associated with in vivo experiments make in vitro 
reconstitution assays a more attractive method for the evaluation o f cytochrome P450 
activity.
The objective of this chapter is to attempt to deorphanise AlklL456S using the 
purified protein produced in chapter 4 in binding studies and reconstitution assays. 
As AlklL456S shares homology with CYP52A3 from Candida maltosa, a variety o f 
alkanes and fatty acids will be used in binding studies to establish those 
hydrocarbons, which bind to AlklL456S producing a type I binding spectra. These 
substrates will then be used in reconstitution assays to identify if  and how 
AlklL456S metabolises these hydrocarbons, potentially resulting in the production 
of diacids. CYP52A3 will be used as a control. This study will attempt to assign 
function to AlklL456SS, but will also increase the understanding o f proteins 
belonging to the CYP52 family o f cytochromes P450. To date very few of these 
CYP52 enzymes have been characterised at the protein level despite 52 genes being
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identified in a number of yeast/fungal strains
(http://dmelson.uthsc.edu/CvtochromeP45Q.html).
5.2 M aterials and Methods
5.2.1 Buffer D
Based on the buffer used by Scheller et a l 1996.
1M sodium citrate buffer, pH7.4, 30% (w/v) glycerol and 0.1% (w/v) n- 
dodecylmaltoside (Sigma-Aldrich). Stored at 4°C.
5.2.2 Standards
All standards (figure 5.3) were made up to a final concentration of 2mg/ml in 
chloroform. 5pi of each standard was evaporated to complete dryness in a 
SpeedVac, derivatised and run on the GCMS.
142
H e x a d e c a n e
H e x a d e c a n o l
P a lm it ic  A c id
1 6 -H v d r o x y p a lm it ic  A c id
O
T h a p s ic  A c id
O
O
P a lm it ic  A c id -1 6 .,1 6 ,1 6 -d ?
O
D
Figure 5.3 -  S tructures of hexadecane, hexadecanol, palmitic acid, 16- 
hydroxypalmitic acid, thapsic acid and palmitic acid-16,16,16-di. Hexadecanol 
(alcohol) is the hydroxylated version of hexadecane (alkane). Palmitic acid (fatty 
acid) is hydroxylated at the co- (16th) carbon to produce 16-hydroxypalmitic acid 
(fatty alcohol). Thapsic acid is a diacid. All structures are 16 carbons in length. 
Palmitic acid-16 ,16 ,16 -d3 is the deuterated form of palmitic acid. Three heavy 
hydrogen atoms (D) are attached to carbon 16 increasing the molecular weight from 
256 to 259.
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5.2.3 Minimal Salts Media
Based on the recipe o f Dickinson & Wadforth, 1992. Tween 80 was added 
according to Tanaka et al., 1977.
7g potassium dihydrogen phosphate, 2g sodium phosphate, 1.5g magnesium 
sulphate, 1.5g yeast extract, O.lg calcium chloride, 0.008g ferric (iron) chloride, 
0.000lg  zinc sulphate and 15g diammonium tartrate were made to a final volume of 
1 litre using distilled water. The solution was adjusted to pH6.5 and autoclaved. To 
this solution the following were added immediately before use: 2% (w/v) galactose, 
0.1% (v/v) hexadecane and 0.05% (v/v) Tween 80. 5pg/ml histidine was added to all 
media.
5.2.4 Methods
5.2.4.1 Substrate Binding
All binding studies of lipid to protein were undertaken using a Hitachi U-3310 UV- 
Vis scanning spectrophotometer.
5.2.4.1.1 Alkane Binding
The alkanes used for binding studies with purified AlklL456S protein are shown in 
figure 5.4.
Dodecane
Hexadecane
Figure 5.4 -  Structural overview of dodecane (C12) and hexadecane (C l6).
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5.2.4.1.1.1 Titration of Alkane Against Purified AlklL456S Protein
Alkanes were diluted in DMF (dimethylformamide) (5mg/ml stock solution) or 
ethanol (lOOmM stock solution) and titrated against 2pM AlklL456S protein in a 
split cuvette. Depending on the solvent used to dissolve the alkanes, the same 
solvent (minus the hydrocarbon) was added to the protein in the reference cuvette. 
For example, if  DMF was used to dissolve the alkane, then DMF would have been 
added to the reference cuvette. The following buffers were used for all spectral 
determinations: buffer D, 0.1M Tris HC1, pH8.1 containing 25% (w/v) glycerol and 
0.1M potassium phosphate, pH7.4 containing 20% (w/v) glycerol. Spectra were 
measured between 350nm and 500nm.
5.2.4.1.1.2 Scheller et al.. 1996 Method
Based on the method o f Scheller, et al., 1996.
A lOOmM stock solution o f hexadecane was made up in ethanol. This stock was 
diluted to a 2mM solution in buffer D at 37°C. The solution was then sonicated in a 
sonic bath for 1 minute to mix. The 2mM solution was diluted further in buffer D to 
produce different concentrations o f hexadecane. The concentrations used were: 
7.8pM, 15.6pM, 62.5pM, 250pM and ImM. The baseline was recorded using buffer 
D. AlklL456S was added to the hexadecane to produce a final protein concentration 
o f 1 pM. The difference spectra were then recorded. This procedure was repeated for 
each hexadecane concentration.
5.2.4.1.2 Fatty Acid Binding
A range o f fatty acids (from C l0:0 to Cl 8:0 (see figure 5.5)) were dissolved in DMF 
for use in this study. These fatty acids were individually titrated against Ni -NTA 
agarose purified AlklL456S protein (2pM) in a split cuvette. A reference sample 
was also set-up in a second split cuvette with DMF added to the cytochrome P450 
protein. The fatty acid (dissolved in DMF) was added to the buffer in the back 
compartment o f the reference cuvette to prevent precipitation interfering with the 
spectra produced. Buffer containing 0.1M Tris HC1, pH8.1 and 25% (w/v) glycerol 
was used for all spectral determinations. Spectra were measured until saturation with 
the fatty acid was reached.
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Figure 5.5 -  S tructural overview of the saturated  fatty acids used in binding 
studies with purified AlklL456S protein.
5.2.4.2 Reconstitution Assays
5.2.4.2.1 Reconstitution Assays Usinn Purified AlklL456S Protein to Catalyse 
the Reaction
Micelles were created according to the method in section 2.2.11.1 using 1 Ojal of 
2mg/ml of palmitic acid dissolved in chloroform because this fatty acid was shown to 
have the greatest binding affinity of all the hydrocarbons used for binding studies in 
this chapter.
All assays were set-up according to the method described in section 2.2.11.2 with the 
addition of 2.5pM purified AlklL456S protein and lOpM ScA33:CPR, unless 
otherwise stated. Negative controls were set-up without NADPH. lOOpl of 0.2% 
(w/v) sodium bicarbonate was added instead to ensure the pH of the assay remained 
the same in both reactions.
To check whether buffer pH affected product formation, lOOpl of 1M Tris-HCl, 
pH6.4 was substituted in the assay with the same buffer at pH6 .6 , pH6 .8 , pH7.0 or 
pH7.2. Negative controls were set-up with NADPH omitted.
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Different CPRs were also added to the assays as some cytochromes P450 are unable 
to utilise different CPR for electron transfer during the monooxygenase cycle 
(Pompon et al., 1996). ScA33:CPR was replaced with either 3.8pM CaCPR or 
0.052pM human reductase (hCPR) (Sigma-Aldrich). Negative controls were also 
set-up with CPR omitted from the assay.
CPR titrations were set-up using different rations o f CPR to AlklL456S. 
ScA33:CPR was added to the assays at a ratio o f 1:1 and in excess at 2:1, 4:1 and 
10:1. The concentration of ScA33:CPR added was, therefore, 2.5pM, 5pM, lOpM 
and 25pM respectively. The concentration of AlklL456S was reduced from 2.5pM 
to 0.5pM for CaCPR titrations. CaCPR was set-up in excess o f AlklL456S at ratios 
of 2.5:1, 5:1 and 10:1. Therefore, the concentration o f CaCPR added were 1.25pM, 
2.5pM and 5pM respectively.
CaCPR titrations were repeated increasing incubation at 37°C from lhour to 18 
hours.
Micelles were created using lOpl of 2mg/ml palmitic acid-16,16,16-d3 dissolved in 
chloroform rather than palmitic acid. CaCPR titrations were repeated using these 
micelles. Assays were incubated at 37°C for 1 hour and 18 hours before extraction.
In all titrations, negative controls were set-up without CPR.
All assays were terminated on ice and extracted with 5ml o f a chloroform :methanol 
(2:1, v/v) solution. Samples were evaporated to complete dryness in a SpeedVac 
prior to derivatisation (sections 5.2.4.3 and 2.2.12) and analysed on the GCMS 
(section 2.2.13.1).
All reactions were set-up in duplicate.
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5.2.4.2.2 Reconstitution Assays Using Microsomal Preparations of
CYP52A3 yeast to Catalyse the Reaction
2.2pM of CYP52A3 microsomal preparations were added to lOpl of 2mg/ml palmitic 
acid-16,16,16-d3 (dissolved in ethanol), lOOpl of 1M potassium phosphate, pH6.4, 
50pl o f 40mM glucose-6-phosphate and 50pl glucose-6-phosphate dehydrogenase. 
The solution was made up to a final volume of 900pl with distilled water and mixed 
thoroughly. The solution was incubated on ice for 30 minutes prior to pre-incubation 
at 30°C for 5 minutes. The reaction was initiated by the addition of lOOpl of lOmM 
NADPH dissolved in 0.2% (w/v) sodium bicarbonate. The solution was mixed 
thoroughly before incubation at 30°C for 1 hour. Samples were terminated on ice, 
extracted with 5ml of chloroform:methanol (2:1, v/v) and evaporated to complete 
dryness in a SpeedVac. Samples were then derivatised (sections 5.2.4.3 and 2.2.12) 
and analysed on the GCMS (section 2.2.13.1).
3.8pM of CaCPR was added to some reactions to aid product formation.
Reactions were also set up with alternative substrate. Either lOpl of lOmg/ml 
palmitic acid-16,16,16-d3 or hexadecane dissolved in DMF was added to the 
samples.
Negative controls were set up as above with either the substrate or NADPH removed. 
Microsomal preparations were also set up as blank controls. 2.2pM of CYP52A3 
microsomes was diluted to a final volume o f 1ml with 1M potassium phosphate, 
pH6.4 with the reconstitution system omitted. All controls were extracted and 
analysed as above.
All reactions were set-up in duplicate.
5.2.4.2.3 Metabolism of Hexadecane by S. cerevisiae Transformed with 
YEp51:AlklL456S veast Plasmid
Based on the methods of Ohkuma et al., 1998; Kogure et al., 2007 and Uppuluri & 
Chaffin, 2007. The extraction method was based on the protocols o f Bligh & Dyer, 
1959 and Iverson el al., 2001.
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10ml o f YEPD was inoculated with one S. cerevisiae colony (containing either 
YEp51:AlklL456S_yeast, YEp51:CYP52A3_yeast (positive control) or YEp51 only 
(negative control)) and incubated overnight in a shaker set at 30°C and 150rpm. 
Following overnight growth, the number o f cells in the culture was counted using a 
light microscope and haemocytometer. The cells were washed in distilled water and 
added to 50ml of minimal salts media (containing 2% (w/v) galactose, 0.1% (v/v) 
hexadecane and 0.05% (v/v) Tween 80) at a final cell density o f lx l0 5 cells/ml. 
Cultures were grown at 30°C and 150rpm and samples were taken at regular 
intervals. Experiments were set-up in duplicate.
5ml o f the culture was extracted from the growth sample at each interval and 
centrifuged for 3 minutes at 3000g. The supernatant was discarded and the cell pellet 
was resuspended in 1ml o f distilled water. 3.75ml o f a chloroform:methanol (1:2) 
mixture was added to the suspension followed by 1.25ml o f chloroform and 1.25ml 
o f distilled water. The mixture was thoroughly mixed on a vortex after each 
addition. The lower chloroform phase was extracted with a glass Pasteur pipette and 
evaporated to complete dryness in a SpeedVac. Samples were derivatised (section 
5.2.4.3) and run on the GCMS (section 2.2.13.1).
5.2.4.3 Derivatisation of Samples
5.2.4.3.1 Base Catalysed Esterification
Based on method C from Basconcillo & McCarry, 2008.
lm l o f 0.5M sodium methoxide in methanol (Sigma-Aldrich) was added to the dried 
sample and mixed on the vortex thoroughly. The mixture was then incubated in a 
waterbath for 15 minutes at 50°C. The reaction was stopped by adding lOOpl of 
glacial acetic acid. This was followed by the addition o f lm l o f hexane and lm l of 
distilled water. The mixture was thoroughly mixed and the top phase was extracted 
with a glass Pasteur pipette. The hexane extraction step was repeated twice (2 x lml) 
and the extracted layers combined. To these combined layers 0.5g o f sodium 
sulphate (anhydrous) (Sigma-Aldrich) was added and mixed thoroughly. The sample 
was left to settle for 5 minutes before the liquid layer was extracted carefully with a 
glass Pasteur pipette. The extracted mix was then evaporated to complete dryness in
149
GC vials using the Speed Vac. Samples were resuspended in methanol and the lid 
was crimped on.
5.2.4.3.2 Acid Catalysed Esterification
Based on method B from Basconcillo & McCarry, 2008.
To the dried sample 2ml o f 3% (v/v) sulphuric acid dissolved in methanol was added 
and the mixture was thoroughly mixed on a vortex. The suspension was then 
incubated in a waterbath set at 50°C for 12-24 hours. Following the period of 
incubation, the samples were removed from the waterbath and left to cool for 10 
minutes, lm l of hexane was added to the mixture, mixed and the top phase was 
extracted with a glass Pasteur pipette. The hexane extraction steps were repeated 
twice and the extracted layers combined. To these combined layers 0.5g o f sodium 
sulphate (anhydrous) (Sigma-Aldrich) was added and mixed thoroughly. The sample 
was left to settle for 5 minutes before the liquid layer was extracted carefully with a 
glass Pasteur pipette. The extracted mix was then evaporated to complete dryness in 
GC vials using the Speed Vac. Samples were resuspended in methanol and the lid 
was crimped on.
5.3 Results
5.3.1 Alkane Binding
The alkanes dodecane (C l2) and hexadecane (C l6) were dissolved in DMF and 
titrated against 2pM of purified AlklL456S protein. Dodecane binding produced no 
discemable binding spectra, but hexadecane showed a slight trough at 418nm, which 
suggests possible type I binding (figure 5.6). Therefore, hexadecane was used for 
further binding studies with AlklL456S.
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Figure 5.6 -  Spectra produced by dodecane and hexadecane in binding studies 
with AIklL456S. Dodecane produced no discemable binding spectra. Spectra 
produced by hexadecane showed a peak at 418nm, suggesting type I binding.
To evaluate whether the solvent used to dissolve the hexadecane was preventing the 
production of a clear binding spectra, hexadecane was dissolved in ethanol to a stock 
concentration of lOOmM. Titration of this solution against 2pM of AlklL456S 
produced neither type 1 nor type II binding spectra, but did show a degree of 
precipitation. To evaluate whether the ethanol was causing this precipitation, the 
lOOmM ethanol stock was diluted in buffer D. Diluting the lOOmM stock to a 10mM 
working solution in this buffer resulted in a cloudy suspension, which could not be 
used for binding studies. A 2mM concentration of hexadecane in this buffer was 
then produced and was used for binding as the suspension remained clear. Binding 
with this solution again resulted in no discemable binding spectra. Increasing the 
concentration of purified AlklL456S protein from 2pM to 8pM also failed to show 
any evidence of substrate binding. Figure 5.7 shows an example of the spectra 
obtained.
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Figure 5.7 -  An example of the spectra produced when using hexadecane 
resuspended in buffer D as the substrate probe in binding studies with 
AlklL456S.
To increase the concentration of hexadecane used in these binding studies, the stock 
lOOmM ethanol solution of this hydrocarbon was diluted in different buffers (table 
5.1). Table 5.1 shows that a 5mM solution of hexadecane could be produced using 
0.1M potassium phosphate, pH7.4 containing 20% (w/v) glycerol. Binding studies 
undertaken using this hexadecane solution produced no binding spectra.
B u ffe r
H e x a d e c a n e  C o n c e n tr a tio n
2 m M 3 m M 4 m M 5 m M 6 m M
Buffer D X - -
O .IM T ris HC1 pH 8.1 ,25%  
(w/v) glycerol X - -
0.1M potassium phosphate 
pH 7.4, 20% (w/v) glycerol
S X
Table 5.1 -  Buffers used to dilute lOOmM hexadecane (in ethanol) for use in 
binding studies with AlklL456S. The table shows the concentrations of 
hexadecane achieved by diluting a stock solution of this alkane. Clear suspensions 
are indicated as v/ in the table. X shoes the concentrations at which hexadecane 
produced a cloudy suspension. Concentrations not tried are indicated by
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To show the binding of hexadecane to CYP52A3, Scheller and co-workers (1996) 
added protein to different concentrations of substrate rather than titrating the 
substrate against the protein (the method used in this study). Therefore, this 
alternative method was used for hexadecane binding studies with AlklL456S. 
Rather than producing typical type I or type II binding spectra this method produces 
an absolute binding spectra where binding is indicated by a shift in the peak to 
different wavelengths. If hexadecane were to bind to AlklL456S there would be a 
shift in the peak from 419nm towards 390nm representing a shift in the conformation 
of the haem from a low spin complex to a high spin complex. However, no shift in 
the peak was observed suggesting no binding had taken place between AlklL456S 
and hexadecane. The concentration of AlklL456S protein was increased from 2pM 
to 8pM and the experiment was repeated. This, again, failed to show a shift in the 
peak towards 390nm, suggesting no binding o f hexadecane to AlklL456S. An 
example of the spectra obtained is shown in figure 5.8.
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Figure 5.8 -  Example of spectra produced using the Scheller el al., 1996 method 
for binding studies involving AlklL456S and hexadecane.
5.3.2 Fatty Acid Binding
Various concentrations (5mg/ml and lOmg/ml) of palmitic acid (C l6:0) were 
dissolved in DMF for fatty acid binding studies. 5mg/ml palmitic acid dissolved in 
DMF showed type I spectra, but failed to reach saturation in titration studies (figure 
5.9). Using lOmg/ml, saturation of palmitic acid was reached (figure 5.9).
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Figure 5.9 -  Type I binding spectra produced by 5mg/ml and lOmg/ml of 
palmitic acid dissolved in DMF.
As palmitic acid showed type I binding spectra with Alkl L456S, other saturated fatty 
acids were titrated against the protein. Laurie acid (C l2:0) and myristic acid (C l4:0) 
both showed type I binding spectra (figure 5.10). Stearic acid (C l8:0) produced no 
discemable spectra and capric acid (C l0:0) showed neither a type I nor type II 
binding spectra (figure 5.10). However, a trough at 416nm was shown, but no 
identifiable peak at either 385nm or 425-435nm was seen.
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Figure 5.10 — Spectra produced by fatty acids used in binding studies with 
AlklL456S. Binding with lauric acid and myristic acid produced type I spectra. 
Stearic acid showed no discemable spectra and capric acid produced a trough at 
416nm, which represents neither type I nor type II binding spectra.
As lauric acid, myristic acid and palmitic acid all showed type I binding with 
AlklL456S, the substrate binding constant (Ks) for each fatty acid was calculated 
using the Lineweaver-Burke equation (see table 5.2).
Fatty Acid Ks (pM)
Lauric Acid 3466.94±260.55
Myristic Acid 934.05±42.05
Palmitic Acid 139.89±52.97
Table 5.2 -  Substrate binding constants (Ks) of the fatty acid-AIklL456S 
complexes.
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Using the data shown in table 5.2, it is possible to rank the fatty acid binding affinity 
for Alkl456S from the strongest to the weakest as the greater the binding affinity the 
smaller the binding constant:
Palmitic acid > Myristic acid > Lauric acid
Palmitic acid was shown to have the smallest Ks value, thus giving it the greatest 
binding affinity to AlklL456S. Therefore, this fatty acid was to be used for 
reconstitution assays with AlklL456S.
5.3.3 Detection of Hexadecane. Palmitic Acid and their Derivatives on the 
GCMS
To ensure that hexadecane, palmitic acid and their derivatives could be detected on 
the GCMS for analysis, standards were produced. These standards were derivatised 
by a number o f methods (silylation (section 2 .2 .12), base catalysed esterification 
(section 5.2.4.3.1) and acid catalysed esterification (section 5.2.4.3.2)) and run on the 
GCMS using the method printed in section 2.2.13.1.
5.3.3.1 Hexadecane
The retention time for hexadecane is 11.304min and the mass ion is 226 (figure 
5.11).
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Figure 5.11 -  Hexadecane. GCMS results showing the GC chromatograph (top) 
and mass spectrum (bottom) for hexadecane. Inset is the structure of this alkane.
5.3.3.2 Palmitic Acid
To identify fatty acids using the GCMS, they first require derivatisation. Therefore, 
palmitic acid was derivatised using silylation, base catalysed esterification and acid 
catalysed esterification methods to identify the optimal protocol for identification of 
this standard on the GCMS.
5.3.3.2.1 Silylation
Silylation did not result in the full conversion of palmitic acid to its derivatised form. 
76% of the palmitic acid standard used was derivatised to its TMS version, while 
24% remained underivatised. The retention time for underivatised palmitic acid is 
15.176min and the mass ion is 256 (figure 5.12).
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Figure 5.12 -  Underivatised palmitic acid. GCMS results produced following the 
silylation of palmitic acid. The underivatised palmitic acid peak is indicated on the 
GC chromatograph (top). The MS spectrum (bottom) shows the fragmentation 
pattern o f this underivatised fatty acid. The structure is shown inset.
The addition of Si(CH3)3 to the carboxyl side-chain of palmitic acid during silylation 
adds 71 to the fatty acids molecular weight (underivatised molecular weight = 256). 
Therefore, the mass ion for TMS derivatised palmitic acid is 327 and the retention 
time is 15.8min (figure 5.13).
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Figure 5.13 -  TM S-derivatised palmitic acid. The GC chromatograph (top) shows 
the peak produced by TMS derivatised palmitic acid. The fragmentation pattern for 
this hydrocarbon is shown in the MS spectrum (bottom). Inset is the structural 
overview of the TMS-derivatised palmitic acid molecule.
5.3.3.2.2 Base Catalysed Esterification
The entire palmitic acid standard was derivatised to its methyl ester form using this 
method. The addition of CH3 to the hydroxyl group of the carboxyl side-chain 
increased the molecular weight o f the fatty acid from 256 to 270. Therefore, the 
mass ion o f palmitic acid methyl ester is 270 and the retention time is 13.953min 
(figure 5.14).
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Figure 5.14 -  Palmitic acid, methyl ester produced using sodium methoxide as 
the catalyst in esterification. The GC chromatograph (top) shows a peak 
corresponding to palmitic acid, methyl ester. The MS spectrum (bottom) shows the 
fragmentation pattern. Inset is the esterified structure of palmitic acid.
5.3.3.2.3 Acid Catalysed Esterification
As with base catalysed esterification (section 5.3.3.2.2), the entire palmitic acid 
standard was converted to its methyl ester form. The retention time for palmitic acid 
methyl ester is 13.102min and the mass ion is 270 (figure 5.15).
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Figure 5.15 -  Palmitic acid, methyl ester produced using 3% (v/v) sulphuric 
acid as the catalyst in esterification. GCMS results showing the GC 
chromatograph (top) and mass spectrum (bottom) of palmitic acid, methyl ester. 
Inset is the structure of this esterified standard.
5.3.3.3 Thapsic Acid
5.3.3.3.1 Base Catalysed Esterification
Using the base catalysed esterification method, thapsic acid was unable to be 
detected on the GCMS (figure 5.16).
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Figure 5.16 -  GC chrom atograph following the base catalysed esterification of 
the thapsic acid standard. No peak representing thapsic acid can be identified on 
the GC chromatograph.
5.3.3.3.2 Acid Catalysed Esterification
Thapsic acid was able to be identified on the GCMS using this method. The 
retention time is 15.5min and the mass ion is 283 (figure 5.17).
As the acid catalysed method can both esterify palmitic acid and allow thapsic acid 
to be detected by the GCMS, it is the method of choice to esterify the products of this 
study.
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Figure 5.17 -  Thapsic acid. GCMS results showing the GC chromatograph (top) 
and mass spectrum (bottom) of this standard. The structure o f the standard is shown 
inset.
5.3.3.4 Hexadecanol
The retention time of hexadecanol is 12.886min and the mass ion is 242 (figure 
5.18).
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Figure 5.18 -  Hexadecanol. The GC chromatograph (top) shows a peak 
corresponding to hexadecanol. The MS spectrum (bottom) shows the fragmentation 
pattern and inset is the alcohol structure.
5.3.3.5 16-Hydroxypalmitic Acid
16-hydroxypalmitic acid could not be detected on the GCMS following acid 
catalysed esterification alone. The substrate required both esterification and 
silylation. This resulted in a retention time of 14.705min and a mass ion for 16- 
hydroxypalmitic acid of 358 (figure 5.19).
As both derivatisation techniques are required to detect 16-hydroxypalmitic acid on 
the GCMS, both of these methods will be used to identify the hydrocarbons in this 
study.
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Figure 5.19 - 16-Hydroxypalmitic acid, TMS, methyl ester. The GCMS results 
for 16-hydroxypalmitic acid, TMS, methyl ester showing the GC chromatograph 
(top) and MS spectrum (bottom) produced. Inset the structure of the silylated and 
esterified fatty alcohol is shown.
5.3.3.6 Palmitic Acid-16,16,16,d^
Acid catalysed esterification resulted in the production of palmitic acid-16 ,16 ,16-d3, 
methyl ester. This hydrocarbon has a retention time of 13.066min and a mass ion of 
273 (figure 5.20). The additional silylation step had no effect on the methyl ester 
molecule produced by esterification.
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Fieure 5.20 - Palmitic acid-16,16,16-d3, methyl ester. GCMS results showing the 
GC chromatograph (top) and mass spectrum (bottom) for the methyl ester form of 
palmitic acid-16 ,16 ,16 -d3. The structure is shown inset.
5.3.4 Reconstitution Assays
5.3.4.1 Reconstitution Assays Usinn Purified AlklL456S Protein to Catalyse the 
Reaction
As palmitic acid was shown to have the greatest binding affinity to AlklL456S of the 
hydrocarbons used for binding studies in this chapter, this fatty acid was used as the 
substrate in reconstitution assays. Initially, assays were set-up using ScA33:CPR as 
the electron donor and a buffer of pH6.4. Negative controls were set-up with 
NADPH omitted from the assay as NADPH is required for electron donation. No 
product (16-hydroxypalmitic acid or thapsic acid) was detected in either of these 
reactions (figure 3.21).
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Figure 5.21 -  GC chrom atographs for reconstitution assays undertaken in the 
presence and absence of NADPH. Both GC traces show similar peaks. The peak 
representing palmitic methyl ester is indicated above. The pink ring identifies the 
retention time at which a peak representing 16-hydroxypalmitic acid, TMS, methyl 
ester should be seen if detected by the GCMS. This ring shows no peak in this area. 
The other large peaks detected on this GC trace correlate to silane molecules, which 
are indicative of column bleed (degradation of the column).
To identify whether the failure of AlklL456S to produce product from palmitic acid 
in these assays was due to pH, a number of 1M potassium phosphate buffers were 
used each with a different pH (pH6.4, pH6 .6 , pH6 .8 , pH7.0 and pH7.2). Negative 
controls were set-up for each pH without NADPH. Again, no product was detected 
on the GCMS (figure 5.22) suggesting product formation in these assays was not 
affected by the pH of the buffer used.
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Finure 5.22 -  GC chrom atographs for reconstitution assays using different 1M 
potassium phosphate buffers, each with a different pH. The substrate peak is 
indicated. A pink ring indicates where a peak representing 16-hydroxypalmitic acid, 
TMS, methyl ester should be found on the GC trace. There is no peak indicating no 
product detection. The other large peaks are again due to column bleed.
To discover if the CPR used (ScA33:CPR) in these assays with AlklL456S was 
affecting product formation (possibly due to poor electron transfer between the 
reductase and AlklL456S), CaCPR and hCPR were also used. Negative controls 
were also set-up with CPR omitted from the assay. Product was not detected in any 
of the GC chromatographs produced in this experiment (figure 5.23), suggesting the 
reductase used was not the limiting factor in product formation.
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Figure 5.23 -  GC chrom atographs for reconstitution assays using different 
reductases for electron transfer. The substrate is indicated. Pink ring represents 
the retention time at which a peak representing 16-hydroxypalmitic acid, TMS, 
methyl ester should be seen. The blue ring represents thapsic acid. Peaks 
representing either metabolite were not identified.
The lack of product formation in these assays could be due to the concentration of 
CPR used in these reactions, rather than the type of CPR being used. Other 
cytochrome P450 enzymes have been shown to require increased ratios of reductase 
to cytochrome P450 protein for substrate metabolism to occur. For instance, 
CYP4A1 requires reductase to be present in the assay in excess at a ratio of 10:1 for 
product formation to occur (He et al., 2005). Therefore, CPR titrations were set-up 
using various ratios of CPR to AlklL456S. Assays containing ScA33:CPR were set­
up at ratios of 1:1 with AlklL456S and in excess at 2:1, 4:1 and 10:1. Therefore, in 
assays containing 2.5pM of AlklL456S protein, 2.5pM, 5pM, lOpM and 25pM of 
ScA33:CPR was added respectively. Negative controls were set-up with CPR 
omitted. These titration experiments, again, resulted in a failure to detect any 
product on the GC chromatographs produced (figure 5.24).
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Figure 5.24 -  GC chrom atographs for reconstitution assays using different 
ratios of ScA33:CPR to AlklL456S. The substrate peak is identified. The pink and 
blue rings represent the location at which peaks representing 16-hydroxypalmitic 
acid, TMS, methyl ester and thapsic acid (respectively) should be detected. No 
peaks corresponding to these metabolites were identified.
CaCPR was used for similar CPR titration experiments with AlklL456S. Ratios 
were set-up with CaCPR in excess at 2.5:1, 5:1 and 10:1. To be able to titrate 
CaCPR at a ratio of 10:1 with AlklL456S, the concentration of AlklL456S needed 
to be reduced from 2.5pM (as used in ScA33:CPR titration experiments) to 0.5pM. 
Therefore, this concentration of AlklL456S protein was used in all assays with the 
addition of 1.25pM, 2.5pM and 5pM of CaCPR respectively. CPR was not added to 
the negative controls. As with the ScA33:CPR titration experiments, no product was 
detected on the GCMS (figure 5.25).
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Figure 5.25 -  GC chrom atographs for reconstitution assays using different 
ratios of CaCPR to AIklL456S. The substrate peak is identified. Pink and blue 
rings identify the retention times at which the alcohol and diacid (respectively) 
metabolites should be detected. No products were identified.
The incubation period (1 hour) at 37°C may be too brief for the reaction to take place 
and for product formation to occur. Therefore, the CaCPR titration experiments 
mentioned above were repeated, except the period o f incubation at 37°C was 
increased from 1 hour to 18 hours to ensure the experiment was of sufficient length 
for the reaction to take place. No product was detected in GC chromatographs 
produce as a result of each assay (figure 5.26).
171
No CaCPR
P alm itic  Acid. 
M ethyl Ester
Palm itic  Acid. 
M ethy l E ster
P alm itic  A cid , 
M ethyl E ster
2.5:1
1000000
110011*01140110011 80120012.2012 <0126012 B013 0013 2013 4013 6013 BO
P alm itic  A cid , 
M ethyl E ster
-V., , .Q  - Qi4Q0l4 2Qi4 4014\(m^l15 001!.?>l6\0A&^ b
1 fl*«OT 
1.6*«0T
10:1
trw»— ii*oo ii'3o ii® n® M ® i3® 13 20 13 4013 ® 12® 13 00 13 30 13 4013®
J L
13®14®14 3014 40 ICSOJOOO H
Figure 5.26 -  GC chrom atographs for reconstitution assays using different 
ratios of CaCPR to AlklL456S and an increased incubation period at 37°C. The 
substrate is identified on the GC chromatograph. The pink and blue rings show the 
potential locations of peaks representing 16-hydroxypalmitic acid, TMS, methyl ester 
and thapsic acid (respectively). Peaks representing these metabolites were not 
identified.
Kim and co-workers (2007) utilised a deuterated version of lauric acid in 
reconstitution assays with Alk8 from C. albicans, therefore a similar version of 
palmitic acid, palmitic acid-16 ,16 ,16-d3, was used in assays with AlklL456S to 
identify whether product formation could be detected on the GCMS. CaCPR 
titrations were set-up as mentioned previously using palmitic acid-16,16,16-d3 as the 
substrate. Samples were initially incubated for 1 hour. Product was not detected on 
the GCMS (figure 5.27).
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Figure 5.27 -  GC chrom atographs for reconstitution assays using different 
ratios of CaCPR to A lklL456S and palmitic acid-16,16,16-d3 as the substrate.
The peak representing palmitic acid-16,16,16-di acid, methyl ester was identified on 
the GC trace. The pink and blue rings highlight the area where peaks representing 
16-hydroxypalmitic acid, TMS, methyl ester and thapsic acid (respectively) should 
occur. No peaks were detected on this GC chromatograph.
As no product was detected after 1 hour the period of incubation was increased to 18 
hours. No product was detected as a result o f these assays (figure 5.28).
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Fiiiure 5.28 -  GC chrom atographs for reconstitution assays using different 
ratios of CaCPR to AlklL456S, an increased incubation period at 37°C and 
palmitic acid-16,16,16-d3 as the substrate. The substrate is identified on the GC 
chromatograph. The pink and blue rings show the potential locations o f peaks 
representing 16-hydroxypalmitic acid, TMS, methyl ester and thapsic acid 
(respectively). No peaks were identified.
5.3.4.2 Reconstitution Assays Using M icrosomal Preparations of 
CYP52A3 yeast to Catalyse the Reaction
Microsomal preparations o f CYP52A3_yeast were used in reconstitution assays to 
catalyse the reactions. Initially lOpl of 2mg/ml of palmitic acid-16 ,16 ,16 -d3 was 
dissolved in ethanol and used as the substrate for this reaction. This substrate was 
used as microsomal controls set-up with the substrate and reconstitution system 
omitted showed the presence of palmitic acid, methyl ester on the GC 
chromatograph. The use of deuterated palmitic acid will allow the two peaks to be 
distinguished from one another on the GC chromatograph and MS spectum. Ethanol 
was used as the solvent to prevent the precipitation of microsomal proteins, which 
would occur with chloroform. These assays showed no product formation (with or 
without the presence o f CaCPR) and the substrate, palmitic acid-16 ,16 ,16 -d3, could 
not be detected on the GC chromatograph (see figure 5.29).
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Figure 5.29 -  GC chrom atographs for reconstitution assays using
CYP52A3_yeast microsomes and palmitic acid-16,16,16-d 3 dissolved in ethanol 
as substrate. The probable membrane lipids are identified. The red ring indicates 
the location/retention time at which a peak representing palmitic acid-16, 16,16-d3, 
methyl ester should be identified. The pink ring represents 16-hydroxypalmitic acid, 
TMS, methyl ester. The blue ring correlates to thapsic acid.
The inability to identify palmitic acid-16 ,16 ,16-d3 could either be due to the large 
peaks representing the membrane lipids (including palmitic acid, methyl ester) 
obscuring the peak produced by the substrate or the solvent used to dissolve the 
substrate was not compatible for this assay. The reconstitution assays were repeated 
using an increased amount of palmitic acid-16, 16, 16-d3 (lOpl of lOmg/ml) dissolved 
in DMF rather than ethanol. These reactions produced similar results as neither the 
substrate nor the product was detected (figure 5.30). A.gain, the addition of CaCPR 
had no effect on product formation (figure 5.30).
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Figure 5.30 -  GC chrom atographs for reconstitution assays using
CYP52A3_yeast microsomes and palmitic acid-16,16,16-d3 dissolved in DMF as 
substrate. The red ring indicates the location/retention time at which a peak 
representing palmitic acid-16 ,16 ,16-d3, methyl ester should be identified. The pink 
ring represents 16-hydroxypalmitic acid, TMS, methyl ester. The blue ring 
correlates to thapsic acid.
To check whether the solvent being used in this assay was preventing the detection 
of the hydrocarbon, lOpl of lOmg/ml hexadecane dissolved in DMF was used as an 
alternative substrate. Hexadecane was detected on the GC chromatograph (figure 
5.31), but as a small peak on the trace as the peaks representing the membrane lipids 
were large and obscuring the other peaks produced. This made it difficult to identify 
any other peaks, including those that may have been produced by any metabolites 
formed by these assays. Therefore, microsomal preparations containing AlklL456S 
were not produced to act as the lipid component of reconstitution assays instead of 
DLPC.
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Figure 5.31 -  GC chrom atographs for reconstitution assays using
CYP52A3_yeast microsomes and hexadecane as substrate. The substrate is 
indicated on the GC traces. The green and blue rings show the potential locations of 
peaks representing hexadecanol and thapsic acid (respectively). No peaks were 
identified.
5.3.4.3 Metabolism of Hexadecane by S. cerevisiae Transform ed with 
YEp51:AlklL456S yeast Plasmid
As reconstitution assays failed to show product formation in reaction catalysed by 
AlklL456S, in vivo experiments were set up. S. cerevisiae cells transformed with 
YEp51:Aik 1 L456S_yeast plasmid were grown on media containing hexadecane, 
despite hexadecane producing no binding spectra in binding studies with AlklL456S. 
This is because S. cerevisiae is able to utilise fatty acids for growth, but not alkanes 
(Rehm & Reiff, 1981), thereby allowing S. cerevisiae containing only the YEp51 
vector to be used as a negative control in this study.
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S. cerevisiae cells containing YEp51 :Alkl L456S_yeast, YEp51 :CYP52A3_yeast 
(positive control) and YEp51 only (negative control) were grown in minimal salts 
media containing 2% (w/v) galactose and 0.1% (v/v) hexadecane (figure 5.32). 
Galactose was added to the media to induce the transcription of Alkl L456S_yeast 
and CYP52A3_yeast in these cells.
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Fiuure 5.32 -  Growth curve showing the growth of S. cerevisiae cells containing 
YEp51:AIkl L456S_yeast, YEp51:CYP52A3_yeast (positive control) or YEp51 
only (negative control) in media containing hexadecane.
Both Alkl L456S_yeast and CYP52A3_yeast S. cervisiae cells were able to grow on 
media containing hexadecane suggesting that despite the inability of AlklL456S 
protein to produce binding spectra with alkane, in this experiment Alkl L456S_yeast 
is able to convert hexadecane into a substrate that could be used by the yeast cell for 
growth. The negative control showed minimal growth in this media compared to the 
cells containing YEp51 :Alkl L456S_yeast and YEP51 :CYP52A3_yeast plasmids. 
This suggests the growth seen in these plasmid-containing cells was not due to the 
galactose in the media, but rather the hexadecane as S. cerevisiae is normally unable 
to grow on alkanes (Rehm & Reiff, 1981).
At an average cell count of 2.02x105 cells/ml, the GC chromatographs produced 
showed a large peak at 12.5minutes representing hexadecane (figure 5.33).
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Figure 5.33 -  GC chrom atographs produced when S. cerevisiae cells were 
extracted after reaching an average cell count of 2.02x105cells/ml. All GC
chromatographs show a peak correlating to hexadecane.
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All three types o f S. cerevisiae cells showed a visibly detectable hexadecane peak on 
the chromatographs produced (figure 5.34). YEp51:AlklL456S_yeast and 
YEp51:CYP52A3_yeast containing cells show large peaks representing fatty acid 
methyl ester versions o f palmitic acid, 9-hexadecenoic acid, 9-octadecenoic acid and 
stearic acid (figure 5.34). These fatty acids probably correlate to the lipids found in 
the membranes o f the cell. However, the negative control does not show similarly 
large fatty acid peaks, but do show the presence o f other fatty acids in the 
chromatograph (figure 5.34). The GCMS detected the same fatty acid methyl esters 
in the negative control as in the AlklL456S_yeast and CYP52A3_yeast samples with 
the additional identification o f the fatty acid methyl esters: 12-methyl myristic acid, 
15-methyl palmitic acid, 14-methyl palmitic acid and 14-methyl stearic acid (figure 
5.34). This suggests CYP52A3_yeast and Alkl L456S_yeast were able to metabolise 
hexadecane resulting in the alternative lipid composition of the membranes o f the 
cell.
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Figure 5.34 -  Lipid composition of the S. cerevisiae cells following growth on 
hexadecane. Cells transformed with YEp51: Aik 1 L456S_yeast and
YEp51 :CYP52A3_yeast plasmids show similar lipid profiles, suggesting AlklL456S 
was involved in the metabolism of hexadecane. The unlabelled fatty acid peaks 
represent silane molecules, which are indicative of the degradation of the column.
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5.4 Discussion
5.4.1 Binding Studies
Despite the CYP52 family o f cytochrome P450 proteins being regarded as alkane- 
assimilating enzymes, AlklL456S failed to show type I binding spectra with these 
substrates. However, this protein did produce type I binding spectra in binding 
studies with fatty acids. This is not unusual as Alk8 from C. albicans has been 
shown to bind to (and metabolise) lauric acid, but not alkanes (Kim et al., 2007). 
Although no binding spectra have been published for CYP52A13 and CYP52A17 
from C. tropicalis, they have also been shown to preferentially metabolise fatty acids 
(Eschenfeldt et al., 2003). This suggests that some members o f the CYP52 family 
may preferentially bind to and metabolise fatty acids over alkanes.
AlklL456S was shown to be able to bind to lauric acid, myristic acid and palmitic 
acid. Palmitic acid was shown to have the lowest substrate binding constant (Ks) 
value for AlklL456S and, therefore, the greatest binding affinity o f these fatty acids. 
Stearic acid and capric acid produced no discemable spectra with this protein. This 
data suggests palmitic acid is the fatty acid of choice for AlklL456S and should be 
used in reconstitution assays with this protein.
Table 5.3 shows cytochrome P450 enzymes from C. albicans and other organisms 
that have been shown to bind fatty acids.
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O f the enzymes in table 5.3, AlklL456S was shown to bind to lauric acid, myrisitic 
acid and palmitic acid more weakly than any o f the other cytochromes P450. 
However, CYP52A4 from C. maltosa (Scheller et al., 1996), CYP124 from M  
tuberculosis (Johnston et al., 2009), CYP152A2 from C. acetobutylicum (Girhard et 
al., 2007) and CYP102A2 from B. licheniformis (Dietrich et al., 2008) all have a Ks 
value of over IOOjiM for at least one of these fatty acids (table 5.3), but have still 
been shown to be involved in the hydroxylation o f these substrates. Interestingly, 
lauric acid binds to Alk8 more tightly than it does to CYP52A4 (table 5.3), despite 
both enzymes belonging to the CYP52 family and being able to metabolise this fatty 
acid. This suggests that despite the high Ks values produced by palmitic acid, 
myristic acid and lauric acid in binding studies with AlklL456S, this protein is still a 
candidate for investigation in the metabolism o f these fatty acids in further 
reconstitution assays.
Interestingly, many o f the cytochrome P450 enzymes described above are also able 
to bind to other substrates with greater binding affinity. For instance, CYP102A7 is 
able to bind to methylated fatty acids including 12-methyl myrisitic acid (Ks = 
3.5±0.6pM) and 13-methyl myristic acid (5.1±0.9pM) (Dietrich et al., 2008). 
CYP124 is also involved in the binding o f similar forms o f fatty acid substrates, 
including 15-methyl palmitic acid (1.01±0.07pM), phytanic acid (0.22±0.006pM), 
famesol (1.04±0.05pM) and geranylgeraniol (0.48±0.06pM) (Johnston et al., 2009). 
Both enzymes were also involved in the metabolism of these hydrocarbons (Dietrich 
et al., 2008; Johnston et al., 2009). This suggests AlklL456S may be able to interact 
with substrates other than alkanes and saturated fatty acids.
5.4.2 Detection of Hexadecane. Palmitic Acid and their Derivatives on the 
GCMS
Before some chemicals, such as fatty acids, can be detected on a GCMS they require 
derivatisation to make them more volatile. Making the compound more volatile 
means it is able to vaporise more readily, so it can travel along the column. This can 
be done by silylation or esterification.
In silylation, a silyl group (Si(CH3)3) can bind to the compound displacing a 
hydrogen atom (see figure 5.35) (Pierce, 1968). This addition makes the compound
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more volatile so it can be run on a GCMS and increases the molecular weight by 71. 
The technique can be used to derivatise a number o f involatile chemicals, including 
sterols and fatty acids (Pierce, 1968). However, hydroxyl side-chains are more 
readily silylated than carboxyl side-chains meaning silylation can result in 
incomplete derivatisation o f this group and the TMS versions produced can be 
relatively unstable (Pierce, 1968). Therefore, the silylation of palmitic acid is not 
practical in this experiment as any product produced would not be completely 
derivatised, resulting in multiple peaks on the GC trace (as seen in figures 5.12 and 
5.13).
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Figure 5.35 -  Silylation of fatty acid by TCMS. The TCMS binds to the fatty acid 
at the carboxyl group displacing the hydrogen and the CT on the TCMS itself. This 
results in the production of a TMS derivatised fatty acid molecule and hydrochloric 
acid, which is scavenged by pyridine added to the sample reaction.
Another method for the derivatisation o f fatty acids is esterification, most commonly 
protocols which result in the formation o f methyl esters. This reaction involves 
methanol interacting with the compound in a reaction catalysed by either bases (such 
as sodium methoxide) or acids (such as sulphuric acid) (Christie, 1989) (see figure 
5.36). As with silylation, a hydrogen atom in the carboxyl side-chain is displaced as 
a methyl group (CH3) binds to the oxygen (Christie, 1989) (see figure 5.36). This 
results in the production o f a volatile compound, with an increased molecular weight 
(standard molecule weight plus 14), which is suitable for analysis using GCMS. 
Although, both sodium methoxide (base) and 3% (v/v) sulphuric acid (acid) (in the 
presence o f methanol) catalysed the formation o f palmitic acid methyl esters in this 
study, the acid catalysed method was used as thapsic acid could not be identified on 
the GCMS when the basic conditions were used. The base catalysed esterification
185
method can, also, result in the production of methoxy derivatives (Carrapiso & 
Garcia, 2000; Murrieta et al., 2003; Juarez et al., 2008) and if water is not 
completely removed from the sample before esterification can take place, then 
hydrolysis can occur (Juarez et al., 2008). Therefore, acid catalysed esterification 
was the method of choice for this study as it resulted in the complete esterification of 
palmitic acid and allowed the identification of thapsic acid on the GCMS.
[ OHI /  ^
R - C
\
o c h 3
Fatty Acid Methanol Intermediate
/ /
R - C  + FRO
\
o c h 3
Fatty Acid W ater
Methyl Ester
Figure 5.36 -  Esterification of fatty acids. Fatty acid methyl esters are produced 
when methanol is used in the reaction. Other alcohols can be used to esterify fatty 
acids. For instance, if ethanol is used then ethyl esters are produced. This 
mechanism is the same for both acid (e.g. sulphuric acid) and base (e.g. sodium 
methoxide) catalysed esterification.
However, esterification alone was not sufficient for the analysis o f 16- 
hydroxypalmitic acid on the GCMS. Acid catalysed esterification was required to 
add a methyl group to the carboxyl side chain of the fatty alcohol and silylation for 
the derivatisation of the hydroxyl group. Neither technique could be used as the sole 
method for derivatisation in this study as either palmitic acid or 16-hydroxypalmitic 
acid would not be detected on the GCMS if only one of these methods was used.
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Therefore, all samples in this study required both acid catalysed esterification and 
silylation before analysis on the GCMS.
5.4.3 Reconstitution Assays
5.4.3.1 Reconstitution Assays Using Purified AlklL456S Protein or 
CYP52A3 yeast Microsomes to Catalyse the Reaction
Reconstitution assays using purified AlklL456S protein to catalyse the reaction 
failed to result in the detection o f metabolised palmitic acid product (i.e. either 16- 
hydroxypalmitic acid or thapsic acid). This was either due to the inability o f the 
enzyme to hydroxylate palmitic acid or low level product formation occurred, which 
could not be detected on the GCMS.
To aid detection of the substrate and any products formed in these assays, labelled 
substrate or chromatographic techniques, such as TLC (thin layer chromatography) 
and HPLC (high-pressure liquid chromatography) could be used. In this experiment, 
deuterated palmitic acid (palmitic acid-16,16,16-da) was used as substrate. This 
substrate contains three heavy hydrogen atoms at the co-carbon of the palmitic acid 
chain producing a stable isotope o f this substrate. The mass o f these heavy hydrogen 
atoms is 2 , which is twice that o f the unlabelled hydrogen atoms, thus increasing the 
molecular mass of the palmitic acid molecule. Normally palmitic acid has a 
molecular weight o f 256 (270 when in its methyl ester form), but when in its 
deuterated form the molecular weight increases to 259 (or 273). This slight increase 
in molecular weight is sufficient to allow different mass spectrums to be produced 
for each substrate, thereby allowing both substrates to be identified on the GCMS. In 
experiments with AlklL456S, no substrate formation was seen when palmitic acid- 
16, 16,16 -d3 was used as the substrate. These results suggest either AlklL456S is not 
able to catalyse the hydroxylation o f palmitic acid-16,16 ,16-d3 or the amount of 
substrate used in these reactions was not sufficient for product detection. This 
deuterated hydrocarbon was also used in reconstitution assays with microsomal 
preparations o f CYP52A3_yeast, however, product formation was not detected 
neither was the substrate. This was due to the presence o f large peaks (possibly) 
correlating to membrane lipids, obscuring the detection of smaller peaks on the GC 
chromatograph. This suggests the concentration o f palmitic acid-16,16,16-d3 in the 
reactions was insufficient for the detection o f any products produced, despite the
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concentration o f this substrate being increased. The lack o f product detection in 
these assays was probably not due to the CYP52A3_yeast protein being unable to 
catalyse the reaction as previous experiments have shown CYP52A3 to be involved 
in the hydroxylation o f palmitic acid to the alcohol, 16-hydroxypalmitic acid 
(Scheller et al., 1998). A similar deuterated fatty acid, lauric acid-12 ,12 , 12-d3, has 
been used in experiments with purified Alk8 protein and was shown to catalyse the 
hydroxylation o f this substrate to 12-hydroxylauric acid (Kim et al., 2007), thus 
suggesting the deuterated palmitic acid used in assays with AlklL456S and 
CYP52A3_yeast was not the reason why product was not detected in these 
experiments.
Alternatively, radiolabelled substrate could be used in reconstitution assays to aid 
substrate detection. Many o f the cytochrome P450 enzymes that have been shown to 
be involved in alkane/fatty acid hydroxylation have used carbon 14 (14C) labelled 
radioactive substrate in enzymatic reactions. These enzymes include CYP52A3 
(Scheller et al., 1996; Scheller et al., 1998), CYP94A5 from Nicotiana tabacum (Le 
Bouquin et al., 2001), human CYP4F3B (Fer et al., 2008) and human CYP4F11 
(Tang et al., 2010). This list is not exhaustive as many other cytochrome P450 
proteins have also been shown to use this type o f substrate. Product formation can 
then either be detected by HPLC or on TLC plates followed by detection on an 
autoradiogram or a scintillation counter (examples include Scheller et al., 1996; 
Kikuta et al., 1999 and Le Bouquin et al., 2001). This method could be used to 
identify product formation with AlklL456S.
The chromatographic techniques HPLC and TLC could be used to detect substrate 
formation not only with radiolabelled substrates, but also with unlabelled substrates. 
Although, TLC and HPLC are less sensitive than GCMS, they may be more 
ameneable to using radio-labelled substrates.
Fatty acids are ubiquitous in nature and these substrates can be detected by the 
GCMS from the reconstitution assay mix, although they do not interfere with the 
reaction. This was evident in the reconstitution assays where microsomal 
preparations of CYP52A3_yeast were used to catalyse the reaction as large peaks 
representing membrane lipids obscured the identification/detection of the peaks
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correlating to the substrate and any products produced. Using TLC prior to running 
the samples on a GCMS would allow the fatty acids/substrates to be separated on a 
silica plate (Waxman, 1991) and products identified by comparison o f the R f  value o f 
known standards. The R f  value is determined by measuring the distance o f the 
analyte from the origin (where the sample was loaded onto the plate). Solvent is 
used to separate the components o f the substrate on the TLC plate (mobile phase), 
which can then be visualised using a dye that binds to the lipid fraction (e.g. 2,7- 
dichlorofluorescein, which binds to the lipid producing yellow spots under UV light) 
(Fuchs et al., 2011). Using the correct mobile phase solvents (e.g. hexane/diethyl 
ether/acetic acid (40:60:1, v/v/v (Scheller et al., 1996) would ensure the membrane 
lipids separate from the substrates/products depending on polarity, thus allowing 
each type o f fatty acid to be distinguished. Usually membrane lipids are identified as 
fatty acids on the GCMS as fractionation occurs separating the polar head o f the 
molecule and the fatty acid chain allowing membrane lipids to be identified as fatty 
acids (Chrisite, 1989).
TLC can be used on its own to identify substrates/products or alternatively the 
substrates/products can be removed from the TLC plate and run on a GCMS (or 
other mass spectrometric detectors, such as LCMS (liquid chromatography mass 
spectrometry)) for identification (Fuchs et al., 2011). However, substrates identified 
using TLC may not always be detected on a GCMS as the concentration o f the 
substrate may be too low for detection. Following reconstitution assays with 
CYP92B1 from Petunia hybrida and linoleic acid (C l8:2) or linolenic acid (C l8:3), 
metabolites were detected on a TLC plate, but they could not be identified on the 
GCMS (Petkova-Andonova et al., 2002). Comparing these products to standards 
representing oo-hydroxylinoleic acid and co-hydroxylinolenic acid on the TLC plate, it 
was shown that CYP92B1 is not involved in the co-hydroxylation o f these fatty acids 
as the R f  values for these standards and the products produced were not similar 
(Petkova-Andonova et al., 2002). To date, these metabolites have not been 
identified.
Alternatively, HPLC can be used for the analysis o f lipid metabolites. The samples 
can be loaded on the HPLC and separated on the column by (high) pressure rather 
than temperature (as with GCMS). The retention time for each molecule is recorded
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and can be used to identify the metabolite produced. HPLC can also be coupled with 
a detector (such as a MS detector) to further identify the lipid fractions (Lima & 
Abdalla, 2002). The advantages o f using this technique over GCMS are increased 
sensitivity and increased specificity when coupled with radio-labelled substrate, 
which allows the metabolites produced at low levels to be detected (Lima & Abdalla, 
2002). This would be useful for the analysis o f reactions catalysed by AlklL456S as 
it may determine if  the products formed were at low levels or if  the enzyme was 
unable to catalyse the metabolism o f the substrate. Therefore, HPLC or TLC (either 
coupled with the labelled or unlabelled substrate) could be used as an alternative to 
GCMS for the detection of metabolites following reconstitution assays using purified 
AlklL456S protein or CYP52A3_yeast microsomes as the catalysts. This would 
then identify whether the failure to detect product in these assays was due to the 
inability o f the protein to hydroxylate palmitic acid or if  product was formed at 
undetectable levels.
Alternatively, modifications to the reconstitution system could be made to enhance 
product formation. In this study, alterations in the pH, CPR, CPR concentration and 
an increase in reaction time occurred, but no product was identified in reconstitution 
assays catalysed by AlklL456S. Further, modifications to the reconstitution system 
could be made, including alteration to the lipid component. As described in section 
5.1, a lipid component is required for the protein stability and correct orientation of 
membrane-bound cytochrome P450 and CPR proteins in the assay (Paine et al., 
2005; van Bogaert et al., 2007). In reconstitution assays with AlklL456S micelles 
were created using DLPC. These micelles have been used in experiments with other 
cytochromes P450 (including CYP4F11 (Tang et al., 2010)) and have resulted in the 
formation o f metabolites. However, some cytochromes P450 are unable to couple to 
the micelles preventing product formation. For example, rat CYP3A1 was unable to 
metabolise testosterone when micelles were used as the lipid component, but was 
able to catalyse the production of 2(3-, 6 p- and 15P-hydroxytestosterone in the 
presence o f phospholipids (Eberhart & Parkinson, 1991). This suggests some 
cytochromes P450 are unable to couple with micelles and that this coupling is 
dependent on the fatty acid composition of the lipid component used (Duppel et al., 
1973; Eberhart & Parkinson, 1991).
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In this study, yeast microsomal preparations o f CYP52A3 were also used in 
reconstitution assays to catalyse the hydroxylation o f palmitic acid and hexadecane. 
However, no products o f the reaction were detected on the GCMS despite CYP52A3 
previously being shown to metabolise these substrates (Scheller et al., 1996; Scheller 
et al., 1998). This was due to the presence of large peaks representing membrane 
lipids (on the GC chromatograph) obscuring the identification o f other products 
produced. Thus microsomal preparations o f AlklL456S were not used in this study 
(instead o f DLPC micelles) as labelled substrates would be required to distinguish 
between the peaks. Therefore, the inability o f AlklL456S to catalyse the metabolism 
of palmitic acid may be due to the protein being unable to couple with the micelles 
and, in turn, interact with the CPR and fatty acid correctly preventing hydroxylation. 
Further experiments could be undertaken using phospholipids or yeast microsomes 
as the lipid component o f the assay.
5.4.3.2 Metabolism of Hexadecane by S. cerevisiae Transformed with 
YEp51 :AlklL456S veast Plasmid
As reconstitution assays containing recombinant AlklL456S protein were unable to 
show enzymatic activity, YEp51:AlklL456S_yeast plasmid was transformed into S. 
cerevisiae cells for in vivo experiments. These cells were shown to be able to grow 
on hexadecane, despite the alkane not producing any spectra in binding studies with 
the recombinant AlklL456S protein. Hexadecane was used as the substrate in these 
experiments as S. cerevisiae is able to utilise fatty acids for growth, but is unable to 
grow on alkanes. Therefore, using hexadecane in this experiment ensured any 
growth o f the transformed cells was due to the AlklL456S protein being expressed 
rather than normal cell growth.
YEp51:CYP52A3_yeast transformed S. cerevisiae cells were used as a positive 
control as previous experiments involving CYP52A3 have shown the protein to be 
involved in hexadecane hydroxylation (Scheller et al., 1996). In this experiment, 
these cells were able to grow on hexadecane and produced similar GC 
chromatographs as YEp51:AlklL456S_yeast cells following extraction, suggesting 
AlklL456S is involved in the hydroxylation o f hexadecane as both types o f cells 
share similar lipid membrane compositions following growth on this substrate.
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When fatty acids are used for growth in S. cerevisiae, they are taken up into the cell 
and transported to the peroxisome where they are subjected to P-oxidation and are 
used for growth (van Roermund et al., 1998; Gurvitz et al., 2001). In other yeast 
species, which can utilise alkanes, such as the soil-dwelling C. maltosa, CYP52 
enzymes are required to catalyse the initial conversion o f the alkane to its respective 
alcohol (Scheller et al., 1998). The alcohol can then be further converted to an 
aldehyde and, in turn, a fatty acid, which can then be subjected to p-oxidation 
(Scheller et al., 1998; Fickers et al., 2005). As S. cerevisiae is unable to utilise 
alkanes as it does not contain any CYP52 genes within its genome, the growth seen 
with cells transformed with YEp51:AlklL456S_yeast and YEp51:CYP52A3_yeast 
plasmids suggests that these genes were translated and transcribed into functional 
CYP52 proteins, which were involved in the conversion o f hexadecane into palmitic 
acid. This fatty acid could then be utilised by the cell for growth as normal.
Fatty acids are not only utilised by yeast for growth, they can also be used for other 
cell functions, including membrane lipid formation (e.g. phospholipids and 
sphingolipids) because the natural hydrophobic nature o f these hydrocarbons allows 
them to be involved in the production o f membrane bilayers (Tehlivets et al., 2007). 
Therefore, growth on a particular fatty acid can result in a membrane lipid 
conformation that contains a high percentage of that particular hydrocarbon. This 
could explain why a large peak representing palmitic acid (methyl ester) was seen in 
the GC traces produced by YEp51:AlklL456S_yeast and YEp51:CYP52A3_yeast 
transformed cells, but not in the negative control. The plasmid transformed cells also 
showed large peaks on the GC chromatograph depicting (methyl ester versions of) 
stearic acid, 9-hexadecenoic acid and 9-ocatadecenoic acid.
In yeast, fatty acids can be subjected to elongation in the endoplasmic reticulum 
(Tehlivets et al., 2007). This process involves two carbon atoms being added to the 
fatty acid molecule extending its chain length (Tehlivets et al., 2007). Palmitic acid, 
which was produced in excess in this experiment, can be elongated to form the 18 
carbon saturated fatty acid stearic acid and be used in the formation o f membrane 
lipids. Saturated fatty acids can also be subjected to A9-desaturase in the 
endoplasmic reticulum to produce unsaturated forms o f the hydrocarbon (Tehlivets et 
al., 2007). At carbon 9 in the saturated fatty acid chain, hydrogen atoms are removed
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and a double bond is formed producing a monounsaturated version of the fatty acid 
that can be used to form membrane lipids (Tehlivets et al., 2007). The palmitic acid 
and stearic acid molecules formed in this study were subjected to this process 
producing 9-hexadecenoic acid and 9-octadecanoic acid respectively, which were 
then identified on the GCMS.
The production o f these saturated and unsaturated (16 and 18 carbon chain length) 
membrane lipids in plasmid transformed S. cerevisiae cells grown on hexadecane 
suggests functional CYP52A3 and AlklL456S proteins were expressed in the cells 
and were involved in the conversion o f hexadecane to palmitic acid. This is the first 
time AlklL456S has been shown to be involved in alkane assimilation.
In conclusion, AlklL456S was shown to be implicated in the hydroxylation of 
alkanes, despite binding studies and reconstitution assays failing to show any 
interaction between this protein and these substrates. In vivo experiments showed 
that S. cerevisiae cells containing the YEp51 :AlklL456S_yeast plasmid were able to 
grow in media containing hexadecane despite this organism being unable to utilise 
these hydrocarbons normally. The lipid profile o f the plasmid containing cells was 
similar to the positive control (S. cerevisiae cells containing the plasmid 
YEp51 :CYP52A3_yeast) showing the formation o f palmitic acid from hexadecane. 
Not only does this suggest that AlklL456S is involved in the hydroxylation o f 
hexadecane, it also suggests that this alkane is a substrate o f this protein despite 
binding studies and reconstitution assays implying the contrary.
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Chapter 6: The Effects of Azole Antifungal Drugs and Sterol Substrates on
AlklL456S Protein in Binding and Metabolism Studies
6.1 Introduction
Azole antifungal drugs are used in the treatment o f fungal infections, such as 
candidosis. The azoles work by targeting the 14a-demethylase, CYP51 in the 
ergosterol biosynthetic pathway. This causes inhibition of the enzyme’s activity 
preventing the demethylation of lanosterol and in turn the production of ergosterol 
(Strushkevich et al., 2010) (see figure 6.1). Ergosterol is required to maintain the 
fluidity and permeability of fungal membranes (Ghannoum & Rice, 1999; 
Strushkevich et al, 2010) and treatment with azoles depletes the concentration o f this 
sterol in the cell. This depletion, in conjunction with an increase in the concentration 
of 14a-demethylated sterols, disrupts the membrane structure, preventing membrane 
transport (and other functions) resulting in the inhibition of fungal growth (also 
known as fungistasis) (Sheehan et al., 1999).
Figure 6.1 -  Role of CYP51 in the ergosterol biosynthetic pathway. CYP51 is 
involved in the conversion of lanosterol to 4,4-dimethylcholesta-8,14,24-trienol, 
which can be metabolised further to produce ergosterol. Azole antifungal drugs 
inhibit the action of CYP51 preventing the production o f ergosterol.
L anosterol
Inhibition o f  CYP51 
by A zo le  Antifungal 
Drugs
C Y P 5 1
4.4-D im ethvlcholesta-
8 .14 .24-trien ol
E rgosterol
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Azole antifungal drugs were first introduced in 1969 with the marketing o f the 
topical azoles miconazole and clotrimazole (Gupta et al., 1994). The combination of 
drug resistance and the requirement for new drugs that could be used to treat a 
greater range o f infections and/or be administered by different routes (e.g. orally) 
resulted in the continued development o f this class o f antifungal agents (Sheehan et 
al., 1999). There are two types o f azole antifungal drugs: imidazoles (e.g. 
clotrimazole) and triazoles (e.g. voriconazole), which are classified according to the 
number o f nitrogens in the azole ring (two and three respectively) (figure 6.2) 
(Vanden Bossche et al., 1995; Lamb et al., 1999). The azole attaches as the sixth 
ligand o f the haem iron o f the target enzyme either by the N-3 o f the imidazole ring 
or by the N-4 of the triazole ring (circled in figure 6.2) (Lamb et al., 1999). In 
binding studies with cytochrome P450, this results in the production of type II 
spectra due to a low-spin complex being formed. The azoles used in this study are 
shown in figure 6.3 and are clotrimazole, fluconazole, itraconazole, ketoconazole and 
voriconazole.
Imidazole Triazole
OH
—N
F
Example: Clotrimazole Example: Voriconazole
Figure 6.2 -  Examples of imidazole and triazole drugs. Red circles indicate the 
nitrogen (N) atoms, which bind to the haem iron (of the cytochrome P450) as the 
sixth ligand.
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Clotrimazole Fluconazole Voriconazole
OH
F
OH
—N
F
Ketoconazole
N O
Cl
Itraconazole
Cl
T
Figure 6.3 -  Azole antifungal drugs used in this study. Clotrimazole and 
ketoconazole belong to the imidazole class o f azoles. Fluconazole, voriconazole and 
itraconazole are triazoles.
Clotrimazole (figure 6.3) is an imidazole antifungal drug, which was first discovered 
in 1969 (Gupta et al., 1994; Sheehan et al., 1999). It is used as a topical treatment 
against a number o f superficial infections, including mucocutaneous candidiasis 
(caused by Candida infection affecting oropharyngeal and cutaneous tissue), 
onychomycosis (nail infection) and dermatophytosis (fungal skin infections affecting 
various areas of the body, including the feet (athlete’s foot/tinea pedis), facial hair 
(tinea barbae) and the scalp (tinea capitis)) (Sheehan et al., 1999).
Ketoconazole (figure 6.3) is also an imidazole antifungal drug, however, unlike 
clotrimazole it can be used to treat both systemic and superficial infections as it is
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available in both topical and oral preparations (Kauffman & Carver, 1997). In its 
topical form, ketoconazole can be used to treat onychomycosis caused by Candida. 
It can be used to treat many o f the same superficial infections as clotrimazole, except 
it can also be used in the treatment o f oesophageal and chronic mucocutaneous 
candidasis (Sheehan et al., 1999). In its oral formulation, ketoconazole can be used 
to treat a number o f systemic infections, including blastomycosis (rare infection 
caused by the inhalation o f Blastomyces dermatitidis), histoplasmosis (caused by the 
inhalation o f Histoplasma capsulatum), coccidioidomycosis (caused by Coccidioides 
immitis spores), paracoccidioidomycosis (caused by Paracoccidioides brasiliensis) 
and pseudallescheriasis (caused by Pseudallescheria boydii) (Sheehan et al., 1999). 
However, the ability o f the oral preparation o f ketoconazole to treat these systemic 
and superficial infections is limited by food and gastric acidity as it is absorbed more 
effectively in acidic conditions (Chin et al., 1995; Sheehan et al., 1999).
Itraconazole (figure 6.3) is a triazole antifungal drug, which is available as an oral 
preparation (in tablet and liquid forms) for the treatment o f superficial and systemic 
infections (Bartroli et al., 1995). This drug can be used to treat many o f the same 
infections as ketoconazole, except itraconazole is also used in the treatment o f many 
other systemic infections, including aspergillosis, candidiemia, cryptococcosis and 
sporotrichosis (chronic skin infection caused by Sporothrix schenckii) (Sheehan et 
al., 1999). As with ketoconazole, the effects o f itraconazole are limited by food and 
gastric acidity (Sheehan et al., 1999).
Fluconazole (figure 6.3) is a triazole antifungal agent, which is considered to be the 
most successful clinically used triazole (McLean et al., 2002). It is available in both 
oral and intravenous preparations and can be used to treat similar superficial and 
systemic infections as itraconazole, however, it is not used to treat 
pseudallescheriasis nor infections caused by Aspergillus (Sheehan et al., 1999). 
Unlike itraconazole and ketoconazole, this drug is able to readily enter the cerebral 
spinal fluid so it can be used in the treatment o f fungal meningitis (Goa & Barradell, 
1995).
Voriconazole (figure 6.3) is a triazole antifungal drug, which is available in oral and 
intravenous preparations. It is a derivative o f fluconazole (Ally et al., 2001; Goa &
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Barradell, 1995; Sheehan et al., 1999). As with the other commercially available 
trizoles, itraconazole and fluconazole, this azole has been used to treat a wide variety 
o f systemic fungal infections. However, it has been shown to be more potent than 
fluconazole against a number o f infections, particularly those that are caused by 
Candida and Aspergillus species (Ally et al., 2001; Hoffman & Rathbun, 2002; 
McLean et al., 2002; Smith et al., 2006).
Resistance to a particular azole can occur due to the need for long-term azole 
treatment, particularly in patients with weakened immune systems (e.g. HIV/AIDS 
sufferers), thus promoting the need for alternative treatments to these infections 
(Hitchcock, 1993; Morio et al., 2010). Interestingly, all o f these azoles inhibit fungal 
CYP51 activity, but at therapeutic doses do not affect human CYP51s as higher 
concentrations are required to inhibit these enzymes (Ghannoum & Rice, 1999; 
Sheehan et al., 1999). This is because fungal CYP51s have a greater binding affinity 
to the azoles developed as drugs than the human CYP51 (Ghannoum & Rice, 1999; 
Sheehan et al., 1999).
The CYP51 family o f cytochrome P450 enzymes is ubiquitous in nature. They are 
found not only in fungi and humans, but also in other animals, plants and some 
bacteria (Yoshida et al., 2000). Each o f these enzymes is involved in the production 
o f membrane sterols, but the initial substrates and final products o f the sterol 
biosynthetic pathway differ according to the organism. For example, fungal CYP51s 
are involved in the 14a-demethylation o f lanosterol, which eventually results in the 
production o f ergosterol, but in animals this final sterol product is cholesterol (figure 
6.4). In plants, however, CYP51 is involved in the 14a-demethylation o f obtusifoliol 
(figure 6.4), rather than lanosterol, and the sterol synthesis pathway results in the 
production o f campesterol, stigmasterol and sitosterol (figure 6.4), instead of 
ergosterol or cholesterol.
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Cholesterol Obtusifoliol
HOHO
Campesterol Stigmasterol
HOHO
Sitosterol
HO
Figure 6.4 -  Structures of cholesterol, obtusifoliol, campesterol, stigmasterol 
and sitosterol. Cholesterol is the final product o f sterol synthesis. In plants, 
obtusifoliol is metabolised by CYP51. The sterol synthesis pathway in this organism 
results in the production o f campesterol, stigmasterol and sitosterol.
In fungi, another cytochrome P450 enzyme, CYP61 has also been shown to be 
involved in the ergosterol biosynthetic pathway (Kelly et al., 1995; Kelly et al., 
1997). It is a C22-desaturase, which catalyses the metabolism of ergosta-5,7-dienol 
(figure 6.5) in the formation o f ergosterol (Kelly et al., 1995; Kelly et al., 1997). It is 
not the target o f azole antifungal drugs (unlike CYP51), however, its activity has 
been shown to be inhibited by fluconazole and ketoconazole, suggesting azoles may 
also act on this enzyme during treatment to prevent ergosterol production (Kelly et
199
al., 1997). To date, no other fungal cytochromes P450 have been shown to bind or 
metabolise sterols.
Ergosta-5.7-dienol
HO
Figure 6.5 -  Structure of ergosta-5,7-dienol.
CYP51 and CYP61 have been shown to be inhibited by azole antifungal drugs. To 
evaluate whether AlklL456S can bind to these drugs the azoles in figure 6.3 will be 
used in binding studies with this protein. Although, AlklL456S is not thought to be 
a target o f these drugs, binding studies will allow the calculation o f the [azole]o.s to 
occur, which will allow the binding affinity for each azole to AlklL456S to be 
determined. This may indicate whether this cytochrome P450 has a potential role in 
the inhibition of cell growth, such as on lipid or alkane substrate, or in the resistance 
o f Candida albicans to azole antifungal drugs. Although sterols have been shown to 
be the substrates o f fungal CYP51 and CYP61 in this chapter, in other species, such 
as Mycobacterium tuberculosis, cytochrome P450 enzymes other than CYP51 (or 
other enzymes involved in sterol synthesis) have been shown to bind and metabolise 
sterols (e.g. CYP125) (Capyk et al., 2009; Ouellet et al., 2010). Therefore, these 
substrates will be used in binding studies with AlklL456S to determine whether they 
can bind to this protein. Sterols that exhibit type I binding, which is an indicator o f a 
potential substrate will be used in reconstitution assays to assess whether AlkL456S 
is involved in the metabolism o f sterol.
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6.2 Materials and Methods
6.2.1 Azoles -  Stock Solutions for Azole Binding to AlklL456S
Azole antifungal drugs were dissolved in dimethyl sulfoxide (DMSO) to a final 
concentration of 0.05mg/ml. Stored at -20°C.
6.2.2 Sterols -  Stock Solutions for Sterol Binding to AlklL456S
The sterols used for binding were dissolved in a solution of 200pl chloroform, 2ml 
acetone and 5% (v/v) Tween 80. The solution was evaporated under nitrogen gas 
until all the solvent was removed. The residue was resuspended in water to produce 
a stock sterol solution o f 0.5mg/ml. Stored at 4°C.
Figure 6.6 shows the structural overview of the sterols used in this study.
6.2.3 Sterol Standards
The sterols: cholesterol, 14-methyl-zymosterol and 32-cyclopropylidenemethyl- 
dihydrolansterol were made up in chloroform to a final concentration o f 2mg/ml. 5 pi 
of each standard was evaporated to complete dryness in the Speed Vac, silylated 
(section 2.2.12) and run on the GCMS (section 2.2.13.2). For 32- 
cyclopropylidenemethyl-dihydrolanosterol the final temperature (280°C) was held 
for 40 minutes.
201
14-Methvl-Zvmosterol Lanosterol
HO HO
32-CvcloDroDviidenemethvl- Cholesterol
Dihvdrolanosterol
HO HO
Dihvdrolanosterol Argosterol
HO HO
31-Nor-Lanosterol Obtusifoliol
HO HO
A7-Dihvdrolanosterol
HO
Figure 6.6 -  Sterols used in this study were kindly provided by Prof. David Nes, 
Texas Tech University.
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6.2.4 Methods
6.2.4.1 Substrate Binding
All binding studies were undertaken using a Hitachi U-3310 UV-Vis scanning 
spectrophotometer.
6.2.4.1.1 Azole Binding to AlklL456S
rji
Azoles were individually titrated against 1ml o f Ni -NTA agarose purified 
AlklL456S protein (at a final concentration of 1 nmole/ml o f protein) in a split 
cuvette. A reference sample was also set-up in a second split cuvette with DMSO 
being added to the cytochrome P450. Buffer containing 0.1M Tris HC1, pH8.1 and 
25% (w/v) glycerol was used for all spectral determinations. Spectra were measured 
between 350 and 550nm and until saturation with azole drug was reached.
6.2.4.1.2 Sterol Binding to AlklL456S
The sterols in section 6.2.1.2 were titrated against 2pM of purified AlklL456S 
protein. 5% (v/v) Tween 80 was added to the same concentration o f protein in the 
reference cuvette. 0.1M Tris HC1, pH8.1 and 25% (w/v) glycerol buffer was used for 
all spectral determinations. Spectra were measured between 350 and 550nm until 
saturation with the sterol had been reached.
CYP51 protein from C. albicans was used as a control in these binding studies. 
CYP51 protein was a gift from Dr. Andrew Warrilow, Swansea University.
6.2.4.2 Reconstitution Assays
Micelles were created according to the method in section 2.2.11.1 using lOpl of 
2mg/ml o f lanosterol, 14-methyl zymosterol, 32-cyclopropylidenemethyl- 
dihydrolanosterol or cholesterol dissolved in chloroform.
All assays were set-up according to the method described in section 2.2.11.2 with the 
addition o f 2pM of purified AlklL456S or CYP51 protein and either lOpM of 
ScA33:CPR or 3.8pM CaCPR. All samples were saponified (section 2.2.11.3), 
silylated (section 2.2.12) and analysed on the GCMS (section 2.2.13.2).
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Reconstitution assays were also undertaken using CYP51 as a positive control. 
Negative controls were set-up with either the purified cytochrome P450 or CPR 
protein omitted.
6,3 Results
6.3.1 Azole Binding
The binding o f azole antifungal drugs to AlklL456S resulted in the production of 
type II binding spectra (figure 6.7) implying that these azoles may be active in the 
inhibition o f AlklL456S activity.
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Figure 6.7 -  Spectra produced in binding studies with AlklL456S and azole 
antifungal drugs. All the azoles used in this study produced type II binding spectra 
when titrated against AlklL456S.
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To determine i f  tight 1:1 binding occurred the [azole]o.5 value for each azole was 
calculated. [Azolejo.s is the azole concentration at which half SAmax for a known 
protein concentration is generated. A proportional increase in this value to the 
cytochrome P450 protein concentration indicates tight binding. At lpM  AlklL456S  
the [clotrimazole]o.5 value was 0.6pM. Increasing the protein concentration five fold 
to 5pM resulted in a [clotrimazole]o.5 value o f 2.5pM. This increase in 
[clotrimazole]o.5 was proportional to the increase in AlklL456S concentration 
suggesting tight binding between Alkl L456S and the azoles used in this study.
[Azole]o.5 values for each azole are shown in table 6.1. This data can be used to 
determine the binding affinity o f  these azoles to A lklL456S where the more tightly 
bound the azole is to the enzyme, the smaller the binding constant. Using the data
! shown in table 6.1, it is possible to rank the azole binding affinity for AlklL456S
from the most tightly bound to the least:
|
Ketoconazole > Itraconazole > Clotrimazole > Voriconazole > Fluconazole
ii|
ii!
i
t
I Table 6.1 -  [Azolejo.s values of the azole-AlklL456S complex.
6.3.2 Sterol Binding
Figure 6.8 shows the spectra produced on adding sterol to A lkl L456S and CYP51.
Azole [Azole] 0.5 (pM)
Ketoconazole 0.37±0.06
Itraconzole 0.40±0.10
Clotrimazole 0.58±0.19
Voriconazole 0.72±0.08
Fluconazole 1.04±0.33
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Figure 6.8 -  Spectra produced when different sterols were titrated against 
CYP51 (control) and AlklL456S. CYP51 showed type I binding with 14-methyl 
zymosterol, dihydrolanosterol, 31-nor-lanosterol, lanosterol, argosterol andn
obtusifoliol. Cholesterol, A -dihydrolanosterol and 32-cyclopropylidenemethyl- 
dihydrolanosterol showed no binding. AlklL456S showed type I binding with all the 
sterols used in this study, except dihydrolanosterol, which produced reverse type I 
spectra.
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The sterols used in this study showed type I binding with AlklL456S, except for 
dihydrolanosterol, which showed reverse type I (also known as modified type II) 
(figure 6.8). This spectra is a mirror image of type I spectrum with a peak at 419nm 
and trough at 379nm (figure 6.8). This data suggests that the sterols used in this 
study are potential substrates of AlklL456S as this shift is very often predictive of 
cytochrome P450 substrates.
Interestingly, not all the sterols used in this study were shown to bind to CYP51. As 
expected lanosterol binding to CYP51 showed type I binding spectra as did 14- 
methyl-zymosterol, argosterol, 31-nor-lanosterol, obtusifoliol and dihydrolanosterol 
(albeit weakly) (figure 6.8). However, cholesterol, A7-dihydrolanosterol and 32- 
cyclopropylidenemethyl-dihydrolanosterol did not produce any binding spectra when 
titrated against CYP51.
The Michaelis-Menten equation was used to calculate the substrate binding constant 
(Ks) for each sterol. This data is shown in table 6.2.
Sterol Structure
Alkl CYP51
Binding K s(uM ) Binding Ks (uM)
14- M eth y 1 -Zym  osterol T yp e 1 2 .8 7 ± 0 .8 6 T yp e 1 3 .8 4 ± 0 .2 8
32-C yclop rop ylidenem eth y l-
dihydrolanosterol
T yp e 1 4 .7 7 ± 0 .6 0 N o  B inding
D ihydrolanosterol
R everse  
T yp e 1
5.40± 0 .51 W eak T yp e 1 l .7 6 ± 0 .6 7
Lanosterol T yp e 1 5 .21 ± 0 .5 3 T yp e 1 5 .28± 0 .21
C holesterol x t  9 ^ T yp e 1 4 .7 2 ± 1 .5 5 N o  B inding
31 -N o r -la n o stero l T yp e I 9 .2 2 ± 1 .4 2 1 y p e I 9 .6 1 ± 0 .8 6
A rgosterol T yp e I 5 .7 8 ± 2 .18 T yp e 1 4 .8 5 ± 0 .6 8
D elta -7 -D ih yd ro lan ostero l T yp e 1 2 .63± 0 .71 N o  B inding
O b tu sifo lio l . 0 ^ T yp e I 2 .8 0 ± 0 .4 7 8 W eak T yp e 1 3 . 12± 1 .20
Table b.2 -  Substrate binding constants (Ks) of the sterol-Alkl L456S and sterol- 
CYP51 complexes.
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Table 6.2 shows that AlklL456S and CYP51 share similar binding affinities for 
lanosterol and 31-nor-lanosterol. However, CYP51 showed greater affinity for 
dihydrolanosterol and argosterol, whereas AlklL456S showed greater affinity for 
obtusifoliol and 14-methyl-zymosterol (table 6.2). It is important to note the weak 
nature of the binding between CYP51 and the sterols dihydrolanosterol and 
obtusifoliol interfered with the accurate determination of Ks.
Using data from table 6.2 it is possible to rank the binding affinities of each sterol for 
AlklL456S. The sterols are ranked from the sterol with the strongest binding 
affinity to the weakest:
A7-dihydrolanosterol > obtusifoliol > 14-methyl-zymosterol > cholesterol > 32- 
cyclopropylidenemethyl-dihydrolanosterol > dihydrolanosterol > argosterol > 31- 
nor-lanosterol
Lanosterol and 14-methyl-zymosterol were used for reconstitution assays (despite 
A7-dihydrolanosterol having the greatest binding affinity to AlklL456S) as both 
these sterols showed similar affinities for AlklL456S and CYP51. Cholesterol was 
chosen for reconstitution assays because it has been shown to be the substrate of 
other cytochromes P450, such as CYP125 from M. tuberculosis, which also 
metabolise fatty acids (Capyk et al., 2009; Ouellet et al., 2010). 32-
cyclopropylidenemethyl-dihydrolanosterol was used in reconstitution assays with 
Alkl L456S due to its unique structure (compared to other sterols used in this study).
6.3.3 Detection of Sterols on the GCMS
The sterol standards were run on the GCMS to ensure they could be detected for 
analysis.
6.3.3.1 Cholesterol
Cholesterol has a molecular weight of 386, which when silylated becomes a mass ion 
of 458. The retention time is 25.444 minutes (figure 6.9).
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Figure 6.9 -  TM S-derivatised cholesterol. GCMS results showing the GC 
trace/chromatograph (top) and mass spectrum (bottom) for cholesterol. Inset (top) is 
the TMS-derivatised structure of the standard.
6.3.3.2 14-Methyl Zymosterol
Silylated 14-methyl-zymosterol has a mass ion of 470 and a retention time of 27.059 
minutes (figure 6.10).
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Figure 6.10 -  TM S-derivatised 14-methyl zymosterol. GCMS results showing the 
GC chromatograph (top) and mass spectrum (bottom) of TMS-derivatised 14-methyl 
zymosterol. Inset (top) is the structure of this standard.
6.3.3.3 32-Cvclopropylidenemethvl-Dihvdrolanosterol
The GCMS oven program was increased to ensure 32-cyclopropylidenemethyl- 
dihydrolanosterol could be detected as it has a larger molecular weight (MW = 466) 
compared to the other sterols. The silylated version of this sterol has a mass ion of 
538 and a retention time of 42.038 minutes (figure 6.11).
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Figure 6.11 — TM S-derivatised 32-cyclopropylidenemethyl-dihydolanosterol.
GCMS results showing the GC chromatograph (top) and mass spectrum (bottom) of 
this standard. Inset (top) is the TMS-derivatised structure.
6.3.4 Reconstitution Assays
When AlklL456S was incubated with lanosterol no product formation was seen in 
the presence of ScA33CPR and CaCPR (figure 6.12). In contrast, CYP51 was able 
to demethylate lanosterol under the same assay conditions (figure 6.12). The use of 
CaCPR resulted in a 2.5 fold increase in product formation from 8% (using 
ScA33:CPR) to 20%.
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Figure 6.12 -  GC chrom atographs for reconstitution assays using lanosterol as 
the substrate. Reconstitution assays involving CYP51 show the presence of a peak 
representing the demethylated version of lanosterol. No product peak was seen when 
Alkl L456S was used to catalyse the reaction.
Neither AlklL456S nor CYP51 (in the presence of ScA33:CPR or CaCPR) were 
shown to produce demethylated or hydroxylated products of cholesterol (figure 
6.13), 14-methyl-zymosterol (figure 6.14) or 32-cyclopropylidenemethyl- 
dihydrolanosterol (figure 6.15) when these sterols were used as substrates in 
reconstitution assays.
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Figure 6.13 -  GC chrom atographs for reconstitution assays using cholesterol as 
the substrate. No product seen. The red square shows the potential location of 
peaks representing either demethylated or hydroxylated cholesterol.
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Fiiiure 6.14 -  GC chrom atographs for reconstitution assays using 14-methyl 
zymosterol as the substrate. No product produced. The red square shows the 
potential location of peaks representing either demethylated or hydroxylated 14- 
methyl zymosterol.
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Figure 6.15 -  GC chrom atographs for reconstitution assays using 32- 
cyclopropylidenemethyl-dihydrolanosterol as the substrate. No product 
formation. The red square shows the potential location of peaks representing either 
demethylated or hydroxylated 32-cyclopropylidenemethyl-dihydrolanosterol.
6.4 Discussion
6.4.1 Azole Binding
Azole antifungal drugs are known to inhibit CYP51 activity, preventing ergosterol 
production and resulting in fungistasis (Strushkevich et al., 2010). They bind tightly 
with these enzymes producing type II spectra binding data, which is indicative of 
inhibition. Binding experiments in this study with these drugs and AlklL456S also 
showed similar results, i.e. tight type II binding, suggesting azoles are potential 
inhibitors of AlklL456S. Table 6.3 shows the [azole]o.5 data for azole binding to
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AlklL456S compared to those for CYP51 from C. albicans and Phanerochaete 
chrysosporium.
Enzyme Species
|Azole|n.5 (MM)
Reference
|Clot.|«_, |FIuc. |0,5 |Itra.|o.5 |Keto.|o.s |V ori.|0.5
A lk lL 456S C. albicans 0.58 1.04 0.40 0.37 0.72 This Study
CYP51 C. albicans 0.11 0.13
K elly et a l., 1999; Lamb et al., 
1999; Warrilow e t al., 2008
CYP51 P. chrysosporium 0.54 0.56 0.51 0.56 0.49 Warrilow et al., 2008
Table 6.3 -  Comparison of |AzoIe]o.5 values for AlklL456S, CYP51 from C. 
albicans and CYP51 from P. chrysosporium.
The available [azole]o.5 data shown in table 6.3 shows that the azoles fluconazole and 
ketoconazole have a greater binding affinity for CYP51 from C. albicans than 
AlklL456S. This suggests that despite the ability of azoles to bind to AlkL456S, 
CYP51 is still the main target of these drugs in C. albicans. Interestingly, 
AlklL456S shows smaller [Azole]o.5 values for itracontrazole and ketoconazole than 
CYP51 from P. chrysosporium suggesting a potential role for Alkl in antifungal 
treatment. For instance, if Alkl was expressed under certain conditions (e.g. growth 
in a lipid-rich environment) azoles may inhibit the activity of this enzyme. This 
could prevent growth of the organism on hydrocarbons or pathogenic processes that 
require lipid metabolism.
In chapter 5, reconstitution assays failed to show functional AlklL456S protein 
activity so IC50 experiments could not be undertaken with this protein to determine if 
these azoles do inhibit AlklL456S. However, Kim and co-workers (2007) showed 
that Alk8  (CYP52A21) from C. albicans was not inhibited by fluconazole, but 
weakly inhibited by ketaconazole (IC50 = 104pM). This suggests that CYP52 
enzymes may not be a target of azole antifungal drugs (Kim et al., 2007). The weak 
inhibition of Alk8  by azoles was also shown by Panwar and his colleagues (2001) 
who found a 1 0 0  fold excess of itraconazole was required to inhibit lauric acid 
oxidation in a C. albicans strain overexpressing Alk8 . No azole binding data is
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available for this enzyme and AlklL456S has not been used in IC50 experiments so 
no direct comparison can be made regarding the interaction o f azole drugs between 
these enzymes. As the affinity for different alkanes and fatty acids differs between 
CYP52 members from the same organism, the affinity for azoles may also differ 
between these same enzymes. Furthermore, no other published data have shown 
interactions between other CYP52 enzymes and azole antifungal drugs, suggesting 
more work needs to be done in this area as the CYP52 family o f cytochromes P450 
may influence azole antifungal treatment and resistance.
Yeast and fungi, such as C. albicans, can become resistant to azole antifungal drugs. 
The mechanisms involved in this resistance include alterations in the CYP51 
sequence (whereby the enzyme remains active, but resistant to azoles), CYP51 
overexpression and an increase in efflux (ABC and major facilitator superfamily) 
transporter activity (Ghannoum & Rice, 1999). There are also considered to be other 
mechanisms by which antifungal resistance is influenced (including alterations in 
other enzymes o f the sterol biosynthetic pathway), but these mechanisms are largely 
unknown. Panwar and co-workers (2001) suggest that Alk8 may act as one of these 
mechanisms as they hypothesise CYP52 enzymes may be involved in the 
modification o f azole antifungal drugs into potentially harmless substrates causing 
resistance o f the cell to these drugs. Although, this has yet to be proven, another 
cytochrome P450 enzyme has been shown to have an ability to modify these drugs in 
a fashion similar to that proposed in this hypothesis.
CYP3A4 from liver extract has been shown to produce type II binding spectra in 
studies with azole drugs. Fluconazole binding to CYP3A4 was shown to produce a 
K<i value of 9.8±0.5pM (9.4 fold higher than AlklL456S), but CYP3A4 had a similar 
binding affinity for itraconazole as AlklL456S (0.456±0.008pM) (Locuson et al., 
2007). Interestingly, CYP3A4 was also shown to be able to metabolise itraconazole, 
but not fluconazole (Locuson et al., 2007). This suggests that the hypothesis o f 
Panwar and co-workers (2001) may be correct as at least one cytochrome P450 
enzyme has been shown to metabolise an azole antifungal drug. Alternatively, 
CYP52 enzyme may not be involved in azole metabolism, but rather bind to these 
drugs, thus removing them from the immediate environment. This would mean an 
increased dosage o f the azole may be required to inhibit CYP51 activity in the cell.
217
However, more research needs to be undertaken to understand how CYP52 enzymes 
and azole antifungal drugs interact before assigning a role for CYP52s in azole 
resistance.
6.4.2 Sterol Binding and Reconstitution Assays
Sterols are involved in the production o f membrane lipids, which are required for 
membrane permeability and fluidity (Ghannoum & Rice, 1999; Strushkevich et al., 
2010). In yeast and fungi, CYP51 and CYP61 have been shown to be the only 
cytochromes P450 involved in the sterol biosynthetic pathway. No other fungal 
cytochromes P450 to date have been shown to either bind or metabolise sterols. 
Binding studies in this chapter have shown that AlklL456S is able to bind to a 
variety o f sterols producing type I or reverse type I spectra. This is the first time a 
member of the CYP52 family has been shown to bind these substrates. Interestingly, 
CYP51 did not bind to all o f the sterols used, suggesting that AlklL456S and CYP51 
do not bind to the substrate in the same way and proving that there is a structural 
basis for sterol binding to cytochromes P450.
Figure 6.16 shows the similar/dissimilar areas o f the sterol structures (used in this 
study) that produce the different types of binding spectra seen with CYP51.
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31-Nor-Lanosterol
14-Methvl-Zvmosterol
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Argosterol
Dihvdrolanosterol Obtusifoliol
Weak Type I
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32-Cvclopropvlidenemethvl-
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No Binding
Figure 6.16 -  Binding spectra produced by each sterol titrated against CYP51.
Sterols are grouped by the binding spectra produced. Red circles show areas o f 
similarity in the alkyl chains o f sterols that produce type I binding spectra. Pink 
circles show alkyl chain structures that do not match those highlighted by the red 
circles, but are similar in structure. The dashed pink circle shows an alkyl side chain 
that does not fit into either group. The blue circle indicates the 14-methyl group in 
these sterol structures. Green circles highlight sterols that do not contain this 
structure. The dashed green circle shows sterols that do not fit into either category.
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CYP51 enzymes metabolise sterols that contain a methyl group (-CH3) at carbon 14 
(shown as a blue circle in figure 6.16), e.g. lanosterol. It would be expected that all 
sterols with a methyl group at this position would produce type I spectra where used 
in binding studies with CYP51 as this side group interacts with the haem. However,
n
A -dihydrolanosterol produced no binding spectra despite containing this methyl 
group at carbon 14 suggesting other areas o f the sterol structure are important for the 
production of type I binding spectra. Interestingly, the four sterols, which produced 
type I spectra (lanosterol, 14-methyl-zymosterol, 31-nor-lanosterol and argosterol) 
all contain a double bond between carbons 24 and 25 (red circle), which is missing
n
from the structures o f those sterols (cholesterol, A -dihydrolanosterol and 32- 
cyclopropylidenemethyl-dihydrolanosterol) that do not bind to CYP51 (pink circle) 
suggesting this could be the part o f the sterol structure that interacts with the 
substrate binding site. However, the two sterols, which produce weak type I binding 
spectra, dihydrolanosterol and obtusifoliol, do not contain this double bond
 ^ n
suggesting other interactions may be taking place. Dihydrolanosterol and A - 
dihydrolanosterol are similar in structure. Both contain a double bond between 
carbons 24 and 25 (pink circle) and a methyl group at carbon 14 (blue circle). Yet 
dihydrolanosterol binds to CYP51 with weak type I spectra and A?-dihydrolanosterol 
does not produce any discemable spectra. The difference between these two 
structures is the position o f the double bond in the second ring (also known as ring 
B). In dihydrolanosterol this double bond is situated between carbons 8 and 9, but in 
A7-dihydrolanosterol it is adjacent to the methyl group between carbons 7 and 8 .
n
This suggests the sole hydrogen atom projecting from carbon 7 in A - 
dihydrolanosterol is at an orientation where it can interfere with the coordination o f 
the methyl group to the haem, thus preventing the production o f type I binding 
spectra. Obtusifoliol differs from the other sterols used in this study as the double 
bond is at carbon 24, but projects to another carbon (carbon 28), which is not part o f 
the other sterol structures (dashed pink circle). Obtusifoliol has a similar structure to 
eburicol, a substrate o f CYP51 (not used in this study) (figure 6.17) as both 
structures contain a double bond between carbons 24 and 28 (red circle). Although, 
a methyl group at carbon 4 is omitted from the obtusifoliol structure, thus making 
this sterol a C4-mono-methylated sterol (opposed to eburicol, which is a C4-double- 
methylated sierol). This suggests double bonds are required to be present in the alkyl 
side chain of the sterol to ensure the substrate is at the correct orientation to
220
coordinate the methyl group at carbon 14 with the haem, thus producing type I 
binding spectra.
Eburicol Obtusifoliol
HO HO
Figure 6.17 -  Comparison of eburicol and obtusifoliol structures. The red circle 
indicates the similar alkyl chain structures in both molecules.
Interestingly, binding studies with CYP51 from Leishmania infantum (a human 
pathogen, which grows in the intestine o f the sand fly and is transmitted by its bite) 
showed that this enzyme favours obtusifoliol and norlanosterol over eburicol and 
lanosterol, which is in contrast to CYP51 from C. albicans (Hargrove et al., 2011). 
CYP51 from L. infantum appears to bind to sterols with different affinities depending 
on the number o f methylated side-chains at carbon 4. This enzyme binds more 
tightly to sterols with one methyl group at this carbon (C4-mono-methylated, i.e. 
obtusifoliol and norlanosterol) and weaker to C4-double-methylated sterols (i.e. 
lanosterol, dihydrolanosterol and eburicol) (Hargrove et al., 2011). It is also able to 
bind to sterols that do not contain a methyl group at this position (C4-des- 
methylated, i.e. 14-methyl-zymosterol) (Hargrove et al., 2011). (Type I spectra was 
produced in all cases.) This is in contrast to C. albicans CYP51, which seems to 
discriminate between sterol structures depending on the composition o f the alkyl 
side-chain and the presence o f a double bond at carbon 7 rather than the number o f 
methylated side-chains at carbon 4.
Unlike CYP51 from C. albicans, AlklL456S was shown to bind to all the sterols 
used for binding in this study, producing either type I or reverse type I binding 
spectra (see figure 6.18).
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Figure 6.18 -  Binding spectra produced titrating sterols against AlklL456S.
Sterols are separated into groups according to the binding spectra produced.
Unlike CYP51, AlklL456S was able to bind sterols that do not contain a methyl 
group at carbon 14 in the structure, like cholesterol and 32-cyclopropylidenemethyl- 
dihydrolanosterol (which contains a cycloalkyl group at this position). This 
indicated this side chain is not a requirement for type I binding with AlklL456S. 
The sterols that show type I binding (figure 6.18) with AlklL456S have different 
alkyl side chains. Lanosterol, 14-methyl-zymosterol, 31-nor-lanosterol and
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argosterol contain a double bond between carbons 24 and 25. 32-
n
cyclopropylidenemethyl-dihydrolanosterol, cholesterol and A -dihydrolanosterol 
have no double bonds in their alkyl side chain. Obtusifoliol has a double bond 
between carbon 24 and 27 (and is C4-mono-methylated). This suggests that unlike 
CYP51 the double bond composition o f the alkyl side chain and the presence o f a 
double bond at carbon 7 are not integral to type I binding with Alkl L456S.
All the sterols used in this study have methyl groups at carbon 18 and 19, which may 
play a role in binding to AlklL456S. However, how the sterols bind to AlklL456S 
is difficult to ascertain as the majority o f the sterols used in this study bind producing 
a type I spectra. Dihydrolanosterol is the only sterol not to produce “classical” type I 
spectra, but rather reverse type I. These spectra can either be produced by the 
hydroxyl group (OH-) at carbon 3 (on ring A) interacting with the haem or the 
substrate interacting with the enzyme at a different site to the other substrates used in 
this study (Schenkman et al., 1972). Interestingly, while dihydrolanosterol produces 
reverse type I binding spectra, A7-dihydrolanosterol (which has a similar structure) 
produces type I. However, until these substrates have been shown to be metabolised 
in reactions catalysed by Alkl L456S it will be difficult to ascertain how these sterols 
bind to AlklL456S.
Lanosterol was used in reconstitution assays with AlklL456S and CYP51 as this 
sterol was shown to have similar binding affinities for both o f these enzymes. As 
expected, CYP51 was shown to demethylate lanosterol. However, no activity was 
seen with AlklL456S, suggesting this enzyme is not involved in lanosterol 
demethylation, although, an active reconstitution assay for this protein remains a 
future aim. 14-methyl-zymosterol was also used for reconstitution assays as it also 
shares similar binding affinities for AlklL456S and CYP51. Interestingly, no 
product was detected by GCMS with either enzyme despite 14-methyl-zymosterol 
sharing structural similarities with lanosterol. This means either CYP51 and 
AlklL456S proteins can bind to this sterol, but not metabolise it or these enzymes 
did catalyse the metabolism of this sterol, but the turnover was so low it could not be 
detected on the GCMS. Cholesterol and 32-cyclopropylidenemethyl- 
dihydrolanosterol were also used in reconstitution assays (despite the inability of 
these sterols to bind to CYP51) because cholesterol has been shown to be
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metabolised by other cytochromes P450 from other organisms and 32- 
cyclopropylidenemethyl-dihydrolanosterol has a unique sterol structure. As expected 
no product was identified in reactions catalysed by CYP51. AlklL456S also failed 
to produce any products in reconstitution assays with these sterols.
The reconstitution assays undertaken in this chapter seem to suggest that AlklL456S 
is able to bind to lanosterol, 14-methyl-zymosterol, 32-cyclopropylidenemethyl- 
dihydrolanosterol and cholesterol, but not metabolise them. Reconstitution assays 
using AlklL456S to catalyse the reaction may require an increased concentration of 
CaCPR to produce detectable product. In this study 3.8pM of CaCPR was used as 
higher concentrations o f protein could not be obtained in the volume o f the 
reconstitution system used (i.e. 1ml). To rectify this problem either the volume o f 
the reconstitution system used needs to be increased so that greater volumes o f 
CaCPR can be used (thereby increasing the concentration), the concentration o f 
AlklL456S protein needs to be reduced to increase the ratio o f CaCPR to 
AlklL456S or a greater yield o f CaCPR needs to be produced during protein 
expression. However, 3.8pM of CaCPR was sufficient to produce 20% 
demethylated product in reconstitution assays using CYP51 to catalyse the reaction 
and lanosterol as the substrate, compared to 8% when lOpM of ScA33:CPR was 
used. This difference in the product yield could be due to CaCPR being the 
homologous CPR of the CYP51 used in this study or it could be due to CaCPR being 
a full-length reductase whereas ScA33:CPR is a truncated version o f CPR from S. 
cerevisiae. Full-length CPR contains a membrane anchor region in its N-terminus, 
which allows the protein to bind/anchor itself to the membrane allowing it to be 
involved in electron transfer to the haem iron o f the (membrane-bound) cytochrome 
P450 (Paine et al., 2005). A truncated CPR protein, such as ScA33:CPR, may not be 
able to fully interact with the cytochrome P450 as it is not anchored to the membrane 
and this binding is thought to be essential for the correct spatial orientation o f this 
redox partner (Paine et al., 2005). However, ScA33:CPR has been shown to achieve 
similar results as full-length S. cerevisiae CPR in kinetic studies (Lamb et al., 
2001b), suggesting the lack o f N-terminus may not be responsible for the decreased 
14-demethylated product formation seen in this study.
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Alternatively, AlklL456S may catalyse the metabolism of these sterols, but the 
turnover may be too low to be detected on the GCMS. As with the fatty acid 
reconstitution assays undertaken in chapter 5, other chromatographic methods, such 
as TLC and HPLC, may be required in conjunction with radioactive substrate to 
detect products o f AlklL456S sterol metabolism. These detection methods may also 
be required as AlklL456S may be involved in the hydroxylation o f these sterols 
(rather than the demethylation o f lanosterol and possibly 14-methyl-zymosterol) and 
these products may not be easily detected using the current method o f detection.
Other cytochromes P450 from other organisms have been shown to be involved in 
the hydroxylation o f cholesterol. Table 6.4 and figure 6.19 show the cytochromes 
P450, which catalyse this reaction and the products produced.
Enzym e Species Product K s (pM ) Reference
CYP46A1 Brain 24-Hydroxycholesterol 8.58±1.51 Mast et al., 2004
CYP125 M. tuberculosis 26-Hydroxycholesterol 0.20±0.02 Capyk et al., 2009
CYP125A1 M. tuberculosis 26-Hydroxycholesterol 0.107±0.064 Ouellet et al., 2010
CYP125 Rhodococcus josh ii RHA1 26-Hydroxycholesterol 0.20±0.08 Rosloniec et al., 2009
CYP7A1 Liver 7a-Hydroxycholesterol 4.3±0.01 Mast et al., 2005
A lklL 456S C. albicans ? 4.7±1.55 This study
Table 6.4 -  Comparison of cholesterol binding and metabolising cytochromes 
P450. All the cytochromes P450 shown here (except AlklL456S) are involved in 
the hydroxylation of cholesterol. AlklL456S and CYP7A1 share a similar binding 
affinity for this substrate, but it binds tighter to CYP125 from M. tuberculosis and R. 
joshii RHA1. CYP46A1 binds to cholesterol the weakest o f all the enzymes shown 
in this table.
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Figure 6.19 -  Products of cholesterol hydroxylation catalysed by cytochrome 
P450 enzymes. CYP46A1 catalyses the hydroxylation o f cholesterol at carbon 24. 
CYP125 is involved in the hydroxylation o f this molecule at carbon 26. CYP7A1 
catalyses the hydroxylation of the cholesterol at carbon 7 (ring B).
CYP46A1 from brain extracts (Mast et al., 2004), CYP7A1 from liver extracts (Mast 
et al., 2005) and CYP125 from M. tuberculosis and Rhodococcus joshii RHA1 
(Capyk et al., 2009; Rosloniec et al., 2009; Ouellet et al., 2010) have all been shown 
to hydroxylate cholesterol at different carbons within the structure (table 6.4 and 
figure 6.19). CYP46A1 has been implicated in Alzheimer’s disease. It is believed to 
reduce the concentration o f cholesterol in the brain o f healthy individuals by 
converting it to its hydroxy alternative (figure 6.19), which can be eliminated in the 
cerebral spinal fluid (Garcia et al., 2009). However, when this enzyme is impaired 
or inhibited, cholesterol is thought to be accumulated in the brain leading to the 
formation of p-amyloid plaques, which in turn are involved in the pathology of 
Alzheimer’s disease (Garcia et al., 2009). CYP7A1 is also involved in the 
breakdown o f cholesterol. It catalyses the first step o f bile salt production whereby
cholesterol is converted to 7a-hydroxylcholesterol (figure 6.19) (Mast et al., 2005). 
These bile salts can then be used to eliminate cholesterol from the body preventing 
the accumulation o f cholesterol in the arteries (Mast et al., 2005). Unlike CYP46A1 
and CYP7A1, which are involved in the elimination of cholesterol, CYP125 (in some 
bacteria) is involved in the metabolism of this sterol for use in growth (Capyk et al., 
2009). CYP125 catalyses the conversion o f  cholesterol to 26-hydroxycholesterol 
(figure 6.19), which can be broken down further by other enzymes to form pyruvate. 
This molecule can then be used by the organism for growth (Capyk et al., 2009). 
The role o f CYP125 in cholesterol metabolism may suggest a potential role for 
AlklL456S in the growth o f C. albicans on cholesterol and, in turn, the 
pathogenicity o f the organism in humans if  AlklL456S can be shown to hydroxylate 
cholesterol in metabolism studies.
In conclusion, AlklL456S has been shown to bind tightly with azole antifungal drugs 
producing type II spectra in binding studies, thus indicating a potential role for the 
enzyme in the resistance of C. albicans to azole drugs. AlklL456S has also been 
shown to produce type I binding spectra with sterols in this study. This is the first 
time a fungal cytochrome P450 enzyme other than CYP51 or CYP61 has been shown 
to interact with these substrates. Although, reconstitution assays with AlklL456S 
and the sterols: lanosterol, 14-methyl-zymosterol, 32-cyclopropylidenemethyl- 
dihydrolanosterol and cholesterol failed to show product formation in this study, 
AlklL456S may play a role in the conversion o f cholesterol for the use in growth in 
C. albicans.
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Chapter 7: Discussion
Cytochromes P450 are a superfamily o f haem-containing proteins, which are 
involved in the metabolism of a wide variety o f substrates including xenobiotics and 
sterols. Many cytochromes P450 have been shown to hydroxylate alkanes and/or 
fatty acids and the products formed (particularly diacids) have been shown to be 
important platform chemicals in the production o f many industrial products, 
including hot-melting adhesives, plastics, lubricants, fragrances and antibiotics 
(Eschenfeldt et al., 2003; Liu et al., 2003).
CYP52s are a family o f cytochrome P450 proteins, which are only found in yeast and 
fungi and are involved in the hydroxylation o f alkanes and fatty acids. To date, 52 
CYP52s have been identified in a number o f yeast and fungal species, including 
Candida tropicalis, C. maltosa, Yarrowia lipolytica and Aspergillus nidulans 
(http://dmelson.uthsc.edu/CvtochromeP450.html). However, only 8 o f these proteins 
have been shown to be catalytically active at the protein level, including CYP52A3 
and CYP52A4 from C. maltosa and CYP52A13 and CYP52A17 from C. tropicalis, 
which have been shown to be involved in the production o f diacids from alkanes and 
fatty acids (Zimmer et al., 1995; Zimmer et al., 1996; Scheller et al., 1998; 
Eschenfeldt et al., 2003). The ability o f these enzymes to produce such fatty acid 
derivatives indicates a potential role for CYP52 proteins in biotechnology. These 
fatty acid derivatives could be used as platform chemicals to form the basis o f a 
number of products including plastics, lubricants, fragrances and antibiotics 
(Eschenfeldt et al., 2003; Liu et al., 2003).
To understand frilly the role o f this family o f cytochromes P450 in the physiology o f 
yeast and fungi and their potential use in biotechnology, the enzymatic activity o f 
each protein needs to be determined. Therefore, in this study the potential CYP52 
from C. albicans with the greatest homology to the known alkane-assimilating 
CYP52 from C. maltosa, CYP52A3, was expressed at the protein level and studied. 
Using a bioinformatic approach, 10 putative cytochrome P450 genes were identified 
in C. albicans. These were ALK1, ALK2, ALK3, ALK6, ALK8, TRI4, DIT2, PAH1, 
ERG5 and ERG11. O f these genes, five were identified as putative alkane- 
assimilating CYP52s: ALK1, ALK2, ALK3, ALK6 and ALK8. ALK1 was shown to
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have the greatest homology (79% identity) to CYP52A3 and was used in subsequent 
studies.
ALK1 was cloned into E. coli for the expression o f recombinant protein. However, 
protein expression experiments resulted in the formation o f protein with a reduced 
carbon monoxide peak of 420nm, rather than a peak at 450nm, which is indicative of 
cytochrome P450 (Omura & Sato, 1964). The inability to express active protein was 
due to an alteration in the universal genetic code, which occurs in C. albicans. In 
this species, the triplet CUG encodes for the amino acid serine rather than the 
expected leucine (Santos & Tuite, 1995). As serine is a polar, hydrophilic amino 
acid and is non-polar and hydrophobic, such a difference in the properties o f the two 
amino acids can have a detrimental effect on the folding of protein leading to 
inactive protein, as in the case o f A lkl. In the ALK1 nucleotide sequence, the CUG 
codon was altered to TCT, which encodes for serine, resulting in the expression of 
protein producing a reduced carbon peak at 447nm, which is indicative o f active and 
correctly folded cytochrome P450. The resultant AlklL456S protein was purified 
and used for binding studies and reconstitution assays.
As AlklL456S is a putative member o f the CYP52 family o f cytochromes P450, 
alkanes were initially used in substrate binding studies. Hexadecane (C l6:0 alkane) 
was used as the control CYP52 in this study, CYP52A3 had previously been shown 
to bind to this alkane and catalyse its hydroxylation (Scheller et al., 1996; Scheller et 
al., 1998). Binding studies with AlklL456S and this alkane, as well as dodecane 
(C l2:0 alkane), failed to produce any discernible binding spectra. However, binding 
studies with the fatty acids lauric acid (C l2:0), myrisitic acid (C l4:0) and palmitic 
acid (C l6:0) resulted in type I binding spectra suggesting these hydrocarbons are 
substrates o f AlklL456S. Alk8 , another CYP52 enzyme from C. albicans, was 
shown to be able to bind to (and metabolise) fatty acids, but not alkanes (Kim et al., 
2007), indicating some CYP52 proteins from C. albicans are unable to interact with 
these hydrocarbons. Interestingly, Alk8 has a greater binding affinity for lauric acid 
than AlklL456S has for the same fatty acid and preferentially catalyses the 
hydroxylation o f lauric acid over myrisitic acid and palmitic acid in reconstitution 
assays (Kim et al., 2007), indicating that CYP52 proteins from C. albicans are
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involved in the preferential hydroxylation o f different hydrocarbons, but are also able 
to hydroxylate/bind to multiple fatty acid substrate.
The ability for a cytochrome P450 enzyme to be involved in the hydroxylation of 
multiple fatty acids is not exclusive to CYP52s as other cytochromes P450 have been 
shown to have similar enzymatic activities. CYP105D5 from Streptomyces 
coelicolor A3(2) is able to hydroxylate both lauric acid and oleic acid (C l8:1) (Chun 
et al., 2007), wherease CYP124 from Mycobacterium tuberculosis is able to 
terminally hydroxylate a number o f methyl-branched fatty acids, including 15- 
methyl palmitic acid, phytanic acid and isoprenoids (Johnston et al., 2009). The 
plant cytochrome P450, CYP77A4 is not only able to hydroxylate lauric acid and 
palmitic acid, but is also involved in the epoxidation o f oleic acid (Sauveplane et al.,
2009). Other cytochromes P450 have also been shown to be involved in the 
metabolism o f a broad range o f substrates, most notably the liver cytochrome P450, 
CYP3A4. This enzyme has been shown to be involved in the metabolism o f a 
number o f therapeutic compounds, including antibiotics (e.g. erythromycin (Watkins 
et al., 1985)), cancer therapeutic agents (e.g. tamoxifen (Jacolot et al., 1991)), azole 
antifungals (e.g. itraconazole (Locuson et al., 2007) and cholesterol lowering drugs 
(e.g. lovastatin (Wang et al., 1991)).
As palmitic acid was shown to have the greatest binding affinity for AlklL456S, it 
was used in reconstitution assays with this protein. Reconstitution assays with this 
substrate and protein failed to show the production o f metabolites when analysed on 
the GCMS. This was either due to the inefficacy o f the method used to detect any 
product formed at low levels or the inability o f AlklL456S to catalyse the reaction.
To determine substrate specificity in vivo experiments using S. cerevisiae AH22 cells 
transformed with the YEp51:AlklL456S_yeast plasmid grown on hexadecane 
showed that AlklL456S was able to catalyse the hydroxylation o f this alkane, despite 
hexadecane producing no discemable binding spectra with AlklL456S. Hexadecane 
is the substrate o f choice for CYP52A3 and S. cerevisiae is unable to use this 
hydrocarbon for growth, although, it has been shown to grow on a range o f fatty 
acids (Rehm & Reiff, 1981). Therefore, growth could be attributed to AlklL456S 
expression and function. This was unexpected as binding studies with alkanes (as
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previously mentioned) failed to show any discernible binding suggesting these 
hydrocarbons were not substrates o f AlklL456S. The lack o f binding spectra in this 
study may have been due to either the conditions o f the methods used not favouring 
alkane binding to AlklL456S, or the binding o f the substrate to the protein was too 
weak to produce any discernible binding spectra. Kim and co-workers (2007) 
showed that Alk8 was unable to bind and metabolise alkanes in reconstitution assays, 
suggesting other proteins/enzymes maybe required for the stability and/or activity of 
CYP52s to occur. However, other CYP52s, including CYP52A13 and CYP52A17 
from C. tropicalis, have been implicated in the hydroxylation o f fatty acids, but not 
alkanes (Craft et al., 2003; Eschenfeldt et al., 2003) despite C. tropicalis being able 
to use alkanes for growth (Picataggio et al., 1992). This suggests more in vivo 
experiments need to be undertaken with CYP52s to investigate whether these 
enzymes (as with AlklL456S) are also involved in the hydroxylation o f alkanes, 
despite no evidence in vitro. Alternatively, the ability for some CYP52s (e.g. Alk8 , 
CYP52A13 and CYP52A17) to be involved in the hydroxylation o f fatty acids rather 
than alkanes may be required for diacid formation. These enzymes may work in 
conjunction with alkane-hydroxylating CYP52s and other enzymes to produce 
diacids, which can be used by the cell for growth. Diacids can also be formed in 
environments rich in fatty acids to prevent their accumulation as high fatty acid 
concentrations can be harmful to the cell (Vamecq et al., 1985; Tehlivets et al.,
2007). High concentrations o f the fatty acids, lauric acid and capric acid (C l0:0) 
have been shown to result in the inhibition o f yeast growth and are thought to have 
potential in vitro uses in long-term antibiotic therapy (Kabara et al., 1972; Bergsson 
et al., 2 0 0 1 ).
In yeast genera, such as Candida, which can utilise alkanes and fatty acids, CYP52 
enzymes are used to catalyse the initial, rate-limiting step of the a-oxidation pathway 
in the endoplasmic reticulum; the hydroxylation o f the alkane to its respective 
alcohol (figure 7.1) (Scheller et al., 1998; Fickers et al., 2005). As described in 
chapter 1, following this step the alcohol is further converted to its respective 
aldehyde and fatty acid (figure 7.1). These conversions are either catalysed by 
CYP52 alone or by the enzymes alcohol dehydrogenase and aldehyde dehydrogenase 
(figure 7.1) (Scheller et al., 1998; Eschenfeldt et al., 2003; Fickers et al., 2005). The 
fatty acid produced can either be transported from the endoplasmic reticulum to the
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peroxisome to be subjected to P-oxidation or alternatively it can be converted further 
in the endoplasmic reticulum, by the co-oxidation pathway, to produce diacid (figure 
7.1) (Porter & Coon, 1991; Jiao et al., 2000; Eschenfeldt et al., 2003). If this occurs 
then the fatty acid is initially converted, by CYP52, to its respective fatty alcohol 
(hydroxyl fatty acid), which is further converted to the fatty aldehyde and diacid 
(figure 7.1). As with the a-oxidation pathway, these latter conversions are either 
catalysed by only CYP52 enzymes or by alcohol dehydrogenase and aldehyde 
dehydrogenase (figure 7.1) (Scheller et al., 1998; Eschenfeldt et al., 2003; Fickers et 
al., 2005). The diacid produced, like the fatty acid, can be transported to the 
peroxisome, where it is subjected to p-oxidation and used for growth (figure 7.1) 
(Porter & Coon, 1991; Jiao et al., 2000; Eschenfeldt et al., 2003). As described, 
CYP52 enzymes can generate diacids alone (which has been shown to occur in in 
vitro assays with hexadecane and CYP52A3 (Scheller et al., 1996)), which is an 
advantage in the biotechnological applications and production o f this hydrocarbon. 
However, in vivo, this would cause a reduction in NADPH, which is required for 
CYP52 activity, reducing the cells ability to hydroxylate alkanes/produce fatty acids 
and diacids. Therefore, CYP52 enzymes may act in conjunction with alcohol 
dehydrogenase and aldehyde dehydrogenase to increase the efficiency o f the 
conversion/hydroxylation of the alkane substrate (Scheller et al., 1998; Eschenfeldt 
et al., 2003). However, if  other enzymes are used by the cell to convert alcohols to 
fatty acids/diacids then the cell may also use separate CYP52s to hydroxylate alkanes 
and fatty acids to ensure maximal alkane hydroxylation for growth. This may 
explain the presence o f multiple enzymes belonging to the CYP52 family o f enzymes 
in the cell and the ability o f these enzymes to catalyse the hydroxylation o f multiple 
hydrocarbons (despite having a preferred substrate).
232
G#o
■4— >03
'x
Oi
a
G_o
+->
03
"O
x
O
x :
Alkane
NA D P H  + H
o2
HjO
NADP
C Y P 5 2
Alcohol
A lc o h o l
D eh y d ro g en a se
Aldehyde
N A D
A ld e h y d e
D eh y d ro g en a se
Fatty Acid
N A D P H  + H
H.O <=1 
NAD P  <T
C Y P 5 2
Fatty Alcohol j
SAD
N A D H
i i
| Fatty Aldehyde j
A lc o h o l
D e h y d ro g en a se
N A D
NAPJttB. ) A ld e h y d eD e h y d ro g en a se
Diacid
Endoplasm ic Reticulum
Peroxisom e
Fatty Acyl-CoA
A cyl CoA  
O xidase C FADH + H
a,p-Unsaturated 
Fatty Acyl-CoA
2-E noyl-C oA
Hydratase
>A L  h 2o
 V
P-Hydroxy Fatty 
Acyl-CoA
3-H ydroxyacyl-C oA
Dehydrogenase
P-Oxo Fatty 
Acyl- CoA
Thiolase
HS-CoA
Fatty Acyl- CoA 
and Acetyl-CoA
-coI
0x
01
o '
G
Figure 7.1 -  Overview of the a-, co- and p-oxidation pathways identifying the 
enzymes involved and the products produced. The a- and co-oxidation pathways 
both take place in the endoplasmic reticulum, whereas the p-oxidation pathway takes 
place in the peroxisome. The products o f the major pathways in alkane metabolism 
are in solid boxes. The products of the minor diacid-producing pathway are in 
dashed boxes. * Alcohol dehydrogenase is substituted for alcohol oxidase in some 
papers.
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The in vivo experiments undertaken with S. cerevisiae AH22 cells transformed with 
the plasmid YEp51 :AlklL456S_yeast is the first time AlklL456S has been shown to 
be involved in the hydroxylation of alkanes. However, the activity o f this enzyme 
was inferred from the ability o f the transformed cells to grow on alkanes (unlike the 
negative control) and the similarities o f the lipid profile produced between these cells 
and the positive control (AH22 cells containing YEp51:CYP52A3_yeast). Peaks 
representing hexadecanol, 16-hydroxypalmitic acid and thapsic acid were not 
identified on the GC chromatograph, although this does not mean AlklL456S was 
unable to produce these metabolites as the positive control also failed to show peaks 
representing these hydrocarbons despite CYP52A3 having been shown previously to 
catalyse the conversion o f hexadecane to thapsic acid (Scheller et al., 1998). This 
experiment shows that other enzymes such as those that make up the p-oxidation 
pathway (figure 7.1) were acting on the products o f AlklL456S (and CYP52A3) as 
the metabolites were required for cell growth.
The p-oxidation pathway (figure 7.1) is ubiquitous in nature and is required for the 
break down o f fatty acids (and diacids) for use in growth (Wanders et al., 2007). 
This pathway is not only used by yeast, but it is also used by a number o f other 
organisms, including animals, which utilise hydrocarbons for growth. Interestingly, 
in these organisms p-oxidation is carried out in both the mitochondrion and 
peroxisome (to a lesser extent), but in yeast p-oxidation only occurs within the 
peroxisome as it does not have enzymes for p-oxidation located within the 
mitochrondria (Kunau et al., 1988; Hettema & Tabak, 2000; Kragt et al., 2006). 
Picataggio and co-workers (1992) showed that it is possible to produce diacids from 
dodecane and myrisitic acid in an industrial strain o f C. tropicalis by disrupting the 
genes that encode for acyl CoA oxidase (POX4 and POX5), the first enzyme in the 
P-oxidation pathway (figure 7.1). The media used contained glucose as co-substrate 
for growth, which aided diacid production. Diacid yield was further increased by 
amplifying the diacid-producing CYP52 enzymes and CPR in the POX knockout 
strain (Picataggio et al., 1992). This method could be used to aid diacid production 
in S. cerevisiae cells containing YEp51:AlklL456S_yeast. As with the above 
method an additional growth substrate such as glucose, would be required to 
maintain cell growth while diacid is being formed. To aid with this experiment it 
may be beneficial to replace the inducible YEp51 vector (Rose & Broach, 1991) with
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a constitutive expression vector, such as pMA91 (Mellor et al., 1983). This vector 
contains a strong PGK promoter, which does not require the addition o f galactose for 
the transcription o f the gene (as required by YEp51) (Mellor et al., 1983). However, 
using this type o f vector may cause toxicity so an inducible vector or a weaker 
promoter may be required for this experiment to be viable.
However, other studies investigating the disruption of the POX genes in the P- 
oxidation pathway o f other C. tropicalis strains failed to produce similar results to 
Picataggio and co-workers (1992), suggesting the ability to produce diacids may be 
strain specific as other genes could have also been disrupted in the industrial strain 
used (Hara et al., 2001). Therefore, another possible way o f producing diacids from 
alkanes other than POX gene knockout is the impairment o f carnitine 
acetyltransferase (Cao et al., 2006).
Prior to the breakdown of fatty acids (and diacids) by p-oxidation, they require 
activation by coenzyme A (CoA) (Carman et al., 2008; van Roermund et al., 2008; 
van Roermund et al., 2011). CoA, a thiol (organosulphur compound), interacts with 
the hydroxyl (-OH) group of the fatty acid to produce the thiolester, fatty acyl-CoA 
(figure 7.2). This process is catalysed by acyl-CoA synthetase and the activation of 
the fatty acids allows these normally hydrophobic hydrocarbons to move from the 
cytoplasm to the organelles and/or from one organelle to another (Kanayama et al., 
1998). However, when diacids are present instead o f fatty acids, they are activated 
by dicarboxylyl-CoA synthetase rather than acyl-CoA synthetase (Vamecq et al., 
1985).
235
Cytosol Peroxisome
Fatty A cyl-CoA
. Carnitine
Fatty A cy l-C am itin e  
+ C oA
Fatty A cy l-C am itin e
CoA
Fatty A cy l-C o A  
+  Carnitine
P -O \ i d a t i o n
Figure 7.2 -  T ransport of fatty acyl-CoA into the peroxisome. The fatty acyl- 
CoA molecule is converted to fatty acyl-camitine in the presence of carnitine 
acetyltranseferase (CAT) and carnitine. This molecule is transported across the 
peroxisomal membrane, by an unknown mechanism (possibly involving an ABC 
transporter (Hettema et al., 1996; van der Klei & Veenhuis, 1997)), into the 
peroxisome where it is then converted back into fatty acyl-CoA in the presence of 
CAT and coenzyme A (CoA). This molecule can then enter the p-oxidation 
pathway.
The fatty acyl-CoA works in tandem with carnitine and carnitine transferase to allow 
the fatty acid to cross the peroxisomal membrane into the organelle. The fatty acyl- 
CoA binds to free carnitine producing fatty-acyl carnitine and free CoA at the 
cytosolic side of the peroxisomal membrane, in a reaction catalysed by carnitine 
acetyltransferase (CAT) (figure 7.2) (Bieber, 1988; van Roermund et al., 1995; 
Prigneau et al., 2003; Cao et al., 2006; Carman et al., 2008; Strijbis et al., 2008; 
Zhou & Lorenz, 2008).
The fatty acyl-camitine is transported across the membrane into the peroxisomal 
matrix. Here, the fatty acyl-camitine is converted back into fatty acyl-CoA for use in 
P-oxidation and this reaction is catalysed by another CAT enzyme located within the
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peroxisome (figure 7.2) (Bieber, 1988; van Roermund et al., 1995; Prigneau et al., 
2003; Cao et al., 2006; Carman et al., 2008; Strijbis et al., 2008; Zhou & Lorenz,
2008). The dissociated carnitine then moves out o f the organelle into the cytosol, 
possibly across a diffusion gradient produced in conjunction with the free CoA in the 
cytosol, which moves into the peroxisome.
Therefore, disrupting the CAT gene would prevent the transport o f fatty acids into 
the peroxisome, thus favouring diacid production as fatty acid accumulation would 
occur (Cao et al., 2006) thus disrupting this gene in S. cerevisiae cells containing 
YEp51:AlklL456S_yeast could aid diacid production. This would allow the strain 
to be used as a biotechnological tool in the formation o f platform chemicals.
Although, diacids are the preferential products o f CYP52 hydroxylation for their use 
as platform chemicals in the production o f industrial products, whole-cell 
experiments have also been undertaken to produce large yields o f fatty alcohols. 
Fatty alcohols can be used as the chemical basis for the production o f bioplastics and 
are a product of CYP52 hydroxylation o f fatty acids in yeast and fungi (Lu et al.,
2010). Lu and co-workers (2010) constructed a C. tropicalis knockout mutant, 
which was able to produce fatty alcohols using a strain where the P-oxidation 
pathway was known to be blocked. They knocked out the genes encoding 
CYP52A13 and CYP52A17 (and their allelic pairs CYP52A14 and CYP52A18 
respectively) to prevent the formation o f diacids, which are known to be formed in 
reactions catalysed by these enzymes (Lu et al., 2010). This meant only the CYP52s 
involved in the production o f fatty alcohols from fatty acids remained active. These 
disruptions were insufficient to prevent the further metabolism o f the fatty alcohols 
produced to diacids as other enzymes are involved in this pathway. The additional 
disruption o f alcohol oxidase failed to prevent diacid formation (in this experiment) 
(Lu et al., 2010). However, alcohol dehydrogenase is involved in the conversion o f 
fatty alcohols in the endoplasmic reticulum not alcohol oxidase (which is found in 
the peroxisome) (figure 7.1) (Fickers et al., 2005). Therefore, disruption o f the genes 
encoding alcohol dehydrogenase rather than alcohol oxidase or the disruption o f both 
genes would have been required to prevent diacid production. However, the 
formation of this product was prevented when the gene for aldehyde dehydrogenase 
was disrupted (Lu et al., 2010), thus resulting in the production o f 12-hydroxylauric
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acid (C l2:0 fatty alcohol), 14-hydroxymyrisitic acid (C l4:0 fatty alcohol) and 16- 
hydroxypalmitic acid (C l6:0 fatty alcohol), when the C. tropicalis mutant was grown 
on lauric acid, myristic acid and palmitic acid respectively (Lu et al., 2010). This 
shows that whole pathways need to be considered in the production o f diacids and 
other fatty acid derivatives when using whole-cell techniques in biotechnology as 
enzymes other than CYP52 are involved in the metabolism of fatty acids.
Other techniques have also been employed to increase metabolite production using 
recombinant cytochrome P450. In this study, recombinant assays using AlklL456S 
protein to catalyse the reaction failed to result in the identification o f hydroxylated 
product o f palmitic acid. However, further in vitro experiments using this protein 
(e.g. using labelled substrate or chromatographic techniques, such as TLC and 
HPLC, for analysis) might have been expected to result in the formation and 
detection o f hydroxylated products.
Directed evolution and site-specific mutagenesis strategies have been employed to 
improve enzymatic activity and alter the substrate specificity o f cytochrome P450 
proteins. These are important techniques used in biotechnology for the metabolism 
of novel substrates and have been extensively used with P 450b m -3  (CYP102A1) from 
Bacillus megaterium. This is a self-sufficient cytochrome P450-CPR fusion protein, 
which is involved in the hydroxylation o f fatty acids (Miura & Fulco, 1975; 
Boddupalli et al., 1992; Schneider et al., 1998; Gustafsson et al., 2004; Warman et 
al., 2005; Lamb et al., 2010). Cytochromes P450 has been subjected to direct 
evolution (such as random mutagenesis) and site-specific mutagenesis techniques to 
produce a protein which is able to catalyse the metabolism of substrates other than 
fatty acids. It has been adapted to hydroxylate small alkanes, such as propane (C3:0 
alkane), which it is unable to metabolise in its wild-type form (Fasan et al., 2007; 
Bloom & Arnold, 2009). P 4 5 0 b m -3  has also been altered to show enhanced
enzymatic activity towards the polycyclic aromatic hydrocarbons (PAHs): 
phenanthrene, fluoranthene and pyrene (figure 7.3) (Carmichael & Wong, 2001). 
Other experiments involving the substitution o f the amino acid phenylalanine with 
alanine at residue 87 in the wild-type P 450b m -3  protein has been shown to result in 
the formation o f a mutant, which is able to catalyse fatty acids at the co-carbon 
(Cirino & Arnold, 2002). The wild-type version o f this protein is unable to
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hydroxylate fatty acids at this carbon as it favours the col-, ©2- and co3-carbons of 
these substrates (Miura & Fulco, 1975; Boddupalli et al., 1992; Schneider et al., 
1998; Gustafsson et al., 2004; Lamb et al., 2010).
Phenanthrene
Pvrene
Figure 7.3 -  Poly cyclic aromatic hydrocarbons (PAHs): phenanthrene, 
fluroranthene and pyrene.
Other cytochromes P450 have also been subjected to directed evolution and site- 
specific mutagenesis, including P450cam (CYP101) from Pseudomonas putida, which 
is involved in the hydroxylation o f camphor, a terpenoid commonly found in wood. 
Mutants of this cytochrome P450 have been produced, which show enhanced 
catalytic activity towards the heavily chlorinated benzenes: pentachlorobenzene and 
hexachlorobenzene to produce pentachlorophenol (figure 7.4) (Jones et al., 2001). 
The wild-type version o f this protein is unable to catalyse the hydroxylation o f these 
substrates, but is involved in the metabolism of dichloro- and trichlorobenzene 
(figure 7.4) (Jones et al., 2001).
Fluoranthene
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Figure 7.4 -  Pentachlorobenzene, hexachlorobenzene, pentachlorophenol, 
dichlorobenzene and trichlorobenzene.
These techniques have not only been used to adapt the enzymatic function and 
specificity o f cytochrome P450 protein, they have also been undertaken on other 
related proteins too, including NADPH-cytochrome P450 reductases. A mutated 
form of human CPR has been produced, which is dependent on NADH for electrons 
rather than NADPH (Dohr et al., 2001). The amino acid tryptophan was substituted 
for alanine at residue 676 in the FAD binding domain o f this protein allowing for this 
alteration in cofactor preference (Dohr et al., 2001). The ability o f a CPR to utilise 
NADH instead o f NADPH is an advantage in biotechnology as NADPH is an 
expensive compound to purchase, but NADH is much cheaper thus reducing the 
overall cost o f any in vitro assays performed using CPR as the redox partner 
(Urlacher & Eiben, 2006).
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Alternatively, electrodes can be used to deliver electrons to cytochrome P450 
proteins via CPR eradicating the need for NADPH (or NADH) in the reaction. 
Purified proteins are immobilised on an electrode to allow continuous electron 
transfer to the haem centre o f the cytochrome P450 to drive catalytic activity 
(Krishnan et al., 2011). In this technique it is advantageous to use cytochrome P450- 
CPR fusion proteins as electrons can be passed from the electrode to the CPR and 
then directly to the cytochrome P450 without needing to ensure that the two separate 
proteins can interact with each other and the electrode (Krishnan et al., 2011). 
However, CPR is not necessarily required as electrons can be transferred directly to 
the haem iron o f the cytochrome P450 as hydrogen peroxide can be used instead of 
oxygen to produce the ferryloxy species o f the haem required for the hydroxylation 
o f the substrate to occur (Krishnan et al., 2011). Although, utilising a fusion protein 
would mimic electron transfer in vivo allowing for greater understanding o f the 
activity o f cytochrome P450 in the cell. This would require the production o f an 
artificial cytochrome P450-CPR fusion protein as few have been discovered in 
nature. Many artificial cytochrome P450-CPR fusion proteins have been produced 
including CYP4A1-CPR (Alterman et al., 1995; Chaurasia et al., 1995), human 
CY PlA l-rat CPR (Chun et al., 1996), CYP2D6-CPR (Deeni et al., 2001), CYP51- 
CPR (Kitahama et al., 2009) and CYP71B1-CPR (Lamb et al., 1998). These fusion 
proteins have been used in reconstitution assays and are ideal for enhancing the 
understanding o f how cytochromes P450 and CPR interact with each other and the 
substrate to drive enzymatic activity. Together with electrode immobilisation, these 
proteins can become an important tool in biotechnology.
The in vivo and in vitro experiments described above could be used to enhance 
AlklL456S catalytic activity for the use o f this protein in the production o f platform 
chemicals from alkane and fatty acids. However, the role o f this protein and other 
CYP52s in yeast and fungi is not fully understood.
This study has shown that Alkl L456S is able to bind to sterol substrates producing 
type I binding spectra. This is the first time a cytochrome P450 from yeast/fungi, 
other than CYP51 and CYP61, has been shown to interact with these substrates thus 
suggesting a greater role for these enzymes in the physiology of the cell. 
Interestingly, other cytochromes P450 from other species have also been shown to
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bind to (and metabolise) sterols, including CYP125 from M. tuberculosis, which has 
been shown to be involved in the hydroxylation o f cholesterol (Capyk et al., 2009; 
Ouellet et al., 2010). M. tuberculosis is able to utilise local extracellular stores of 
cholesterol as the sole carbon source for growth (Pandey & Sassetti, 2008). The 
cholesterol is transported into the cell, where it is subjected to hydroxylation by 
CYP125 to form 26-hydroxycholesterol, which is further broken down to form 
pyruvate. This molecule can then be subjected to the Krebs cycle and used for 
growth (Pandey & Sassetti, 2008; Capyk et al., 2009). The role o f CYP125 in the 
metabolism of cholesterol in M. tuberculosis may indicate a potential role for 
AlklL456S in the utilisation of cholesterol for growth in C. albicans. This, in turn, 
may link the pathogenicity o f the organism in humans to cholesterol metabolism by 
AlklL456S, particularly if  the protein can be shown to hydroxylate the substrate in 
further metabolism studies.
AlklL456S has also been shown in this study to bind tightly to azole antifungal 
drugs producing type II binding spectra. These drugs are known to target CYP51 
enzymes, inhibiting the production of ergosterol in yeast, resulting in fungistasis 
(Strushkevich et al., 2010). Comparison o f the [azolejo.s values for AlklL456S to 
those for CYP51s from C. albicans and Phanerochaete chrysosporium showed that 
AlklL456S has a greater binding affinity for ketoconazole and itraconazole than 
CYP51 from P. chrysosporium suggesting a potential role for AlklL456S in 
antifungal treatment and possibly the resistance o f C. albicans to these drugs. This 
may also mean that these drugs may interfere with the growth o f C. albicans on 
hydrocarbons or may inhibit pathogenicity if  AlklL456S is shown to hydroxylate 
cholesterol for growth in a similar manner to CYP125.
In summary, Alkl was shown to have the greatest homology to the archetypal 
alkane-assimilating cytochrome P450, CYP52A3, o f the five putative CYP52s 
identified in C. albicans using a bioinformatic approach. Although, the native ALK1 
gene sequence was unable to be used for expression to an active cytochrome P450 
form, substitution o f the CUG codon resulted in the expression o f protein with a 
reduced carbon peak at 447nm, which is indicative o f cytochrome P450 protein. The 
resultant AlklL456S protein was purified to homogeneity and was shown to bind to 
lauric acid, myristic acid and palmitic acid, producing a type I binding spectra.
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Although, reconstitution assays utilising AlklL456S and palmitic acid failed to show 
product formation, in vivo experiments with S. cerevisiae AH22 cells transformed 
with YEp51 :AlklL456S_yeast plasmid were shown to utilise hexadecane for growth. 
This showed that AlklL456S was involved in the metabolism of hexadecane as S. 
cerevisiae is unable to utilise alkanes for growth and the transformed cells showed a 
similar lipid composition to the positive control (YEp51 :CYP52A3_yeast 
transformed S. cerevisiae cells), which occurred as a result o f palmitic acid 
accumulation. This study was the first time AlklL456S has been shown to be 
involved in alkane metabolism, suggesting a potential role for this protein in 
biotechnology, particularly if  the product o f this enzyme can be identified in further 
reconstitution assays and whole cell experiments. AlklL456S was also shown to be 
the first yeast cytochrome P450, other than the biosynthetic CYP51 and CYP61, to 
bind to sterol substrates. Further metabolism studies will show if and how this 
protein metabolises these substrates, possibly giving rise to a greater understanding 
of the role of AlklL456S in C. albicans growth and possibly pathogenesis. 
AlklL456S was also shown to bind tightly with azole antifungal drugs producing 
type II binding spectra, thus indicating a potential role for this enzyme in the 
resistance o f C. albicans to these drugs and possible inhibition o f growth on 
hydrocarbons. Therefore, this study has shown a potential role for AlklL456S in 
biotechnology and has indicated a possible physiological role for CYP52s in sterol 
metabolism, which was previously unknown.
7.1 Sum m ary of Research
• Using a bioinformatic approach, 10 potential cytochromes P450 were 
identified in C. albicans. O f these, 5 were shown to be putative CYP52s. 
This is in contrast to Kim et al. (2007) and Park et al. (2011) who suggest 
there is only one CYP52 enzyme in C. albicans.
• Alkl was shown to have the greatest homology to CYP52A3. Although, 
reconstitution assays failed to show Alkl enzymatic activity in the presence 
of alkanes or fatty acids, in vivo experiments showed Alkl is involved in the 
hydroxylation o f the long-chain alkane, hexadecane. This suggests a role for 
Alkl in alkane metabolism, membrane lipid formation and growth.
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• Alkl was shown to bind to sterols producing type I spectra. This is the first
time a fungal cytochrome P450, other than CYP51 and CYP61, has been
shown to interact with these substrates. The ability o f Alkl to bind to sterols 
may indicate a potential role for this enzyme in the virulence o f C. albicans 
as other cytochromes P450, e.g. CYP125 from M. tuberculosis, are able to 
hydroxylate cholesterol to produce a precursor for growth (Pandey & Sassetti, 
2008; Capyk et al., 2009).
• Alkl was also shown to bind tightly with azole antifungal drugs producing
type II binding spectra. This suggests a potential role for Alkl in azole
resistance as the enzyme may bind to or modify these drugs preventing them 
from inhibiting CYP51 activity. Also, it may result in the possible inhibition 
o f C. albicans growth on hydrocarbons.
7.2 Future  Research
Alkl has a potential use in biotechnology and further experiments could be 
undertaken to enhance its uses.
• Further experiments could be undertaken to show Alkl activity at the in vitro 
level. Radiolabelled alkanes, fatty acids and sterols could be used as the 
substrates in reconstitution assays to help identify any products produced by 
Alkl catalysed reactions.
• IC50 experiments could be undertaken to determine if  the azole antifungal 
drugs that bind tightly to Alkl do inhibit this enzyme. This would also allow 
a direct comparison to be made between Alkl and Alk8 from C. albicans (as 
well as other cytochromes P450) regarding the interaction o f azole drugs 
between these enzymes.
• The S. cerevisiae cells containing the plasmid YEp51:AlklL456S_yeast 
could be used for further whole-cell experiments to produce large yields o f 
fatty alcohols and/or diacids. For instance, disruption o f the genes encoding 
for acyl CoA oxidase (which is involved in the p-oxidation pathway) may 
result in increased diacid production. Fatty alcohol production could also be 
enhanced in this strain by disrupting alcohol oxidase/dehydrogenase and 
aldehyde dehydrogenase activity preventing any possible conversion o f the 
hydrocarbon to its respective aldehyde and diacid. The products o f these
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experiments could then potentially be used as platform chemicals in the 
production o f bioplastics and other industrial products.
• An Alkl-CPR fusion protein could be constructed, which would be used to 
understand how CPR and Alkl interact with each other and the substrate to 
drive enzymatic activity in the cell.
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